RU2475488C2 - Дигидродиазепины, которые можно использовать в качестве ингибиторов протеинкиназ - Google Patents

Info

Publication number

RU2475488C2

RU2475488C2 RU2008136854/04A RU2008136854A RU2475488C2 RU 2475488 C2 RU2475488 C2 RU 2475488C2 RU 2008136854/04 A RU2008136854/04 A RU 2008136854/04A RU 2008136854 A RU2008136854 A RU 2008136854A RU 2475488 C2 RU2475488 C2 RU 2475488C2

Authority

RU

Russia

Prior art keywords

alkyl

compound

pyrimido

cyclopentyl

denotes

Prior art date

2006-02-14

Links

• Espacenet
• Global Dossier
• Discuss

• 102000001253 Protein Kinase Human genes 0.000 title claims abstract description 33
• 108060006633 protein kinase Proteins 0.000 title claims abstract description 33
• 239000003112 inhibitor Substances 0.000 title abstract description 15
• 238000000034 method Methods 0.000 claims abstract description 345
• 150000001875 compounds Chemical class 0.000 claims abstract description 253
• 239000012634 fragment Substances 0.000 claims abstract description 119
• 229910052736 halogen Inorganic materials 0.000 claims abstract description 47
• 150000002367 halogens Chemical class 0.000 claims abstract description 47
• 125000003118 aryl group Chemical group 0.000 claims abstract description 40
• 125000002950 monocyclic group Chemical group 0.000 claims abstract description 39
• 125000005842 heteroatom Chemical group 0.000 claims abstract description 38
• 229910052757 nitrogen Inorganic materials 0.000 claims abstract description 37
• 229910052799 carbon Inorganic materials 0.000 claims abstract description 31
• 229910052717 sulfur Inorganic materials 0.000 claims abstract description 30
• 229910052760 oxygen Inorganic materials 0.000 claims abstract description 29
• 229920006395 saturated elastomer Polymers 0.000 claims abstract description 25
• 125000004432 carbon atom Chemical group C* 0.000 claims abstract description 23
• 125000000623 heterocyclic group Chemical group 0.000 claims abstract description 23
• 125000004429 atom Chemical group 0.000 claims abstract description 22
• 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims abstract description 21
• 230000000694 effects Effects 0.000 claims abstract description 12
• 230000002401 inhibitory effect Effects 0.000 claims abstract description 9
• 125000006376 (C3-C10) cycloalkyl group Chemical group 0.000 claims abstract 4
• 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims abstract 3
• 125000004433 nitrogen atom Chemical group N* 0.000 claims abstract 2
• 239000000203 mixture Substances 0.000 claims description 87
• 125000000217 alkyl group Chemical group 0.000 claims description 44
• 229910052739 hydrogen Inorganic materials 0.000 claims description 24
• 108010056274 polo-like kinase 1 Proteins 0.000 claims description 24
• 125000001313 C5-C10 heteroaryl group Chemical group 0.000 claims description 18
• 239000003937 drug carrier Substances 0.000 claims description 10
• 238000007363 ring formation reaction Methods 0.000 claims description 9
• 239000012472 biological sample Substances 0.000 claims description 8
• 239000002609 medium Substances 0.000 claims description 8
• 150000001408 amides Chemical class 0.000 claims description 7
• 125000000753 cycloalkyl group Chemical group 0.000 claims description 7
• 230000003993 interaction Effects 0.000 claims description 7
• 102100031463 Serine/threonine-protein kinase PLK1 Human genes 0.000 claims description 5
• 239000002671 adjuvant Substances 0.000 claims description 5
• 125000003277 amino group Chemical group 0.000 claims description 5
• QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 3
• 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 claims description 2
• 238000007259 addition reaction Methods 0.000 claims description 2
• 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims 3
• 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 claims 2
• 239000000126 substance Substances 0.000 abstract description 18
• 239000003814 drug Substances 0.000 abstract description 14
• 239000008194 pharmaceutical composition Substances 0.000 abstract description 12
• 125000001072 heteroaryl group Chemical group 0.000 abstract description 6
• 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 11
• 125000000008 (C1-C10) alkyl group Chemical group 0.000 abstract 4
• 125000004178 (C1-C4) alkyl group Chemical group 0.000 abstract 1
• IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 777
• 238000004128 high performance liquid chromatography Methods 0.000 description 282
• 239000003153 chemical reaction reagent Substances 0.000 description 276
• 238000005481 NMR spectroscopy Methods 0.000 description 270
• -1 nucleoside triphosphate Chemical class 0.000 description 180
• 125000001931 aliphatic group Chemical group 0.000 description 70
• 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 60
• 201000010099 disease Diseases 0.000 description 43
• 206010028980 Neoplasm Diseases 0.000 description 38
• XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 37
• 235000002639 sodium chloride Nutrition 0.000 description 32
• 239000002904 solvent Substances 0.000 description 31
• KXDAEFPNCMNJSK-UHFFFAOYSA-N Benzamide Chemical compound NC(=O)C1=CC=CC=C1 KXDAEFPNCMNJSK-UHFFFAOYSA-N 0.000 description 27
• 150000003839 salts Chemical class 0.000 description 27
• ZKHQWZAMYRWXGA-UHFFFAOYSA-N Adenosine triphosphate Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)C(O)C1O ZKHQWZAMYRWXGA-UHFFFAOYSA-N 0.000 description 26
• 238000003556 assay Methods 0.000 description 25
• 210000004027 cell Anatomy 0.000 description 25
• 239000000243 solution Substances 0.000 description 25
• OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 24
• 201000011510 cancer Diseases 0.000 description 23
• 239000003795 chemical substances by application Substances 0.000 description 21
• XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 21
• AZQDLBJZOAHSAZ-UHFFFAOYSA-N 1,7-dihydrodiazepin-6-one Chemical compound O=C1CNN=CC=C1 AZQDLBJZOAHSAZ-UHFFFAOYSA-N 0.000 description 19
• YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 19
• 239000003909 protein kinase inhibitor Substances 0.000 description 18
• 208000035475 disorder Diseases 0.000 description 17
• 230000001404 mediated effect Effects 0.000 description 17
• 239000007787 solid Substances 0.000 description 17
• RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 16
• 108091000080 Phosphotransferase Proteins 0.000 description 16
• UEZVMMHDMIWARA-UHFFFAOYSA-N Metaphosphoric acid Chemical compound OP(=O)=O UEZVMMHDMIWARA-UHFFFAOYSA-N 0.000 description 15
• KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 15
• 238000006243 chemical reaction Methods 0.000 description 15
• 239000002552 dosage form Substances 0.000 description 15
• 102000020233 phosphotransferase Human genes 0.000 description 15
• LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 14
• 239000007788 liquid Substances 0.000 description 14
• VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 13
• 229940045988 antineoplastic drug protein kinase inhibitors Drugs 0.000 description 13
• 239000002585 base Substances 0.000 description 13
• 235000019439 ethyl acetate Nutrition 0.000 description 13
• DLFVBJFMPXGRIB-UHFFFAOYSA-N Acetamide Chemical compound CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 description 12
• 238000004458 analytical method Methods 0.000 description 12
• 238000006880 cross-coupling reaction Methods 0.000 description 12
• 230000005764 inhibitory process Effects 0.000 description 12
• 230000002062 proliferating effect Effects 0.000 description 12
• 239000011541 reaction mixture Substances 0.000 description 12
• 238000006467 substitution reaction Methods 0.000 description 12
• 238000012360 testing method Methods 0.000 description 12
• GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 11
• ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 11
• 208000009956 adenocarcinoma Diseases 0.000 description 11
• 125000004122 cyclic group Chemical group 0.000 description 11
• 239000003921 oil Substances 0.000 description 11
• 235000019198 oils Nutrition 0.000 description 11
• 239000000725 suspension Substances 0.000 description 11
• 238000011282 treatment Methods 0.000 description 11
• WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 10
• 208000029742 colonic neoplasm Diseases 0.000 description 10
• 208000015122 neurodegenerative disease Diseases 0.000 description 10
• 238000002360 preparation method Methods 0.000 description 10
• 238000013207 serial dilution Methods 0.000 description 10
• 239000011550 stock solution Substances 0.000 description 10
• 0 *C(*)(C(*)(*)N(*)c(nc(N*)nc1)c1N1*)C1=O Chemical compound *C(*)(C(*)(*)N(*)c(nc(N*)nc1)c1N1*)C1=O 0.000 description 9
• CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 9
• WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 9
• 201000009030 Carcinoma Diseases 0.000 description 9
• 206010025323 Lymphomas Diseases 0.000 description 9
• 229910019142 PO4 Inorganic materials 0.000 description 9
• DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 9
• YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 9
• 239000003054 catalyst Substances 0.000 description 9
• 235000021317 phosphate Nutrition 0.000 description 9
• 125000006239 protecting group Chemical group 0.000 description 9
• 230000002285 radioactive effect Effects 0.000 description 9
• IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical group N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 8
• 101150011368 Plk2 gene Proteins 0.000 description 8
• 150000001412 amines Chemical class 0.000 description 8
• 125000006367 bivalent amino carbonyl group Chemical group [H]N([*:1])C([*:2])=O 0.000 description 8
• 150000001721 carbon Chemical group 0.000 description 8
• 238000000576 coating method Methods 0.000 description 8
• 238000005859 coupling reaction Methods 0.000 description 8
• 229940079593 drug Drugs 0.000 description 8
• 208000032839 leukemia Diseases 0.000 description 8
• HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 8
• 238000004519 manufacturing process Methods 0.000 description 8
• 230000004770 neurodegeneration Effects 0.000 description 8
• 229920001223 polyethylene glycol Polymers 0.000 description 8
• 125000001424 substituent group Chemical group 0.000 description 8
• 239000000758 substrate Substances 0.000 description 8
• 210000004881 tumor cell Anatomy 0.000 description 8
• YQLWINMNFVBXQV-UHFFFAOYSA-N 4-[(9-cyclopentyl-5-methyl-6-oxo-7,8-dihydropyrimido[4,5-b][1,4]diazepin-2-yl)amino]-3-methoxybenzoic acid Chemical compound COC1=CC(C(O)=O)=CC=C1NC1=NC=C(N(C)C(=O)CCN2C3CCCC3)C2=N1 YQLWINMNFVBXQV-UHFFFAOYSA-N 0.000 description 7
• QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 7
• 206010009944 Colon cancer Diseases 0.000 description 7
• JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 7
• 206010039491 Sarcoma Diseases 0.000 description 7
• FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 7
• 239000002253 acid Substances 0.000 description 7
• 239000002775 capsule Substances 0.000 description 7
• 230000022131 cell cycle Effects 0.000 description 7
• 230000003463 hyperproliferative effect Effects 0.000 description 7
• 229940043355 kinase inhibitor Drugs 0.000 description 7
• 239000008101 lactose Substances 0.000 description 7
• 239000000546 pharmaceutical excipient Substances 0.000 description 7
• 101150067958 plk-3 gene Proteins 0.000 description 7
• 239000000843 powder Substances 0.000 description 7
• 230000008569 process Effects 0.000 description 7
• 239000003826 tablet Substances 0.000 description 7
• PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 6
• 208000024827 Alzheimer disease Diseases 0.000 description 6
• KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 6
• 101150005816 PLK4 gene Proteins 0.000 description 6
• 238000010521 absorption reaction Methods 0.000 description 6
• 239000004480 active ingredient Substances 0.000 description 6
• 125000002619 bicyclic group Chemical group 0.000 description 6
• 239000000969 carrier Substances 0.000 description 6
• 229940125898 compound 5 Drugs 0.000 description 6
• 239000003085 diluting agent Substances 0.000 description 6
• 235000019441 ethanol Nutrition 0.000 description 6
• 125000000524 functional group Chemical group 0.000 description 6
• 238000010348 incorporation Methods 0.000 description 6
• 230000011278 mitosis Effects 0.000 description 6
• 239000010452 phosphate Substances 0.000 description 6
• NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 6
• 239000001993 wax Substances 0.000 description 6
• 125000006714 (C3-C10) heterocyclyl group Chemical group 0.000 description 5
• JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 5
• OHKJKVBYFIWYPT-UHFFFAOYSA-N 4-[(9-cyclopentyl-5,7,7-trimethyl-6-oxo-8h-pyrimido[4,5-b][1,4]diazepin-2-yl)sulfanyl]-n-methylbenzamide Chemical compound C1=CC(C(=O)NC)=CC=C1SC1=NC=C(N(C)C(=O)C(C)(C)CN2C3CCCC3)C2=N1 OHKJKVBYFIWYPT-UHFFFAOYSA-N 0.000 description 5
• GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 5
• 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 description 5
• 208000010833 Chronic myeloid leukaemia Diseases 0.000 description 5
• VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 5
• 241001465754 Metazoa Species 0.000 description 5
• 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 description 5
• PXHVJJICTQNCMI-UHFFFAOYSA-N Nickel Chemical compound [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 description 5
• 101150003085 Pdcl gene Proteins 0.000 description 5
• 208000015634 Rectal Neoplasms Diseases 0.000 description 5
• NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 5
• 229910052784 alkaline earth metal Inorganic materials 0.000 description 5
• 239000012131 assay buffer Substances 0.000 description 5
• 230000033228 biological regulation Effects 0.000 description 5
• 150000001642 boronic acid derivatives Chemical class 0.000 description 5
• 239000006172 buffering agent Substances 0.000 description 5
• 235000014113 dietary fatty acids Nutrition 0.000 description 5
• 238000001035 drying Methods 0.000 description 5
• 230000008030 elimination Effects 0.000 description 5
• 238000003379 elimination reaction Methods 0.000 description 5
• 239000003995 emulsifying agent Substances 0.000 description 5
• 150000002148 esters Chemical class 0.000 description 5
• 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 5
• 239000000194 fatty acid Substances 0.000 description 5
• 229930195729 fatty acid Natural products 0.000 description 5
• 210000001035 gastrointestinal tract Anatomy 0.000 description 5
• QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 5
• 231100000252 nontoxic Toxicity 0.000 description 5
• 230000003000 nontoxic effect Effects 0.000 description 5
• 229910052763 palladium Inorganic materials 0.000 description 5
• 229940080469 phosphocellulose Drugs 0.000 description 5
• 239000006187 pill Substances 0.000 description 5
• 229920000642 polymer Polymers 0.000 description 5
• 239000003755 preservative agent Substances 0.000 description 5
• 108090000765 processed proteins & peptides Proteins 0.000 description 5
• 108090000623 proteins and genes Proteins 0.000 description 5
• 210000000664 rectum Anatomy 0.000 description 5
• 230000002829 reductive effect Effects 0.000 description 5
• 238000000611 regression analysis Methods 0.000 description 5
• 239000007909 solid dosage form Substances 0.000 description 5
• 206010041823 squamous cell carcinoma Diseases 0.000 description 5
• 239000011593 sulfur Chemical group 0.000 description 5
• 230000000699 topical effect Effects 0.000 description 5
• PKVNVXXWANAAFP-UHFFFAOYSA-N 1,7-dihydro-1,4-diazepin-6-one Chemical compound O=C1CNC=CN=C1 PKVNVXXWANAAFP-UHFFFAOYSA-N 0.000 description 4
• VMCZIPPMGFWHDE-UHFFFAOYSA-N 2-chloro-9-cyclopentyl-5,7,7-trimethyl-8h-pyrimido[4,5-b][1,4]diazepin-6-one Chemical compound C1C(C)(C)C(=O)N(C)C2=CN=C(Cl)N=C2N1C1CCCC1 VMCZIPPMGFWHDE-UHFFFAOYSA-N 0.000 description 4
• DVVYMNCRKNFABW-UHFFFAOYSA-N 2-chloro-9-cyclopentyl-5-methyl-7,8-dihydropyrimido[4,5-b][1,4]diazepin-6-one Chemical compound C1CC(=O)N(C)C2=CN=C(Cl)N=C2N1C1CCCC1 DVVYMNCRKNFABW-UHFFFAOYSA-N 0.000 description 4
• PSNIEFLRLSDKDM-UHFFFAOYSA-N 4-[(9-benzyl-5,7,7-trimethyl-6-oxo-8h-pyrimido[4,5-b][1,4]diazepin-2-yl)amino]-3-methoxy-n-methylbenzamide Chemical compound COC1=CC(C(=O)NC)=CC=C1NC1=NC=C(N(C)C(=O)C(C)(C)CN2CC=3C=CC=CC=3)C2=N1 PSNIEFLRLSDKDM-UHFFFAOYSA-N 0.000 description 4
• DYOORDNJHHVFBL-INIZCTEOSA-N 4-[(9-cyclopentyl-5,7,7-trimethyl-6-oxo-8h-pyrimido[4,5-b][1,4]diazepin-2-yl)amino]-n-[(2s)-2-hydroxypropyl]-3-methoxybenzamide Chemical compound COC1=CC(C(=O)NC[C@H](C)O)=CC=C1NC1=NC=C(N(C)C(=O)C(C)(C)CN2C3CCCC3)C2=N1 DYOORDNJHHVFBL-INIZCTEOSA-N 0.000 description 4
• NGJOECBMVLIXBO-UHFFFAOYSA-N 4-[(9-cyclopentyl-5,7,7-trimethyl-6-oxo-8h-pyrimido[4,5-b][1,4]diazepin-2-yl)amino]-n-[1-(hydroxymethyl)cyclopentyl]-3-methoxybenzamide Chemical compound COC1=CC(C(=O)NC2(CO)CCCC2)=CC=C1NC(N=C12)=NC=C1N(C)C(=O)C(C)(C)CN2C1CCCC1 NGJOECBMVLIXBO-UHFFFAOYSA-N 0.000 description 4
• JIWWRNRQEPHLEC-UHFFFAOYSA-N 4-[(9-cyclopentyl-5,7,7-trimethyl-6-oxo-8h-pyrimido[4,5-b][1,4]diazepin-2-yl)amino]-n-cyclopropyl-3-methoxybenzamide Chemical compound COC1=CC(C(=O)NC2CC2)=CC=C1NC(N=C12)=NC=C1N(C)C(=O)C(C)(C)CN2C1CCCC1 JIWWRNRQEPHLEC-UHFFFAOYSA-N 0.000 description 4
• CIYVLYLVNZPFIY-UHFFFAOYSA-N 4-[(9-cyclopentyl-7,7-dimethyl-2,4,5,9,11,13-hexazatricyclo[8.4.0.02,6]tetradeca-1(14),3,5,10,12-pentaen-12-yl)amino]-3-methoxy-N-methylbenzamide Chemical compound COC1=CC(C(=O)NC)=CC=C1NC1=NC=C2N3C=NN=C3C(C)(C)CN(C3CCCC3)C2=N1 CIYVLYLVNZPFIY-UHFFFAOYSA-N 0.000 description 4
• 208000023275 Autoimmune disease Diseases 0.000 description 4
• PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 4
• DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 4
• 239000007995 HEPES buffer Substances 0.000 description 4
• 241000282412 Homo Species 0.000 description 4
• 108010050904 Interferons Proteins 0.000 description 4
• 102000014150 Interferons Human genes 0.000 description 4
• 206010024612 Lipoma Diseases 0.000 description 4
• CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 4
• 206010033128 Ovarian cancer Diseases 0.000 description 4
• 206010035226 Plasma cell myeloma Diseases 0.000 description 4
• 239000002202 Polyethylene glycol Substances 0.000 description 4
• 229920002472 Starch Polymers 0.000 description 4
• 229930006000 Sucrose Natural products 0.000 description 4
• CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 4
• 208000024770 Thyroid neoplasm Diseases 0.000 description 4
• 235000010443 alginic acid Nutrition 0.000 description 4
• 229920000615 alginic acid Polymers 0.000 description 4
• METKIMKYRPQLGS-UHFFFAOYSA-N atenolol Chemical compound CC(C)NCC(O)COC1=CC=C(CC(N)=O)C=C1 METKIMKYRPQLGS-UHFFFAOYSA-N 0.000 description 4
• 239000008280 blood Substances 0.000 description 4
• 230000037396 body weight Effects 0.000 description 4
• 229910002091 carbon monoxide Inorganic materials 0.000 description 4
• 125000006297 carbonyl amino group Chemical group [H]N([*:2])C([*:1])=O 0.000 description 4
• 239000001768 carboxy methyl cellulose Substances 0.000 description 4
• 210000001072 colon Anatomy 0.000 description 4
• 239000003246 corticosteroid Substances 0.000 description 4
• 229960001334 corticosteroids Drugs 0.000 description 4
• 238000011161 development Methods 0.000 description 4
• 239000000284 extract Substances 0.000 description 4
• 150000004665 fatty acids Chemical class 0.000 description 4
• 239000010685 fatty oil Substances 0.000 description 4
• OAKJQQAXSVQMHS-UHFFFAOYSA-N hydrazine group Chemical group NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 description 4
• 239000003701 inert diluent Substances 0.000 description 4
• 208000027866 inflammatory disease Diseases 0.000 description 4
• 229940047124 interferons Drugs 0.000 description 4
• 239000000543 intermediate Substances 0.000 description 4
• 239000000314 lubricant Substances 0.000 description 4
• 235000019359 magnesium stearate Nutrition 0.000 description 4
• 229910052751 metal Inorganic materials 0.000 description 4
• 239000002184 metal Substances 0.000 description 4
• 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 4
• 210000000214 mouth Anatomy 0.000 description 4
• VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical class CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 4
• 239000002674 ointment Substances 0.000 description 4
• BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 4
• 230000035755 proliferation Effects 0.000 description 4
• 235000018102 proteins Nutrition 0.000 description 4
• 102000004169 proteins and genes Human genes 0.000 description 4
• 235000019698 starch Nutrition 0.000 description 4
• 239000005720 sucrose Substances 0.000 description 4
• 239000000375 suspending agent Substances 0.000 description 4
• 238000003786 synthesis reaction Methods 0.000 description 4
• YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 4
• 229940124597 therapeutic agent Drugs 0.000 description 4
• 210000001519 tissue Anatomy 0.000 description 4
• 230000035899 viability Effects 0.000 description 4
• 239000003643 water by type Substances 0.000 description 4
• DDHPILNVQNHKAZ-UHFFFAOYSA-N 2-(benzylamino)-9-cyclopentyl-5,7,7-trimethyl-8h-pyrimido[4,5-b][1,4]diazepin-6-one Chemical compound N1=C2N(C3CCCC3)CC(C)(C)C(=O)N(C)C2=CN=C1NCC1=CC=CC=C1 DDHPILNVQNHKAZ-UHFFFAOYSA-N 0.000 description 3
• MZFIBQFSRVWAAB-UHFFFAOYSA-N 2-chloro-5,7,7-trimethyl-8,9-dihydropyrimido[4,5-b][1,4]diazepin-6-one Chemical compound N1CC(C)(C)C(=O)N(C)C2=CN=C(Cl)N=C21 MZFIBQFSRVWAAB-UHFFFAOYSA-N 0.000 description 3
• RSRPLYCCLBLNTJ-UHFFFAOYSA-N 2-chloro-9-cyclopentyl-7,8-dihydro-5h-pyrimido[4,5-b][1,4]diazepin-6-one Chemical compound C12=NC(Cl)=NC=C2NC(=O)CCN1C1CCCC1 RSRPLYCCLBLNTJ-UHFFFAOYSA-N 0.000 description 3
• DVLFYONBTKHTER-UHFFFAOYSA-N 3-(N-morpholino)propanesulfonic acid Chemical compound OS(=O)(=O)CCCN1CCOCC1 DVLFYONBTKHTER-UHFFFAOYSA-N 0.000 description 3
• PGMLKIGFULHWHO-UHFFFAOYSA-N 3-methoxy-n-methyl-4-[(5,7,7-trimethyl-6-oxo-9-propan-2-yl-8h-pyrimido[4,5-b][1,4]diazepin-2-yl)amino]benzamide Chemical compound COC1=CC(C(=O)NC)=CC=C1NC1=NC=C(N(C)C(=O)C(C)(C)CN2C(C)C)C2=N1 PGMLKIGFULHWHO-UHFFFAOYSA-N 0.000 description 3
• GJYJEKDFMSTNJO-UHFFFAOYSA-N 3-methoxy-n-methyl-4-[[5,7,7-trimethyl-9-(oxan-4-yl)-6-oxo-8h-pyrimido[4,5-b][1,4]diazepin-2-yl]amino]benzamide Chemical compound COC1=CC(C(=O)NC)=CC=C1NC1=NC=C(N(C)C(=O)C(C)(C)CN2C3CCOCC3)C2=N1 GJYJEKDFMSTNJO-UHFFFAOYSA-N 0.000 description 3
• LVCGCBHNTZDYOJ-UHFFFAOYSA-N 4-[(9-cyclopentyl-5,7,7-trimethyl-6-oxo-8h-pyrimido[4,5-b][1,4]diazepin-2-yl)amino]-3-methoxy-n,n-dimethylbenzamide Chemical compound COC1=CC(C(=O)N(C)C)=CC=C1NC1=NC=C(N(C)C(=O)C(C)(C)CN2C3CCCC3)C2=N1 LVCGCBHNTZDYOJ-UHFFFAOYSA-N 0.000 description 3
• IDXPDDLSXYFBLP-UHFFFAOYSA-N 4-[(9-cyclopentyl-5,7,7-trimethyl-6-oxo-8h-pyrimido[4,5-b][1,4]diazepin-2-yl)amino]-3-methoxy-n-(1-propan-2-ylazetidin-3-yl)benzamide Chemical compound COC1=CC(C(=O)NC2CN(C2)C(C)C)=CC=C1NC(N=C12)=NC=C1N(C)C(=O)C(C)(C)CN2C1CCCC1 IDXPDDLSXYFBLP-UHFFFAOYSA-N 0.000 description 3
• NHTJBDCHGVHNHO-UHFFFAOYSA-N 4-[(9-cyclopentyl-5,7,7-trimethyl-6-oxo-8h-pyrimido[4,5-b][1,4]diazepin-2-yl)amino]-3-methoxy-n-methylbenzamide Chemical compound COC1=CC(C(=O)NC)=CC=C1NC1=NC=C(N(C)C(=O)C(C)(C)CN2C3CCCC3)C2=N1 NHTJBDCHGVHNHO-UHFFFAOYSA-N 0.000 description 3
• RVXHSEQOUQIWSR-UHFFFAOYSA-N 4-[(9-cyclopentyl-5,7,7-trimethyl-6-oxo-8h-pyrimido[4,5-b][1,4]diazepin-2-yl)amino]-n-(1-hydroxy-2-methylpropan-2-yl)-3-methoxybenzamide Chemical compound COC1=CC(C(=O)NC(C)(C)CO)=CC=C1NC1=NC=C(N(C)C(=O)C(C)(C)CN2C3CCCC3)C2=N1 RVXHSEQOUQIWSR-UHFFFAOYSA-N 0.000 description 3
• PDELTZDOFWVRRS-UHFFFAOYSA-N 4-[(9-cyclopentyl-5,7,7-trimethyl-6-oxo-8h-pyrimido[4,5-b][1,4]diazepin-2-yl)amino]-n-(2-hydroxyethyl)-3-methoxybenzamide Chemical compound COC1=CC(C(=O)NCCO)=CC=C1NC1=NC=C(N(C)C(=O)C(C)(C)CN2C3CCCC3)C2=N1 PDELTZDOFWVRRS-UHFFFAOYSA-N 0.000 description 3
• LAMHXNREPNMLAE-UHFFFAOYSA-N 4-[(9-cyclopentyl-5,7,7-trimethyl-6-oxo-8h-pyrimido[4,5-b][1,4]diazepin-2-yl)amino]-n-(3-hydroxy-2,2-dimethylpropyl)-3-methoxybenzamide Chemical compound COC1=CC(C(=O)NCC(C)(C)CO)=CC=C1NC1=NC=C(N(C)C(=O)C(C)(C)CN2C3CCCC3)C2=N1 LAMHXNREPNMLAE-UHFFFAOYSA-N 0.000 description 3
• VLDUQQDPFFDFFL-NFBKMPQASA-N 4-[(9-cyclopentyl-5,7,7-trimethyl-6-oxo-8h-pyrimido[4,5-b][1,4]diazepin-2-yl)amino]-n-[(1r,2r)-2-hydroxycyclohexyl]-3-methoxybenzamide Chemical compound COC1=CC(C(=O)N[C@H]2[C@@H](CCCC2)O)=CC=C1NC(N=C12)=NC=C1N(C)C(=O)C(C)(C)CN2C1CCCC1 VLDUQQDPFFDFFL-NFBKMPQASA-N 0.000 description 3
• BOMMEBIRSJFCKT-UHFFFAOYSA-N 4-[(9-cyclopentyl-5,7,7-trimethyl-6-oxo-8h-pyrimido[4,5-b][1,4]diazepin-2-yl)amino]-n-[1-(cyclopropylmethyl)azetidin-3-yl]-3-methoxybenzamide Chemical compound COC1=CC(C(=O)NC2CN(CC3CC3)C2)=CC=C1NC(N=C12)=NC=C1N(C)C(=O)C(C)(C)CN2C1CCCC1 BOMMEBIRSJFCKT-UHFFFAOYSA-N 0.000 description 3
• OBQFUKADXFMQBU-UHFFFAOYSA-N 4-[(9-cyclopentyl-5,7,7-trimethyl-6-oxo-8h-pyrimido[4,5-b][1,4]diazepin-2-yl)amino]-n-methyl-3-propan-2-yloxybenzamide Chemical compound CC(C)OC1=CC(C(=O)NC)=CC=C1NC1=NC=C(N(C)C(=O)C(C)(C)CN2C3CCCC3)C2=N1 OBQFUKADXFMQBU-UHFFFAOYSA-N 0.000 description 3
• YPEQMMVXFAIRAL-UHFFFAOYSA-N 4-[(9-cyclopentyl-5-methyl-6-oxospiro[8h-pyrimido[4,5-b][1,4]diazepine-7,1'-cyclopropane]-2-yl)amino]-3-methoxy-n-propan-2-ylbenzamide Chemical compound COC1=CC(C(=O)NC(C)C)=CC=C1NC1=NC=C(N(C)C(=O)C2(CC2)CN2C3CCCC3)C2=N1 YPEQMMVXFAIRAL-UHFFFAOYSA-N 0.000 description 3
• LTTKRYZWUXEXIF-UHFFFAOYSA-N 4-[(9-cyclopentyl-5-methyl-6-oxospiro[8h-pyrimido[4,5-b][1,4]diazepine-7,1'-cyclopropane]-2-yl)amino]-n-(1-hydroxy-2-methylpropan-2-yl)-3-methoxybenzamide Chemical compound COC1=CC(C(=O)NC(C)(C)CO)=CC=C1NC1=NC=C(N(C)C(=O)C2(CC2)CN2C3CCCC3)C2=N1 LTTKRYZWUXEXIF-UHFFFAOYSA-N 0.000 description 3
• DVGIMOYXCDUTFN-UHFFFAOYSA-N 4-[(9-cyclopentyl-5-methyl-6-oxospiro[8h-pyrimido[4,5-b][1,4]diazepine-7,1'-cyclopropane]-2-yl)amino]-n-(3,3-difluorocyclobutyl)-3-methoxybenzamide Chemical compound COC1=CC(C(=O)NC2CC(F)(F)C2)=CC=C1NC(N=C1N(C2CCCC2)C2)=NC=C1N(C)C(=O)C12CC1 DVGIMOYXCDUTFN-UHFFFAOYSA-N 0.000 description 3
• YLHDIJWAOXSOPZ-UHFFFAOYSA-N 9-cyclopentyl-2-(4-imidazol-1-ylanilino)-5,7,7-trimethyl-8h-pyrimido[4,5-b][1,4]diazepin-6-one Chemical compound N1=C2N(C3CCCC3)CC(C)(C)C(=O)N(C)C2=CN=C1NC(C=C1)=CC=C1N1C=CN=C1 YLHDIJWAOXSOPZ-UHFFFAOYSA-N 0.000 description 3
• QWBAETPQSDDDRX-LJQANCHMSA-N 9-cyclopentyl-2-[[(1r)-2,3-dihydro-1h-inden-1-yl]amino]-5,7,7-trimethyl-8h-pyrimido[4,5-b][1,4]diazepin-6-one Chemical compound C1C(C)(C)C(=O)N(C)C2=CN=C(N[C@H]3C4=CC=CC=C4CC3)N=C2N1C1CCCC1 QWBAETPQSDDDRX-LJQANCHMSA-N 0.000 description 3
• LELDHRXSWFADMC-UHFFFAOYSA-N 9-cyclopentyl-5,7,7-trimethyl-2-[3-(4-methylpiperazine-1-carbonyl)anilino]-8h-pyrimido[4,5-b][1,4]diazepin-6-one Chemical compound C1CN(C)CCN1C(=O)C1=CC=CC(NC=2N=C3N(C4CCCC4)CC(C)(C)C(=O)N(C)C3=CN=2)=C1 LELDHRXSWFADMC-UHFFFAOYSA-N 0.000 description 3
• SAHXMYJTBCVCQM-UHFFFAOYSA-N 9-cyclopentyl-5,7,7-trimethyl-2-[4-(4-methylpiperazin-1-yl)anilino]-8h-pyrimido[4,5-b][1,4]diazepin-6-one Chemical compound C1CN(C)CCN1C(C=C1)=CC=C1NC1=NC=C(N(C)C(=O)C(C)(C)CN2C3CCCC3)C2=N1 SAHXMYJTBCVCQM-UHFFFAOYSA-N 0.000 description 3
• WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 3
• 208000020084 Bone disease Diseases 0.000 description 3
• 208000003174 Brain Neoplasms Diseases 0.000 description 3
• 206010006187 Breast cancer Diseases 0.000 description 3
• 208000026310 Breast neoplasm Diseases 0.000 description 3
• 239000004215 Carbon black (E152) Substances 0.000 description 3
• 208000024172 Cardiovascular disease Diseases 0.000 description 3
• 102100025064 Cellular tumor antigen p53 Human genes 0.000 description 3
• 229920002261 Corn starch Polymers 0.000 description 3
• CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 3
• 102000004190 Enzymes Human genes 0.000 description 3
• 108090000790 Enzymes Proteins 0.000 description 3
• 201000008808 Fibrosarcoma Diseases 0.000 description 3
• WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
• 206010020751 Hypersensitivity Diseases 0.000 description 3
• 102000000589 Interleukin-1 Human genes 0.000 description 3
• 108010002352 Interleukin-1 Proteins 0.000 description 3
• 206010058467 Lung neoplasm malignant Diseases 0.000 description 3
• 238000006411 Negishi coupling reaction Methods 0.000 description 3
• 208000012902 Nervous system disease Diseases 0.000 description 3
• 208000025966 Neurological disease Diseases 0.000 description 3
• 206010061535 Ovarian neoplasm Diseases 0.000 description 3
• MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
• OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical group [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 3
• OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 3
• 108020004459 Small interfering RNA Proteins 0.000 description 3
• KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 3
• HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
• 238000006069 Suzuki reaction reaction Methods 0.000 description 3
• 206010043276 Teratoma Diseases 0.000 description 3
• 229960000583 acetic acid Drugs 0.000 description 3
• 230000004913 activation Effects 0.000 description 3
• 125000003545 alkoxy group Chemical group 0.000 description 3
• 230000007815 allergy Effects 0.000 description 3
• 208000006673 asthma Diseases 0.000 description 3
• WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 3
• 230000015572 biosynthetic process Effects 0.000 description 3
• 210000004369 blood Anatomy 0.000 description 3
• 125000005620 boronic acid group Chemical class 0.000 description 3
• 235000019437 butane-1,3-diol Nutrition 0.000 description 3
• 239000000460 chlorine Substances 0.000 description 3
• KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
• 239000003240 coconut oil Substances 0.000 description 3
• 235000019864 coconut oil Nutrition 0.000 description 3
• 238000004440 column chromatography Methods 0.000 description 3
• 239000008120 corn starch Substances 0.000 description 3
• 239000006071 cream Substances 0.000 description 3
• 229960004397 cyclophosphamide Drugs 0.000 description 3
• 230000003111 delayed effect Effects 0.000 description 3
• 239000002270 dispersing agent Substances 0.000 description 3
• 239000006185 dispersion Substances 0.000 description 3
• 239000000839 emulsion Substances 0.000 description 3
• 239000003623 enhancer Substances 0.000 description 3
• 239000002702 enteric coating Substances 0.000 description 3
• 238000009505 enteric coating Methods 0.000 description 3
• 230000002255 enzymatic effect Effects 0.000 description 3
• 229940088598 enzyme Drugs 0.000 description 3
• 206010016629 fibroma Diseases 0.000 description 3
• 239000000945 filler Substances 0.000 description 3
• 238000007429 general method Methods 0.000 description 3
• 239000008103 glucose Substances 0.000 description 3
• 125000005456 glyceride group Chemical group 0.000 description 3
• 239000008187 granular material Substances 0.000 description 3
• 201000011066 hemangioma Diseases 0.000 description 3
• 230000003054 hormonal effect Effects 0.000 description 3
• 229930195733 hydrocarbon Natural products 0.000 description 3
• 238000000338 in vitro Methods 0.000 description 3
• 238000011065 in-situ storage Methods 0.000 description 3
• 239000007924 injection Substances 0.000 description 3
• 238000002347 injection Methods 0.000 description 3
• 230000003834 intracellular effect Effects 0.000 description 3
• 238000002955 isolation Methods 0.000 description 3
• 150000003951 lactams Chemical group 0.000 description 3
• 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 3
• 201000005202 lung cancer Diseases 0.000 description 3
• 208000020816 lung neoplasm Diseases 0.000 description 3
• 230000014759 maintenance of location Effects 0.000 description 3
• 201000001441 melanoma Diseases 0.000 description 3
• 208000030159 metabolic disease Diseases 0.000 description 3
• 150000007522 mineralic acids Chemical class 0.000 description 3
• 230000003020 moisturizing effect Effects 0.000 description 3
• 230000000926 neurological effect Effects 0.000 description 3
• 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 3
• 239000004006 olive oil Substances 0.000 description 3
• 210000000056 organ Anatomy 0.000 description 3
• 150000007524 organic acids Chemical class 0.000 description 3
• 235000019271 petrolatum Nutrition 0.000 description 3
• 210000003800 pharynx Anatomy 0.000 description 3
• 239000012071 phase Substances 0.000 description 3
• 150000003013 phosphoric acid derivatives Chemical class 0.000 description 3
• 229910052698 phosphorus Chemical group 0.000 description 3
• 239000011574 phosphorus Chemical group 0.000 description 3
• 239000002504 physiological saline solution Substances 0.000 description 3
• 229920001451 polypropylene glycol Polymers 0.000 description 3
• 239000002243 precursor Substances 0.000 description 3
• 238000002953 preparative HPLC Methods 0.000 description 3
• 229940002612 prodrug Drugs 0.000 description 3
• 239000000651 prodrug Substances 0.000 description 3
• 229960004063 propylene glycol Drugs 0.000 description 3
• 230000004044 response Effects 0.000 description 3
• 230000002441 reversible effect Effects 0.000 description 3
• 230000008054 signal transmission Effects 0.000 description 3
• 239000000741 silica gel Substances 0.000 description 3
• 229910002027 silica gel Inorganic materials 0.000 description 3
• 239000012312 sodium hydride Substances 0.000 description 3
• 229910000104 sodium hydride Inorganic materials 0.000 description 3
• 239000008247 solid mixture Substances 0.000 description 3
• 239000007858 starting material Substances 0.000 description 3
• 239000000829 suppository Substances 0.000 description 3
• 230000004083 survival effect Effects 0.000 description 3
• 239000003765 sweetening agent Substances 0.000 description 3
• UEOFOEBXAFORGA-UHFFFAOYSA-N tert-butyl 4-[4-[(9-cyclopentyl-5-methyl-6-oxo-7,8-dihydropyrimido[4,5-b][1,4]diazepin-2-yl)amino]-3-methoxybenzoyl]piperazine-1-carboxylate Chemical compound COC1=CC(C(=O)N2CCN(CC2)C(=O)OC(C)(C)C)=CC=C1NC(N=C12)=NC=C1N(C)C(=O)CCN2C1CCCC1 UEOFOEBXAFORGA-UHFFFAOYSA-N 0.000 description 3
• 201000002510 thyroid cancer Diseases 0.000 description 3
• JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical class CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 3
• NQPDZGIKBAWPEJ-UHFFFAOYSA-N valeric acid Chemical class CCCCC(O)=O NQPDZGIKBAWPEJ-UHFFFAOYSA-N 0.000 description 3
• WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 2
• KZPYGQFFRCFCPP-UHFFFAOYSA-N 1,1'-bis(diphenylphosphino)ferrocene Chemical compound [Fe+2].C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1 KZPYGQFFRCFCPP-UHFFFAOYSA-N 0.000 description 2
• RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 2
• HTSZQUVMTBELGW-UHFFFAOYSA-N 1-(1-hydroxypropan-2-yl)-5-methoxycyclohexa-2,4-diene-1-carboxamide Chemical compound COC1=CC=CC(C(N)=O)(C(C)CO)C1 HTSZQUVMTBELGW-UHFFFAOYSA-N 0.000 description 2
• DNUTZBZXLPWRJG-UHFFFAOYSA-N 1-Piperidine carboxylic acid Chemical compound OC(=O)N1CCCCC1 DNUTZBZXLPWRJG-UHFFFAOYSA-N 0.000 description 2
• ALOCUZOKRULSAA-UHFFFAOYSA-N 1-methylpiperidin-4-amine Chemical compound CN1CCC(N)CC1 ALOCUZOKRULSAA-UHFFFAOYSA-N 0.000 description 2
• VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
• IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 2
• CHHHXKFHOYLYRE-UHFFFAOYSA-M 2,4-Hexadienoic acid, potassium salt (1:1), (2E,4E)- Chemical compound [K+].CC=CC=CC([O-])=O CHHHXKFHOYLYRE-UHFFFAOYSA-M 0.000 description 2
• AXLBOYZNEFYZBG-UHFFFAOYSA-N 2-(1,3-benzothiazol-6-ylamino)-9-cyclopentyl-5,7,7-trimethyl-8h-pyrimido[4,5-b][1,4]diazepin-6-one Chemical compound C1C(C)(C)C(=O)N(C)C2=CN=C(NC=3C=C4SC=NC4=CC=3)N=C2N1C1CCCC1 AXLBOYZNEFYZBG-UHFFFAOYSA-N 0.000 description 2
• DWNGVJVMHQRPCC-UHFFFAOYSA-N 2-(2-methoxyanilino)-5,9-dimethyl-7,8-dihydropyrimido[4,5-b][1,4]diazepin-6-one Chemical compound COC1=CC=CC=C1NC1=NC=C(N(C)C(=O)CCN2C)C2=N1 DWNGVJVMHQRPCC-UHFFFAOYSA-N 0.000 description 2
• MMTCECLUFNHCAD-UHFFFAOYSA-N 2-(3h-benzimidazol-5-ylamino)-9-cyclopentyl-5,7,7-trimethyl-8h-pyrimido[4,5-b][1,4]diazepin-6-one Chemical compound C1C(C)(C)C(=O)N(C)C2=CN=C(NC=3C=C4NC=NC4=CC=3)N=C2N1C1CCCC1 MMTCECLUFNHCAD-UHFFFAOYSA-N 0.000 description 2
• VLBKFTWQMRWFHN-UHFFFAOYSA-N 2-[(1-acetyl-2,3-dihydroindol-5-yl)amino]-9-cyclopentyl-5,7,7-trimethyl-8h-pyrimido[4,5-b][1,4]diazepin-6-one Chemical compound C1C(C)(C)C(=O)N(C)C2=CN=C(NC=3C=C4CCN(C4=CC=3)C(C)=O)N=C2N1C1CCCC1 VLBKFTWQMRWFHN-UHFFFAOYSA-N 0.000 description 2
• JSHFYWCAFVZVPH-UHFFFAOYSA-N 2-[(3-aminoindazol-1-yl)amino]-9-cyclopentyl-5,7,7-trimethyl-8h-pyrimido[4,5-b][1,4]diazepin-6-one Chemical compound C1C(C)(C)C(=O)N(C)C2=CN=C(NN3C4=CC=CC=C4C(N)=N3)N=C2N1C1CCCC1 JSHFYWCAFVZVPH-UHFFFAOYSA-N 0.000 description 2
• BPDHNQGHQFTYME-UHFFFAOYSA-N 2-anilino-9-cyclopentyl-5,7,7-trimethyl-8h-pyrimido[4,5-b][1,4]diazepin-6-one Chemical compound N1=C2N(C3CCCC3)CC(C)(C)C(=O)N(C)C2=CN=C1NC1=CC=CC=C1 BPDHNQGHQFTYME-UHFFFAOYSA-N 0.000 description 2
• 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 description 2
• LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 2
• MKFHVRPIJCVSLK-UHFFFAOYSA-N 3,3,3-trifluoro-2-phenylpropanamide Chemical compound NC(=O)C(C(F)(F)F)C1=CC=CC=C1 MKFHVRPIJCVSLK-UHFFFAOYSA-N 0.000 description 2
• OMEFBSBBCVEENU-UHFFFAOYSA-N 3-[(9-cyclopentyl-5,7,7-trimethyl-6-oxo-8h-pyrimido[4,5-b][1,4]diazepin-2-yl)amino]-n,n-dimethylbenzamide Chemical compound CN(C)C(=O)C1=CC=CC(NC=2N=C3N(C4CCCC4)CC(C)(C)C(=O)N(C)C3=CN=2)=C1 OMEFBSBBCVEENU-UHFFFAOYSA-N 0.000 description 2
• RRCJECRZJOIAPR-UHFFFAOYSA-N 3-[(9-cyclopentyl-5,7,7-trimethyl-6-oxo-8h-pyrimido[4,5-b][1,4]diazepin-2-yl)amino]-n-cyclopropylbenzamide Chemical compound N1=C2N(C3CCCC3)CC(C)(C)C(=O)N(C)C2=CN=C1NC(C=1)=CC=CC=1C(=O)NC1CC1 RRCJECRZJOIAPR-UHFFFAOYSA-N 0.000 description 2
• YCOCARUYLHCMGP-UHFFFAOYSA-N 3-[(9-cyclopentyl-5,7,7-trimethyl-6-oxo-8h-pyrimido[4,5-b][1,4]diazepin-2-yl)amino]-n-methyl-5-(trifluoromethyl)benzamide Chemical compound FC(F)(F)C1=CC(C(=O)NC)=CC(NC=2N=C3N(C4CCCC4)CC(C)(C)C(=O)N(C)C3=CN=2)=C1 YCOCARUYLHCMGP-UHFFFAOYSA-N 0.000 description 2
• HUPOLWRZCJFKIJ-UHFFFAOYSA-N 3-[(9-cyclopentyl-5,7,7-trimethyl-6-oxo-8h-pyrimido[4,5-b][1,4]diazepin-2-yl)amino]-n-methylbenzamide Chemical compound CNC(=O)C1=CC=CC(NC=2N=C3N(C4CCCC4)CC(C)(C)C(=O)N(C)C3=CN=2)=C1 HUPOLWRZCJFKIJ-UHFFFAOYSA-N 0.000 description 2
• AICPNZWOCKKNCH-UHFFFAOYSA-N 3-methoxy-n-methyl-4-[(5,7,7-trimethyl-6-oxo-9-phenyl-8h-pyrimido[4,5-b][1,4]diazepin-2-yl)amino]benzamide Chemical compound COC1=CC(C(=O)NC)=CC=C1NC1=NC=C(N(C)C(=O)C(C)(C)CN2C=3C=CC=CC=3)C2=N1 AICPNZWOCKKNCH-UHFFFAOYSA-N 0.000 description 2
• JSGWYFSBRVDXKM-UHFFFAOYSA-N 3-methoxy-n-methyl-4-[[5,7,7-trimethyl-6-oxo-9-(2,2,3,3,3-pentafluoropropyl)-8h-pyrimido[4,5-b][1,4]diazepin-2-yl]amino]benzamide Chemical compound COC1=CC(C(=O)NC)=CC=C1NC1=NC=C(N(C)C(=O)C(C)(C)CN2CC(F)(F)C(F)(F)F)C2=N1 JSGWYFSBRVDXKM-UHFFFAOYSA-N 0.000 description 2
• MIDLUWHJXGZTHE-OAHLLOKOSA-N 3-methoxy-n-methyl-4-[[5,7,7-trimethyl-6-oxo-9-[(3r)-oxolan-3-yl]-8h-pyrimido[4,5-b][1,4]diazepin-2-yl]amino]benzamide Chemical compound COC1=CC(C(=O)NC)=CC=C1NC1=NC=C(N(C)C(=O)C(C)(C)CN2[C@H]3COCC3)C2=N1 MIDLUWHJXGZTHE-OAHLLOKOSA-N 0.000 description 2
• SJNFUHUYRNXMRE-OAHLLOKOSA-N 3-methoxy-n-methyl-4-[[5,7,7-trimethyl-6-oxo-9-[(3r)-pyrrolidin-3-yl]-8h-pyrimido[4,5-b][1,4]diazepin-2-yl]amino]benzamide Chemical compound COC1=CC(C(=O)NC)=CC=C1NC1=NC=C(N(C)C(=O)C(C)(C)CN2[C@H]3CNCC3)C2=N1 SJNFUHUYRNXMRE-OAHLLOKOSA-N 0.000 description 2
• MIDLUWHJXGZTHE-HNNXBMFYSA-N 3-methoxy-n-methyl-4-[[5,7,7-trimethyl-6-oxo-9-[(3s)-oxolan-3-yl]-8h-pyrimido[4,5-b][1,4]diazepin-2-yl]amino]benzamide Chemical compound COC1=CC(C(=O)NC)=CC=C1NC1=NC=C(N(C)C(=O)C(C)(C)CN2[C@@H]3COCC3)C2=N1 MIDLUWHJXGZTHE-HNNXBMFYSA-N 0.000 description 2
• LQDAXECEYRLVDU-QGZVFWFLSA-N 3-methoxy-n-methyl-4-[[5,7,7-trimethyl-9-[(3r)-1-methylpiperidin-3-yl]-6-oxo-8h-pyrimido[4,5-b][1,4]diazepin-2-yl]amino]benzamide Chemical compound COC1=CC(C(=O)NC)=CC=C1NC1=NC=C(N(C)C(=O)C(C)(C)CN2[C@H]3CN(C)CCC3)C2=N1 LQDAXECEYRLVDU-QGZVFWFLSA-N 0.000 description 2
• ZHRJVJZFEJZNFG-MRXNPFEDSA-N 3-methoxy-n-methyl-4-[[5,7,7-trimethyl-9-[(3r)-1-methylpyrrolidin-3-yl]-6-oxo-8h-pyrimido[4,5-b][1,4]diazepin-2-yl]amino]benzamide Chemical compound COC1=CC(C(=O)NC)=CC=C1NC1=NC=C(N(C)C(=O)C(C)(C)CN2[C@H]3CN(C)CC3)C2=N1 ZHRJVJZFEJZNFG-MRXNPFEDSA-N 0.000 description 2
• 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 description 2
• 125000004575 3-pyrrolidinyl group Chemical group [H]N1C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 2
• OANJCRFUTVVJHQ-UHFFFAOYSA-N 4-[(9-cyclobutyl-5,7,7-trimethyl-6-oxo-8h-pyrimido[4,5-b][1,4]diazepin-2-yl)amino]-3-methoxy-n-methylbenzamide Chemical compound COC1=CC(C(=O)NC)=CC=C1NC1=NC=C(N(C)C(=O)C(C)(C)CN2C3CCC3)C2=N1 OANJCRFUTVVJHQ-UHFFFAOYSA-N 0.000 description 2
• QADDLVHYBPJAKY-UHFFFAOYSA-N 4-[(9-cyclopentyl-5,7,7-trimethyl-6-oxo-8h-pyrimido[4,5-b][1,4]diazepin-2-yl)amino]-3-methoxy-n-(2-phenylethyl)benzamide Chemical compound COC1=CC(C(=O)NCCC=2C=CC=CC=2)=CC=C1NC(N=C12)=NC=C1N(C)C(=O)C(C)(C)CN2C1CCCC1 QADDLVHYBPJAKY-UHFFFAOYSA-N 0.000 description 2
• OPTFUKYPJGOPOM-UHFFFAOYSA-N 4-[(9-cyclopentyl-5,7,7-trimethyl-6-oxo-8h-pyrimido[4,5-b][1,4]diazepin-2-yl)amino]-3-methoxy-n-(oxan-4-yl)benzamide Chemical compound COC1=CC(C(=O)NC2CCOCC2)=CC=C1NC(N=C12)=NC=C1N(C)C(=O)C(C)(C)CN2C1CCCC1 OPTFUKYPJGOPOM-UHFFFAOYSA-N 0.000 description 2
• SXHFJQHQBAKZAM-SFHVURJKSA-N 4-[(9-cyclopentyl-5,7,7-trimethyl-6-oxo-8h-pyrimido[4,5-b][1,4]diazepin-2-yl)amino]-3-methoxy-n-[(3s)-oxolan-3-yl]benzamide Chemical compound COC1=CC(C(=O)N[C@@H]2COCC2)=CC=C1NC(N=C12)=NC=C1N(C)C(=O)C(C)(C)CN2C1CCCC1 SXHFJQHQBAKZAM-SFHVURJKSA-N 0.000 description 2
• UHGOMPIUHMBZOI-UHFFFAOYSA-N 4-[(9-cyclopentyl-5,7,7-trimethyl-6-oxo-8h-pyrimido[4,5-b][1,4]diazepin-2-yl)amino]-3-methoxy-n-phenylbenzamide Chemical compound COC1=CC(C(=O)NC=2C=CC=CC=2)=CC=C1NC(N=C12)=NC=C1N(C)C(=O)C(C)(C)CN2C1CCCC1 UHGOMPIUHMBZOI-UHFFFAOYSA-N 0.000 description 2
• OBMLGQDUHGEXIO-UHFFFAOYSA-N 4-[(9-cyclopentyl-5,7,7-trimethyl-6-oxo-8h-pyrimido[4,5-b][1,4]diazepin-2-yl)amino]-3-methoxy-n-propan-2-ylbenzamide Chemical compound COC1=CC(C(=O)NC(C)C)=CC=C1NC1=NC=C(N(C)C(=O)C(C)(C)CN2C3CCCC3)C2=N1 OBMLGQDUHGEXIO-UHFFFAOYSA-N 0.000 description 2
• VQHIGBZOYAWLMG-UHFFFAOYSA-N 4-[(9-cyclopentyl-5,7,7-trimethyl-6-oxo-8h-pyrimido[4,5-b][1,4]diazepin-2-yl)amino]-3-methoxy-n-propylbenzamide Chemical compound COC1=CC(C(=O)NCCC)=CC=C1NC1=NC=C(N(C)C(=O)C(C)(C)CN2C3CCCC3)C2=N1 VQHIGBZOYAWLMG-UHFFFAOYSA-N 0.000 description 2
• LRJURAIIMHELTD-UHFFFAOYSA-N 4-[(9-cyclopentyl-5,7,7-trimethyl-6-oxo-8h-pyrimido[4,5-b][1,4]diazepin-2-yl)amino]-3-methoxybenzoic acid Chemical compound COC1=CC(C(O)=O)=CC=C1NC1=NC=C(N(C)C(=O)C(C)(C)CN2C3CCCC3)C2=N1 LRJURAIIMHELTD-UHFFFAOYSA-N 0.000 description 2
• KMHFUKMIIDYKDG-UHFFFAOYSA-N 4-[(9-cyclopentyl-5,7,7-trimethyl-6-oxo-8h-pyrimido[4,5-b][1,4]diazepin-2-yl)amino]-n-(1,3-dihydroxy-2-methylpropan-2-yl)-3-methoxybenzamide Chemical compound COC1=CC(C(=O)NC(C)(CO)CO)=CC=C1NC1=NC=C(N(C)C(=O)C(C)(C)CN2C3CCCC3)C2=N1 KMHFUKMIIDYKDG-UHFFFAOYSA-N 0.000 description 2
• JEJNWQDKCHRKNM-UHFFFAOYSA-N 4-[(9-cyclopentyl-5,7,7-trimethyl-6-oxo-8h-pyrimido[4,5-b][1,4]diazepin-2-yl)amino]-n-(2-fluoroethyl)-3-methoxybenzamide Chemical compound COC1=CC(C(=O)NCCF)=CC=C1NC1=NC=C(N(C)C(=O)C(C)(C)CN2C3CCCC3)C2=N1 JEJNWQDKCHRKNM-UHFFFAOYSA-N 0.000 description 2
• XDNSIABHIZBRPW-UHFFFAOYSA-N 4-[(9-cyclopentyl-5,7,7-trimethyl-6-oxo-8h-pyrimido[4,5-b][1,4]diazepin-2-yl)amino]-n-(3,3-difluorocyclobutyl)-3-methoxybenzamide Chemical compound COC1=CC(C(=O)NC2CC(F)(F)C2)=CC=C1NC(N=C12)=NC=C1N(C)C(=O)C(C)(C)CN2C1CCCC1 XDNSIABHIZBRPW-UHFFFAOYSA-N 0.000 description 2
• UYLGWAIPBGPFFX-UHFFFAOYSA-N 4-[(9-cyclopentyl-5,7,7-trimethyl-6-oxo-8h-pyrimido[4,5-b][1,4]diazepin-2-yl)amino]-n-(3-hydroxybutyl)-3-methoxybenzamide Chemical compound COC1=CC(C(=O)NCCC(C)O)=CC=C1NC1=NC=C(N(C)C(=O)C(C)(C)CN2C3CCCC3)C2=N1 UYLGWAIPBGPFFX-UHFFFAOYSA-N 0.000 description 2
• UHDYMHOGHTYHEE-UHFFFAOYSA-N 4-[(9-cyclopentyl-5,7,7-trimethyl-6-oxo-8h-pyrimido[4,5-b][1,4]diazepin-2-yl)amino]-n-(cyclopropylmethyl)-3-methoxybenzamide Chemical compound COC1=CC(C(=O)NCC2CC2)=CC=C1NC(N=C12)=NC=C1N(C)C(=O)C(C)(C)CN2C1CCCC1 UHDYMHOGHTYHEE-UHFFFAOYSA-N 0.000 description 2
• MEFJJGDPXWULPU-UHFFFAOYSA-N 4-[(9-cyclopentyl-5,7,7-trimethyl-6-oxo-8h-pyrimido[4,5-b][1,4]diazepin-2-yl)amino]-n-(furan-2-ylmethyl)-3-methoxybenzamide Chemical compound COC1=CC(C(=O)NCC=2OC=CC=2)=CC=C1NC(N=C12)=NC=C1N(C)C(=O)C(C)(C)CN2C1CCCC1 MEFJJGDPXWULPU-UHFFFAOYSA-N 0.000 description 2
• WIUVZQNHOJRAPQ-UHFFFAOYSA-N 4-[(9-cyclopentyl-5,7,7-trimethyl-6-oxo-8h-pyrimido[4,5-b][1,4]diazepin-2-yl)amino]-n-[(1-hydroxycyclohexyl)methyl]-3-methoxybenzamide Chemical compound COC1=CC(C(=O)NCC2(O)CCCCC2)=CC=C1NC(N=C12)=NC=C1N(C)C(=O)C(C)(C)CN2C1CCCC1 WIUVZQNHOJRAPQ-UHFFFAOYSA-N 0.000 description 2
• FXTVYWYOVREDHO-XMMPIXPASA-N 4-[(9-cyclopentyl-5,7,7-trimethyl-6-oxo-8h-pyrimido[4,5-b][1,4]diazepin-2-yl)amino]-n-[(1r)-2,3-dihydro-1h-inden-1-yl]-3-methoxybenzamide Chemical compound COC1=CC(C(=O)N[C@H]2C3=CC=CC=C3CC2)=CC=C1NC(N=C12)=NC=C1N(C)C(=O)C(C)(C)CN2C1CCCC1 FXTVYWYOVREDHO-XMMPIXPASA-N 0.000 description 2
• CDZZRJYFCVTNSG-DENIHFKCSA-N 4-[(9-cyclopentyl-5,7,7-trimethyl-6-oxo-8h-pyrimido[4,5-b][1,4]diazepin-2-yl)amino]-n-[(1r,2r)-2-hydroxycyclopentyl]-3-methoxybenzamide Chemical compound COC1=CC(C(=O)N[C@H]2[C@@H](CCC2)O)=CC=C1NC(N=C12)=NC=C1N(C)C(=O)C(C)(C)CN2C1CCCC1 CDZZRJYFCVTNSG-DENIHFKCSA-N 0.000 description 2
• POAYPMCXRNLTKV-UYAOXDASSA-N 4-[(9-cyclopentyl-5,7,7-trimethyl-6-oxo-8h-pyrimido[4,5-b][1,4]diazepin-2-yl)amino]-n-[(1r,3r)-3-(hydroxymethyl)cyclopentyl]-3-methoxybenzamide Chemical compound COC1=CC(C(=O)N[C@H]2C[C@H](CO)CC2)=CC=C1NC(N=C12)=NC=C1N(C)C(=O)C(C)(C)CN2C1CCCC1 POAYPMCXRNLTKV-UYAOXDASSA-N 0.000 description 2
• AUCNIEUQDMWKNC-UHFFFAOYSA-N 4-[(9-cyclopentyl-5,7,7-trimethyl-6-oxo-8h-pyrimido[4,5-b][1,4]diazepin-2-yl)amino]-n-[(2,2-difluorocyclopropyl)methyl]-3-methoxybenzamide Chemical compound COC1=CC(C(=O)NCC2C(C2)(F)F)=CC=C1NC(N=C12)=NC=C1N(C)C(=O)C(C)(C)CN2C1CCCC1 AUCNIEUQDMWKNC-UHFFFAOYSA-N 0.000 description 2
• DCQWJTDMJNHCKJ-OAQYLSRUSA-N 4-[(9-cyclopentyl-5,7,7-trimethyl-6-oxo-8h-pyrimido[4,5-b][1,4]diazepin-2-yl)amino]-n-[(2s)-1-hydroxy-3-methylbutan-2-yl]-3-methoxybenzamide Chemical compound COC1=CC(C(=O)N[C@H](CO)C(C)C)=CC=C1NC1=NC=C(N(C)C(=O)C(C)(C)CN2C3CCCC3)C2=N1 DCQWJTDMJNHCKJ-OAQYLSRUSA-N 0.000 description 2
• BGXWEUSIZFATSU-SFHVURJKSA-N 4-[(9-cyclopentyl-5,7,7-trimethyl-6-oxo-8h-pyrimido[4,5-b][1,4]diazepin-2-yl)amino]-n-[(2s)-2,3-dihydroxypropyl]-3-methoxybenzamide Chemical compound COC1=CC(C(=O)NC[C@H](O)CO)=CC=C1NC1=NC=C(N(C)C(=O)C(C)(C)CN2C3CCCC3)C2=N1 BGXWEUSIZFATSU-SFHVURJKSA-N 0.000 description 2
• UKCFGKCMCQEPBE-QFIPXVFZSA-N 4-[(9-cyclopentyl-5,7,7-trimethyl-6-oxo-8h-pyrimido[4,5-b][1,4]diazepin-2-yl)amino]-n-[(3s)-1-(cyclopropylmethyl)pyrrolidin-3-yl]-3-methoxybenzamide Chemical compound COC1=CC(C(=O)N[C@@H]2CN(CC3CC3)CC2)=CC=C1NC(N=C12)=NC=C1N(C)C(=O)C(C)(C)CN2C1CCCC1 UKCFGKCMCQEPBE-QFIPXVFZSA-N 0.000 description 2
• UIXCMIMWJGMBAQ-UHFFFAOYSA-N 4-[(9-cyclopentyl-5,7,7-trimethyl-6-oxo-8h-pyrimido[4,5-b][1,4]diazepin-2-yl)amino]-n-[1-(2-fluoroethyl)piperidin-4-yl]-3-methoxybenzamide Chemical compound COC1=CC(C(=O)NC2CCN(CCF)CC2)=CC=C1NC(N=C12)=NC=C1N(C)C(=O)C(C)(C)CN2C1CCCC1 UIXCMIMWJGMBAQ-UHFFFAOYSA-N 0.000 description 2
• ZKGJDXKBBNFFJU-UHFFFAOYSA-N 4-[(9-cyclopentyl-5,7,7-trimethyl-6-oxo-8h-pyrimido[4,5-b][1,4]diazepin-2-yl)amino]-n-[2-(2-hydroxyethoxy)ethyl]-3-methoxybenzamide Chemical compound COC1=CC(C(=O)NCCOCCO)=CC=C1NC1=NC=C(N(C)C(=O)C(C)(C)CN2C3CCCC3)C2=N1 ZKGJDXKBBNFFJU-UHFFFAOYSA-N 0.000 description 2
• DLESGSRAZVKIHG-FQEVSTJZSA-N 4-[(9-cyclopentyl-5,7,7-trimethyl-6-oxo-8h-pyrimido[4,5-b][1,4]diazepin-2-yl)amino]-n-[2-[(3s)-3-fluoropyrrolidin-1-yl]ethyl]-3-methoxybenzamide Chemical compound COC1=CC(C(=O)NCCN2C[C@@H](F)CC2)=CC=C1NC(N=C12)=NC=C1N(C)C(=O)C(C)(C)CN2C1CCCC1 DLESGSRAZVKIHG-FQEVSTJZSA-N 0.000 description 2
• GACCQESUPVGTNQ-GBXCKJPGSA-N 4-[(9-cyclopentyl-5,7,7-trimethyl-6-oxo-8h-pyrimido[4,5-b][1,4]diazepin-2-yl)amino]-n-[[(1s,2r)-2-hydroxycyclohexyl]methyl]-3-methoxybenzamide Chemical compound COC1=CC(C(=O)NC[C@H]2[C@@H](CCCC2)O)=CC=C1NC(N=C12)=NC=C1N(C)C(=O)C(C)(C)CN2C1CCCC1 GACCQESUPVGTNQ-GBXCKJPGSA-N 0.000 description 2
• GACCQESUPVGTNQ-RDPSFJRHSA-N 4-[(9-cyclopentyl-5,7,7-trimethyl-6-oxo-8h-pyrimido[4,5-b][1,4]diazepin-2-yl)amino]-n-[[(1s,2s)-2-hydroxycyclohexyl]methyl]-3-methoxybenzamide Chemical compound COC1=CC(C(=O)NC[C@H]2[C@H](CCCC2)O)=CC=C1NC(N=C12)=NC=C1N(C)C(=O)C(C)(C)CN2C1CCCC1 GACCQESUPVGTNQ-RDPSFJRHSA-N 0.000 description 2
• RSYKEOGSQBQGDI-UHFFFAOYSA-N 4-[(9-cyclopentyl-5,7,7-trimethyl-6-oxo-8h-pyrimido[4,5-b][1,4]diazepin-2-yl)amino]-n-ethyl-3-methoxybenzamide Chemical compound COC1=CC(C(=O)NCC)=CC=C1NC1=NC=C(N(C)C(=O)C(C)(C)CN2C3CCCC3)C2=N1 RSYKEOGSQBQGDI-UHFFFAOYSA-N 0.000 description 2
• ADPDFXUXGUPZRC-UHFFFAOYSA-N 4-[(9-cyclopentyl-5,7,7-trimethyl-6-oxo-8h-pyrimido[4,5-b][1,4]diazepin-2-yl)amino]-n-methyl-3-(2-pyrrolidin-1-ylethoxy)benzamide Chemical compound C1CCCN1CCOC1=CC(C(=O)NC)=CC=C1NC(N=C12)=NC=C1N(C)C(=O)C(C)(C)CN2C1CCCC1 ADPDFXUXGUPZRC-UHFFFAOYSA-N 0.000 description 2
• AHZMZOHGUPXOFF-UHFFFAOYSA-N 4-[(9-cyclopentyl-5,7,7-trimethyl-6-oxo-8h-pyrimido[4,5-b][1,4]diazepin-2-yl)amino]-n-methylbenzamide Chemical compound C1=CC(C(=O)NC)=CC=C1NC1=NC=C(N(C)C(=O)C(C)(C)CN2C3CCCC3)C2=N1 AHZMZOHGUPXOFF-UHFFFAOYSA-N 0.000 description 2
• PGRLSIQDOIZYFK-UHFFFAOYSA-N 4-[(9-cyclopentyl-5,7,7-trimethyl-6-oxo-8h-pyrimido[4,5-b][1,4]diazepin-2-yl)oxy]-3-methoxybenzoic acid Chemical compound COC1=CC(C(O)=O)=CC=C1OC1=NC=C(N(C)C(=O)C(C)(C)CN2C3CCCC3)C2=N1 PGRLSIQDOIZYFK-UHFFFAOYSA-N 0.000 description 2
• VFBAFXHFFOATDK-UHFFFAOYSA-N 4-[(9-cyclopentyl-5,7-dimethyl-6-oxo-7,8-dihydropyrimido[4,5-b][1,4]diazepin-2-yl)amino]-3-methoxybenzoic acid Chemical compound COC1=CC(C(O)=O)=CC=C1NC1=NC=C(N(C)C(=O)C(C)CN2C3CCCC3)C2=N1 VFBAFXHFFOATDK-UHFFFAOYSA-N 0.000 description 2
• OSKJUWWDWWGHNV-UHFFFAOYSA-N 4-[(9-cyclopentyl-5-methyl-6-oxo-7,8-dihydropyrimido[4,5-b][1,4]diazepin-2-yl)amino]benzoic acid Chemical compound N1=C2N(C3CCCC3)CCC(=O)N(C)C2=CN=C1NC1=CC=C(C(O)=O)C=C1 OSKJUWWDWWGHNV-UHFFFAOYSA-N 0.000 description 2
• OPDVUYIVVLYJPK-UHFFFAOYSA-N 4-[(9-cyclopentyl-5-methyl-6-oxospiro[8h-pyrimido[4,5-b][1,4]diazepine-7,1'-cyclobutane]-2-yl)amino]-3-methoxy-n-(1-methylpiperidin-4-yl)benzamide Chemical compound COC1=CC(C(=O)NC2CCN(C)CC2)=CC=C1NC(N=C1N(C2CCCC2)C2)=NC=C1N(C)C(=O)C12CCC1 OPDVUYIVVLYJPK-UHFFFAOYSA-N 0.000 description 2
• FJAILXLMBIGWKE-UHFFFAOYSA-N 4-[(9-cyclopentyl-5-methyl-6-oxospiro[8h-pyrimido[4,5-b][1,4]diazepine-7,1'-cyclopropane]-2-yl)amino]-n-(3-hydroxypropyl)-3-methoxybenzamide Chemical compound COC1=CC(C(=O)NCCCO)=CC=C1NC1=NC=C(N(C)C(=O)C2(CC2)CN2C3CCCC3)C2=N1 FJAILXLMBIGWKE-UHFFFAOYSA-N 0.000 description 2
• DDESFIZPPZSWFR-UHFFFAOYSA-N 4-[(9-cyclopentyl-5-methyl-6-oxospiro[8h-pyrimido[4,5-b][1,4]diazepine-7,1'-cyclopropane]-2-yl)amino]-n-(furan-2-ylmethyl)-3-methoxybenzamide Chemical compound COC1=CC(C(=O)NCC=2OC=CC=2)=CC=C1NC(N=C1N(C2CCCC2)C2)=NC=C1N(C)C(=O)C12CC1 DDESFIZPPZSWFR-UHFFFAOYSA-N 0.000 description 2
• COHHQNBDIDGAKH-UYAOXDASSA-N 4-[(9-cyclopentyl-5-methyl-6-oxospiro[8h-pyrimido[4,5-b][1,4]diazepine-7,1'-cyclopropane]-2-yl)amino]-n-[(1r,3r)-3-hydroxycyclopentyl]-3-methoxybenzamide Chemical compound COC1=CC(C(=O)N[C@H]2C[C@H](O)CC2)=CC=C1NC(N=C1N(C2CCCC2)C2)=NC=C1N(C)C(=O)C12CC1 COHHQNBDIDGAKH-UYAOXDASSA-N 0.000 description 2
• QFMADZODHJVBMJ-UHFFFAOYSA-N 4-[(9-cyclopentyl-5-methyl-6-oxospiro[8h-pyrimido[4,5-b][1,4]diazepine-7,1'-cyclopropane]-2-yl)amino]-n-cyclopropyl-3-methoxybenzamide Chemical compound COC1=CC(C(=O)NC2CC2)=CC=C1NC(N=C1N(C2CCCC2)C2)=NC=C1N(C)C(=O)C12CC1 QFMADZODHJVBMJ-UHFFFAOYSA-N 0.000 description 2
• CPUABIALFWXRID-UHFFFAOYSA-N 4-[(9-cyclopentyl-7,7-dimethyl-6-oxo-5,8-dihydropyrimido[4,5-b][1,4]diazepin-2-yl)amino]-3-methoxy-n-methylbenzamide Chemical compound COC1=CC(C(=O)NC)=CC=C1NC1=NC=C(NC(=O)C(C)(C)CN2C3CCCC3)C2=N1 CPUABIALFWXRID-UHFFFAOYSA-N 0.000 description 2
• MGUVLMQHDOHABH-UHFFFAOYSA-N 4-[(9-cyclopentyl-7-ethyl-5-methyl-6-oxo-7,8-dihydropyrimido[4,5-b][1,4]diazepin-2-yl)amino]-3-methoxy-n-methylbenzamide Chemical compound C12=NC(NC=3C(=CC(=CC=3)C(=O)NC)OC)=NC=C2N(C)C(=O)C(CC)CN1C1CCCC1 MGUVLMQHDOHABH-UHFFFAOYSA-N 0.000 description 2
• WWMYXBHGWNEGRQ-UHFFFAOYSA-N 4-[(9-cyclopropyl-5,7,7-trimethyl-6-oxo-8h-pyrimido[4,5-b][1,4]diazepin-2-yl)amino]-3-methoxy-n-methylbenzamide Chemical compound COC1=CC(C(=O)NC)=CC=C1NC1=NC=C(N(C)C(=O)C(C)(C)CN2C3CC3)C2=N1 WWMYXBHGWNEGRQ-UHFFFAOYSA-N 0.000 description 2
• DWLVVFKOYCAZQQ-UHFFFAOYSA-N 4-[[9-(2,2-dimethylpropyl)-5,7,7-trimethyl-6-oxo-8h-pyrimido[4,5-b][1,4]diazepin-2-yl]amino]-3-methoxy-n-methylbenzamide Chemical compound COC1=CC(C(=O)NC)=CC=C1NC1=NC=C(N(C)C(=O)C(C)(C)CN2CC(C)(C)C)C2=N1 DWLVVFKOYCAZQQ-UHFFFAOYSA-N 0.000 description 2
• VSFSVINYPLPWDE-UHFFFAOYSA-N 4-[[9-(3,3-difluorocyclobutyl)-5,7,7-trimethyl-6-oxo-8h-pyrimido[4,5-b][1,4]diazepin-2-yl]amino]-3-methoxy-n-(oxan-4-yl)benzamide Chemical compound COC1=CC(C(=O)NC2CCOCC2)=CC=C1NC(N=C12)=NC=C1N(C)C(=O)C(C)(C)CN2C1CC(F)(F)C1 VSFSVINYPLPWDE-UHFFFAOYSA-N 0.000 description 2
• NFCXFBDQSKTOQA-UHFFFAOYSA-N 4-[[9-(3,3-difluorocyclobutyl)-5,7,7-trimethyl-6-oxo-8h-pyrimido[4,5-b][1,4]diazepin-2-yl]amino]-3-methoxy-n-methylbenzamide Chemical compound COC1=CC(C(=O)NC)=CC=C1NC1=NC=C(N(C)C(=O)C(C)(C)CN2C3CC(F)(F)C3)C2=N1 NFCXFBDQSKTOQA-UHFFFAOYSA-N 0.000 description 2
• PQQNOGZRKJRGGW-UHFFFAOYSA-N 4-[[9-(3-bicyclo[2.2.1]heptanyl)-5,7,7-trimethyl-6-oxo-8h-pyrimido[4,5-b][1,4]diazepin-2-yl]amino]-3-methoxy-n-methylbenzamide Chemical compound COC1=CC(C(=O)NC)=CC=C1NC1=NC=C(N(C)C(=O)C(C)(C)CN2C3C4CCC(C4)C3)C2=N1 PQQNOGZRKJRGGW-UHFFFAOYSA-N 0.000 description 2
• VVKHOINIIWXMIS-UHFFFAOYSA-N 4-[[9-(3-chlorophenyl)-5,7,7-trimethyl-6-oxo-8h-pyrimido[4,5-b][1,4]diazepin-2-yl]amino]-3-methoxy-n-methylbenzamide Chemical compound COC1=CC(C(=O)NC)=CC=C1NC1=NC=C(N(C)C(=O)C(C)(C)CN2C=3C=C(Cl)C=CC=3)C2=N1 VVKHOINIIWXMIS-UHFFFAOYSA-N 0.000 description 2
• OELJXBPNBSQGRL-UHFFFAOYSA-N 4-[[9-[(2,2-difluorocyclopropyl)methyl]-5,7,7-trimethyl-6-oxo-8h-pyrimido[4,5-b][1,4]diazepin-2-yl]amino]-3-methoxy-n-methylbenzamide Chemical compound COC1=CC(C(=O)NC)=CC=C1NC1=NC=C(N(C)C(=O)C(C)(C)CN2CC3C(C3)(F)F)C2=N1 OELJXBPNBSQGRL-UHFFFAOYSA-N 0.000 description 2
• ALYNCZNDIQEVRV-UHFFFAOYSA-N 4-aminobenzoic acid Chemical compound NC1=CC=C(C(O)=O)C=C1 ALYNCZNDIQEVRV-UHFFFAOYSA-N 0.000 description 2
• 125000000339 4-pyridyl group Chemical group N1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 description 2
• LMJXSOYPAOSIPZ-UHFFFAOYSA-N 4-sulfanylbenzoic acid Chemical compound OC(=O)C1=CC=C(S)C=C1 LMJXSOYPAOSIPZ-UHFFFAOYSA-N 0.000 description 2
• KQYDMMKEVWNMTJ-UHFFFAOYSA-N 5,7-dihydropyrimido[4,5-b][1,4]diazepin-6-one Chemical compound N1C(=O)CC=NC2=NC=NC=C21 KQYDMMKEVWNMTJ-UHFFFAOYSA-N 0.000 description 2
• MZBUGUZWGYPLOY-UHFFFAOYSA-N 5-[(9-cyclopentyl-5,7,7-trimethyl-6-oxo-8h-pyrimido[4,5-b][1,4]diazepin-2-yl)amino]-1h-indole-2,3-dione Chemical compound C1C(C)(C)C(=O)N(C)C2=CN=C(NC=3C=C4C(=O)C(=O)NC4=CC=3)N=C2N1C1CCCC1 MZBUGUZWGYPLOY-UHFFFAOYSA-N 0.000 description 2
• KYKIQRLMCNSDOT-UHFFFAOYSA-N 6-[(9-cyclopentyl-5,7,7-trimethyl-6-oxo-8h-pyrimido[4,5-b][1,4]diazepin-2-yl)amino]-n-methylpyridine-3-carboxamide Chemical compound N1=CC(C(=O)NC)=CC=C1NC1=NC=C(N(C)C(=O)C(C)(C)CN2C3CCCC3)C2=N1 KYKIQRLMCNSDOT-UHFFFAOYSA-N 0.000 description 2
• QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 2
• OWBGXZSPBDOPSA-UHFFFAOYSA-N 9-cyclopentyl-2-(2-methoxyanilino)-5-methyl-7,8-dihydropyrimido[4,5-b][1,4]diazepin-6-one Chemical compound COC1=CC=CC=C1NC1=NC=C(N(C)C(=O)CCN2C3CCCC3)C2=N1 OWBGXZSPBDOPSA-UHFFFAOYSA-N 0.000 description 2
• KBCQJKUBGVJFOS-UHFFFAOYSA-N 9-cyclopentyl-2-(3-methoxy-5-nitroanilino)-5,7,7-trimethyl-8h-pyrimido[4,5-b][1,4]diazepin-6-one Chemical compound [O-][N+](=O)C1=CC(OC)=CC(NC=2N=C3N(C4CCCC4)CC(C)(C)C(=O)N(C)C3=CN=2)=C1 KBCQJKUBGVJFOS-UHFFFAOYSA-N 0.000 description 2
• QGAAMBADXLDEKR-UHFFFAOYSA-N 9-cyclopentyl-2-[2-methoxy-4-(3-methoxyazetidine-1-carbonyl)anilino]-5,7,7-trimethyl-8h-pyrimido[4,5-b][1,4]diazepin-6-one Chemical compound C1C(OC)CN1C(=O)C(C=C1OC)=CC=C1NC1=NC=C(N(C)C(=O)C(C)(C)CN2C3CCCC3)C2=N1 QGAAMBADXLDEKR-UHFFFAOYSA-N 0.000 description 2
• YIZGQIYSDRSLFM-UHFFFAOYSA-N 9-cyclopentyl-2-[2-methoxy-4-(morpholine-4-carbonyl)anilino]-5,7,7-trimethyl-8h-pyrimido[4,5-b][1,4]diazepin-6-one Chemical compound COC1=CC(C(=O)N2CCOCC2)=CC=C1NC(N=C12)=NC=C1N(C)C(=O)C(C)(C)CN2C1CCCC1 YIZGQIYSDRSLFM-UHFFFAOYSA-N 0.000 description 2
• INMCUILBZKDOGT-UHFFFAOYSA-N 9-cyclopentyl-2-[2-methoxy-4-(piperazine-1-carbonyl)anilino]-5-methyl-7,8-dihydropyrimido[4,5-b][1,4]diazepin-6-one Chemical compound COC1=CC(C(=O)N2CCNCC2)=CC=C1NC(N=C12)=NC=C1N(C)C(=O)CCN2C1CCCC1 INMCUILBZKDOGT-UHFFFAOYSA-N 0.000 description 2
• IEYMZTMKPSXFCD-UHFFFAOYSA-N 9-cyclopentyl-2-[3-(3-cyclopropyl-3-fluoroazetidine-1-carbonyl)anilino]-5,7,7-trimethyl-8h-pyrimido[4,5-b][1,4]diazepin-6-one Chemical compound N1=C2N(C3CCCC3)CC(C)(C)C(=O)N(C)C2=CN=C1NC(C=1)=CC=CC=1C(=O)N(C1)CC1(F)C1CC1 IEYMZTMKPSXFCD-UHFFFAOYSA-N 0.000 description 2
• AZNAHNPYPQQOCZ-UHFFFAOYSA-N 9-cyclopentyl-2-[4-(1h-imidazol-2-yl)-2-methoxyanilino]-5,7,7-trimethyl-8h-pyrimido[4,5-b][1,4]diazepin-6-one Chemical compound COC1=CC(C=2NC=CN=2)=CC=C1NC(N=C12)=NC=C1N(C)C(=O)C(C)(C)CN2C1CCCC1 AZNAHNPYPQQOCZ-UHFFFAOYSA-N 0.000 description 2
• HGJKCKDTBPBNKV-UHFFFAOYSA-N 9-cyclopentyl-2-[4-(4,5-dihydro-1h-imidazol-2-yl)-2-methoxyanilino]-5,7,7-trimethyl-8h-pyrimido[4,5-b][1,4]diazepin-6-one Chemical compound COC1=CC(C=2NCCN=2)=CC=C1NC(N=C12)=NC=C1N(C)C(=O)C(C)(C)CN2C1CCCC1 HGJKCKDTBPBNKV-UHFFFAOYSA-N 0.000 description 2
• IPTHYFGRNIZZSE-SFHVURJKSA-N 9-cyclopentyl-2-[4-[(3s)-3-fluoropyrrolidine-1-carbonyl]-2-methoxyanilino]-5,7,7-trimethyl-8h-pyrimido[4,5-b][1,4]diazepin-6-one Chemical compound COC1=CC(C(=O)N2C[C@@H](F)CC2)=CC=C1NC(N=C12)=NC=C1N(C)C(=O)C(C)(C)CN2C1CCCC1 IPTHYFGRNIZZSE-SFHVURJKSA-N 0.000 description 2
• CMPWMQURSYHUSO-UHFFFAOYSA-N 9-cyclopentyl-5,7,7-trimethyl-2-(3-pyridin-3-ylanilino)-8h-pyrimido[4,5-b][1,4]diazepin-6-one Chemical compound N1=C2N(C3CCCC3)CC(C)(C)C(=O)N(C)C2=CN=C1NC(C=1)=CC=CC=1C1=CC=CN=C1 CMPWMQURSYHUSO-UHFFFAOYSA-N 0.000 description 2
• BDJNQINAROFJBL-UHFFFAOYSA-N 9-cyclopentyl-5,7,7-trimethyl-2-[(1-oxo-2,3-dihydroisoindol-4-yl)amino]-8h-pyrimido[4,5-b][1,4]diazepin-6-one Chemical compound C1C(C)(C)C(=O)N(C)C2=CN=C(NC=3C=4CNC(=O)C=4C=CC=3)N=C2N1C1CCCC1 BDJNQINAROFJBL-UHFFFAOYSA-N 0.000 description 2
• JWQRPCGCWLWDOS-UHFFFAOYSA-N 9-cyclopentyl-5,7,7-trimethyl-2-[(2-methylindazol-7-yl)amino]-8h-pyrimido[4,5-b][1,4]diazepin-6-one Chemical compound C1C(C)(C)C(=O)N(C)C2=CN=C(NC=3C4=NN(C)C=C4C=CC=3)N=C2N1C1CCCC1 JWQRPCGCWLWDOS-UHFFFAOYSA-N 0.000 description 2
• SRWLSGIFOVRQNO-UHFFFAOYSA-N 9-cyclopentyl-5,7,7-trimethyl-2-[(2-oxo-1,3-dihydroindol-5-yl)amino]-8h-pyrimido[4,5-b][1,4]diazepin-6-one Chemical compound C1C(C)(C)C(=O)N(C)C2=CN=C(NC=3C=C4CC(=O)NC4=CC=3)N=C2N1C1CCCC1 SRWLSGIFOVRQNO-UHFFFAOYSA-N 0.000 description 2
• GZKYXJAZERABLC-UHFFFAOYSA-N 9-cyclopentyl-5,7,7-trimethyl-2-[(3-oxo-1,2-dihydroindazol-5-yl)amino]-8h-pyrimido[4,5-b][1,4]diazepin-6-one Chemical compound C1C(C)(C)C(=O)N(C)C2=CN=C(NC=3C=C4C(=O)NNC4=CC=3)N=C2N1C1CCCC1 GZKYXJAZERABLC-UHFFFAOYSA-N 0.000 description 2
• FOBWLWPQHWKZNU-UHFFFAOYSA-N 9-cyclopentyl-5,7,7-trimethyl-2-[(4-methyl-6-oxo-1h-pyridin-3-yl)amino]-8h-pyrimido[4,5-b][1,4]diazepin-6-one Chemical compound N1=C2N(C3CCCC3)CC(C)(C)C(=O)N(C)C2=CN=C1NC1=CNC(=O)C=C1C FOBWLWPQHWKZNU-UHFFFAOYSA-N 0.000 description 2
• WCRWXDHRPRRYIJ-UHFFFAOYSA-N 9-cyclopentyl-5,7,7-trimethyl-2-[(6-oxo-1h-pyridin-3-yl)amino]-8h-pyrimido[4,5-b][1,4]diazepin-6-one Chemical compound N1=C2N(C3CCCC3)CC(C)(C)C(=O)N(C)C2=CN=C1NC=1C=CC(=O)NC=1 WCRWXDHRPRRYIJ-UHFFFAOYSA-N 0.000 description 2
• YRLXSNRLEZZNCJ-UHFFFAOYSA-N 9-cyclopentyl-5,7,7-trimethyl-2-[3-(2-oxopyrrolidin-1-yl)anilino]-8h-pyrimido[4,5-b][1,4]diazepin-6-one Chemical compound N1=C2N(C3CCCC3)CC(C)(C)C(=O)N(C)C2=CN=C1NC(C=1)=CC=CC=1N1CCCC1=O YRLXSNRLEZZNCJ-UHFFFAOYSA-N 0.000 description 2
• PTQFWIUDQXVTAI-UHFFFAOYSA-N 9-cyclopentyl-5,7,7-trimethyl-2-[4-(1h-pyrazol-5-yl)anilino]-8h-pyrimido[4,5-b][1,4]diazepin-6-one Chemical compound N1=C2N(C3CCCC3)CC(C)(C)C(=O)N(C)C2=CN=C1NC(C=C1)=CC=C1C=1C=CNN=1 PTQFWIUDQXVTAI-UHFFFAOYSA-N 0.000 description 2
• 208000024893 Acute lymphoblastic leukemia Diseases 0.000 description 2
• 208000014697 Acute lymphocytic leukaemia Diseases 0.000 description 2
• 208000036762 Acute promyelocytic leukaemia Diseases 0.000 description 2
• 208000010507 Adenocarcinoma of Lung Diseases 0.000 description 2
• 206010001233 Adenoma benign Diseases 0.000 description 2
• 229920001817 Agar Polymers 0.000 description 2
• QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 2
• 201000003076 Angiosarcoma Diseases 0.000 description 2
• 206010005003 Bladder cancer Diseases 0.000 description 2
• 206010005949 Bone cancer Diseases 0.000 description 2
• 208000018084 Bone neoplasm Diseases 0.000 description 2
• LKIBYWZKLWYZHS-UHFFFAOYSA-N C1C(OC)=CC=CC1(C(N)=O)C1CCN(C(C)C)CC1 Chemical compound C1C(OC)=CC=CC1(C(N)=O)C1CCN(C(C)C)CC1 LKIBYWZKLWYZHS-UHFFFAOYSA-N 0.000 description 2
• OTSKATSCNARLPM-UHFFFAOYSA-N C1C(OC)=CC=CC1(C(N)=O)C1CCN(CC(C)C)CC1 Chemical compound C1C(OC)=CC=CC1(C(N)=O)C1CCN(CC(C)C)CC1 OTSKATSCNARLPM-UHFFFAOYSA-N 0.000 description 2
• BBSBYCOPAGTPOI-UHFFFAOYSA-N C1CN(CC)CCC1C1(C(N)=O)C=CC=C(OC)C1 Chemical compound C1CN(CC)CCC1C1(C(N)=O)C=CC=C(OC)C1 BBSBYCOPAGTPOI-UHFFFAOYSA-N 0.000 description 2
• VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
• KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 description 2
• 229920002134 Carboxymethyl cellulose Polymers 0.000 description 2
• 208000017897 Carcinoma of esophagus Diseases 0.000 description 2
• 206010008342 Cervix carcinoma Diseases 0.000 description 2
• 208000001333 Colorectal Neoplasms Diseases 0.000 description 2
• 230000005778 DNA damage Effects 0.000 description 2
• 231100000277 DNA damage Toxicity 0.000 description 2
• AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 2
• 206010014733 Endometrial cancer Diseases 0.000 description 2
• 206010014759 Endometrial neoplasm Diseases 0.000 description 2
• 102000018233 Fibroblast Growth Factor Human genes 0.000 description 2
• 108050007372 Fibroblast Growth Factor Proteins 0.000 description 2
• 230000010190 G1 phase Effects 0.000 description 2
• 108010010803 Gelatin Proteins 0.000 description 2
• 208000032612 Glial tumor Diseases 0.000 description 2
• 206010018338 Glioma Diseases 0.000 description 2
• 239000004471 Glycine Substances 0.000 description 2
• 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 2
• 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 2
• 206010018691 Granuloma Diseases 0.000 description 2
• 208000002927 Hamartoma Diseases 0.000 description 2
• 208000001258 Hemangiosarcoma Diseases 0.000 description 2
• 239000004705 High-molecular-weight polyethylene Substances 0.000 description 2
• 208000017604 Hodgkin disease Diseases 0.000 description 2
• 208000010747 Hodgkins lymphoma Diseases 0.000 description 2
• 108091006905 Human Serum Albumin Proteins 0.000 description 2
• 102000008100 Human Serum Albumin Human genes 0.000 description 2
• 108010005716 Interferon beta-1a Proteins 0.000 description 2
• XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
• 102100023408 KH domain-containing, RNA-binding, signal transduction-associated protein 1 Human genes 0.000 description 2
• 101710094958 KH domain-containing, RNA-binding, signal transduction-associated protein 1 Proteins 0.000 description 2
• 208000007766 Kaposi sarcoma Diseases 0.000 description 2
• 206010023347 Keratoacanthoma Diseases 0.000 description 2
• 208000008839 Kidney Neoplasms Diseases 0.000 description 2
• 208000018142 Leiomyosarcoma Diseases 0.000 description 2
• 239000007993 MOPS buffer Substances 0.000 description 2
• 241000124008 Mammalia Species 0.000 description 2
• AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
• 208000034578 Multiple myelomas Diseases 0.000 description 2
• LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 2
• CYZAMKJXCMKDNA-UHFFFAOYSA-N N1=C2N(C3CCCC3)CC(C)(C)C(=O)N(C)C2=CN=C1NC(C=C1)=CC=C1N1N=C(C)C=C1O Chemical compound N1=C2N(C3CCCC3)CC(C)(C)C(=O)N(C)C2=CN=C1NC(C=C1)=CC=C1N1N=C(C)C=C1O CYZAMKJXCMKDNA-UHFFFAOYSA-N 0.000 description 2
• 206010029260 Neuroblastoma Diseases 0.000 description 2
• 239000005642 Oleic acid Substances 0.000 description 2
• ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 2
• 229930012538 Paclitaxel Natural products 0.000 description 2
• 206010061902 Pancreatic neoplasm Diseases 0.000 description 2
• OFBQJSOFQDEBGM-UHFFFAOYSA-N Pentane Chemical compound CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 2
• 239000004264 Petrolatum Substances 0.000 description 2
• NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
• 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 description 2
• 208000033826 Promyelocytic Acute Leukemia Diseases 0.000 description 2
• 206010060862 Prostate cancer Diseases 0.000 description 2
• 208000000236 Prostatic Neoplasms Diseases 0.000 description 2
• 102000007327 Protamines Human genes 0.000 description 2
• 108010007568 Protamines Proteins 0.000 description 2
• JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
• 206010038389 Renal cancer Diseases 0.000 description 2
• 201000010208 Seminoma Diseases 0.000 description 2
• XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 2
• 208000000453 Skin Neoplasms Diseases 0.000 description 2
• CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
• UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
• DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 2
• 208000005718 Stomach Neoplasms Diseases 0.000 description 2
• QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
• 239000012317 TBTU Substances 0.000 description 2
• 208000024313 Testicular Neoplasms Diseases 0.000 description 2
• 206010057644 Testis cancer Diseases 0.000 description 2
• DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 2
• 108060008682 Tumor Necrosis Factor Proteins 0.000 description 2
• 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 2
• XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
• 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 2
• 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 2
• 108010046377 Whey Proteins Proteins 0.000 description 2
• 208000008383 Wilms tumor Diseases 0.000 description 2
• CLZISMQKJZCZDN-UHFFFAOYSA-N [benzotriazol-1-yloxy(dimethylamino)methylidene]-dimethylazanium Chemical compound C1=CC=C2N(OC(N(C)C)=[N+](C)C)N=NC2=C1 CLZISMQKJZCZDN-UHFFFAOYSA-N 0.000 description 2
• 230000002159 abnormal effect Effects 0.000 description 2
• DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 2
• 230000001154 acute effect Effects 0.000 description 2
• 235000010419 agar Nutrition 0.000 description 2
• 239000000783 alginic acid Substances 0.000 description 2
• 229960001126 alginic acid Drugs 0.000 description 2
• 150000004781 alginic acids Chemical class 0.000 description 2
• 239000003513 alkali Substances 0.000 description 2
• 125000003342 alkenyl group Chemical group 0.000 description 2
• PNEYBMLMFCGWSK-UHFFFAOYSA-N aluminium oxide Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 2
• CEGOLXSVJUTHNZ-UHFFFAOYSA-K aluminium tristearate Chemical compound [Al+3].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CEGOLXSVJUTHNZ-UHFFFAOYSA-K 0.000 description 2
• 229940063655 aluminum stearate Drugs 0.000 description 2
• 230000001028 anti-proliverative effect Effects 0.000 description 2
• 230000006907 apoptotic process Effects 0.000 description 2
• 239000007900 aqueous suspension Substances 0.000 description 2
• LMEKQMALGUDUQG-UHFFFAOYSA-N azathioprine Chemical compound CN1C=NC([N+]([O-])=O)=C1SC1=NC=NC2=C1NC=N2 LMEKQMALGUDUQG-UHFFFAOYSA-N 0.000 description 2
• 229960002170 azathioprine Drugs 0.000 description 2
• 230000008901 benefit Effects 0.000 description 2
• SESFRYSPDFLNCH-UHFFFAOYSA-N benzyl benzoate Chemical compound C=1C=CC=CC=1C(=O)OCC1=CC=CC=C1 SESFRYSPDFLNCH-UHFFFAOYSA-N 0.000 description 2
• WGQKYBSKWIADBV-UHFFFAOYSA-N benzylamine Chemical compound NCC1=CC=CC=C1 WGQKYBSKWIADBV-UHFFFAOYSA-N 0.000 description 2
• 208000026900 bile duct neoplasm Diseases 0.000 description 2
• 230000027455 binding Effects 0.000 description 2
• 239000011230 binding agent Substances 0.000 description 2
• 229920002988 biodegradable polymer Polymers 0.000 description 2
• 239000004621 biodegradable polymer Substances 0.000 description 2
• 210000000481 breast Anatomy 0.000 description 2
• CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical class [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 2
• 239000011203 carbon fibre reinforced carbon Substances 0.000 description 2
• 235000010948 carboxy methyl cellulose Nutrition 0.000 description 2
• 239000008112 carboxymethyl-cellulose Substances 0.000 description 2
• 239000004359 castor oil Substances 0.000 description 2
• 230000023359 cell cycle switching, meiotic to mitotic cell cycle Effects 0.000 description 2
• 230000036755 cellular response Effects 0.000 description 2
• 235000010980 cellulose Nutrition 0.000 description 2
• 229920002678 cellulose Polymers 0.000 description 2
• 239000001913 cellulose Substances 0.000 description 2
• 201000010881 cervical cancer Diseases 0.000 description 2
• 230000000973 chemotherapeutic effect Effects 0.000 description 2
• 208000006990 cholangiocarcinoma Diseases 0.000 description 2
• 238000004587 chromatography analysis Methods 0.000 description 2
• 210000000349 chromosome Anatomy 0.000 description 2
• 239000003086 colorant Substances 0.000 description 2
• 238000010835 comparative analysis Methods 0.000 description 2
• 238000001816 cooling Methods 0.000 description 2
• 235000012343 cottonseed oil Nutrition 0.000 description 2
• 239000013078 crystal Substances 0.000 description 2
• MFNYBOWJWGPXFM-UHFFFAOYSA-N cyclobutanecarboxamide Chemical compound NC(=O)C1CCC1 MFNYBOWJWGPXFM-UHFFFAOYSA-N 0.000 description 2
• 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 2
• 238000001514 detection method Methods 0.000 description 2
• AQEFLFZSWDEAIP-UHFFFAOYSA-N di-tert-butyl ether Chemical compound CC(C)(C)OC(C)(C)C AQEFLFZSWDEAIP-UHFFFAOYSA-N 0.000 description 2
• CVLAEJNQNKXNNN-UHFFFAOYSA-N diazepin-4-one Chemical compound O=C1C=CC=NN=C1 CVLAEJNQNKXNNN-UHFFFAOYSA-N 0.000 description 2
• 235000005911 diet Nutrition 0.000 description 2
• 230000037213 diet Effects 0.000 description 2
• FAMRKDQNMBBFBR-BQYQJAHWSA-N diethyl azodicarboxylate Substances CCOC(=O)\N=N\C(=O)OCC FAMRKDQNMBBFBR-BQYQJAHWSA-N 0.000 description 2
• GXGAKHNRMVGRPK-UHFFFAOYSA-N dimagnesium;dioxido-bis[[oxido(oxo)silyl]oxy]silane Chemical compound [Mg+2].[Mg+2].[O-][Si](=O)O[Si]([O-])([O-])O[Si]([O-])=O GXGAKHNRMVGRPK-UHFFFAOYSA-N 0.000 description 2
• ZPWVASYFFYYZEW-UHFFFAOYSA-L dipotassium hydrogen phosphate Chemical compound [K+].[K+].OP([O-])([O-])=O ZPWVASYFFYYZEW-UHFFFAOYSA-L 0.000 description 2
• 229910000396 dipotassium phosphate Inorganic materials 0.000 description 2
• 235000019797 dipotassium phosphate Nutrition 0.000 description 2
• BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 2
• 238000004090 dissolution Methods 0.000 description 2
• MOTZDAYCYVMXPC-UHFFFAOYSA-N dodecyl hydrogen sulfate Chemical class CCCCCCCCCCCCOS(O)(=O)=O MOTZDAYCYVMXPC-UHFFFAOYSA-N 0.000 description 2
• ADEBPBSSDYVVLD-UHFFFAOYSA-N donepezil Chemical compound O=C1C=2C=C(OC)C(OC)=CC=2CC1CC(CC1)CCN1CC1=CC=CC=C1 ADEBPBSSDYVVLD-UHFFFAOYSA-N 0.000 description 2
• 239000008298 dragée Substances 0.000 description 2
• 239000003792 electrolyte Substances 0.000 description 2
• 230000001804 emulsifying effect Effects 0.000 description 2
• BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 2
• MMXKVMNBHPAILY-UHFFFAOYSA-N ethyl laurate Chemical compound CCCCCCCCCCCC(=O)OCC MMXKVMNBHPAILY-UHFFFAOYSA-N 0.000 description 2
• 230000029142 excretion Effects 0.000 description 2
• 229940126864 fibroblast growth factor Drugs 0.000 description 2
• 239000000706 filtrate Substances 0.000 description 2
• 238000001914 filtration Methods 0.000 description 2
• 239000000796 flavoring agent Substances 0.000 description 2
• 235000003599 food sweetener Nutrition 0.000 description 2
• 239000000499 gel Substances 0.000 description 2
• 229920000159 gelatin Polymers 0.000 description 2
• 239000008273 gelatin Substances 0.000 description 2
• 239000007903 gelatin capsule Substances 0.000 description 2
• 235000019322 gelatine Nutrition 0.000 description 2
• 235000011852 gelatine desserts Nutrition 0.000 description 2
• 239000012362 glacial acetic acid Substances 0.000 description 2
• 235000011187 glycerol Nutrition 0.000 description 2
• 239000003102 growth factor Substances 0.000 description 2
• 229940093915 gynecological organic acid Drugs 0.000 description 2
• 150000004820 halides Chemical class 0.000 description 2
• LNEPOXFFQSENCJ-UHFFFAOYSA-N haloperidol Chemical compound C1CC(O)(C=2C=CC(Cl)=CC=2)CCN1CCCC(=O)C1=CC=C(F)C=C1 LNEPOXFFQSENCJ-UHFFFAOYSA-N 0.000 description 2
• 230000036541 health Effects 0.000 description 2
• 206010073071 hepatocellular carcinoma Diseases 0.000 description 2
• 150000002430 hydrocarbons Chemical group 0.000 description 2
• 239000001257 hydrogen Substances 0.000 description 2
• 210000000987 immune system Anatomy 0.000 description 2
• 208000026278 immune system disease Diseases 0.000 description 2
• 238000000099 in vitro assay Methods 0.000 description 2
• 238000001727 in vivo Methods 0.000 description 2
• 208000015181 infectious disease Diseases 0.000 description 2
• INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 2
• 238000005342 ion exchange Methods 0.000 description 2
• QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 2
• 201000010982 kidney cancer Diseases 0.000 description 2
• 238000011813 knockout mouse model Methods 0.000 description 2
• 206010023841 laryngeal neoplasm Diseases 0.000 description 2
• 235000010445 lecithin Nutrition 0.000 description 2
• 239000000787 lecithin Substances 0.000 description 2
• 229940067606 lecithin Drugs 0.000 description 2
• 201000010260 leiomyoma Diseases 0.000 description 2
• 210000000088 lip Anatomy 0.000 description 2
• 239000008297 liquid dosage form Substances 0.000 description 2
• 208000014018 liver neoplasm Diseases 0.000 description 2
• 239000006210 lotion Substances 0.000 description 2
• 210000004072 lung Anatomy 0.000 description 2
• 201000005249 lung adenocarcinoma Diseases 0.000 description 2
• 210000004324 lymphatic system Anatomy 0.000 description 2
• 239000000391 magnesium silicate Substances 0.000 description 2
• 229910052943 magnesium sulfate Inorganic materials 0.000 description 2
• 235000019341 magnesium sulphate Nutrition 0.000 description 2
• 229910000386 magnesium trisilicate Inorganic materials 0.000 description 2
• 235000019793 magnesium trisilicate Nutrition 0.000 description 2
• 229940099273 magnesium trisilicate Drugs 0.000 description 2
• 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 2
• 206010027191 meningioma Diseases 0.000 description 2
• 239000002207 metabolite Substances 0.000 description 2
• HNQIVZYLYMDVSB-UHFFFAOYSA-N methanesulfonimidic acid Chemical compound CS(N)(=O)=O HNQIVZYLYMDVSB-UHFFFAOYSA-N 0.000 description 2
• FDKVUTDHFXROQC-UHFFFAOYSA-N methyl 3-[(2-chloro-5-nitropyrimidin-4-yl)-cyclopentylamino]propanoate Chemical compound N=1C(Cl)=NC=C([N+]([O-])=O)C=1N(CCC(=O)OC)C1CCCC1 FDKVUTDHFXROQC-UHFFFAOYSA-N 0.000 description 2
• 239000004530 micro-emulsion Substances 0.000 description 2
• 239000003094 microcapsule Substances 0.000 description 2
• 239000002480 mineral oil Substances 0.000 description 2
• 235000010446 mineral oil Nutrition 0.000 description 2
• 238000002156 mixing Methods 0.000 description 2
• 201000000050 myeloid neoplasm Diseases 0.000 description 2
• URIITZNDQCGUGM-UHFFFAOYSA-N n-(1-tert-butylpiperidin-4-yl)-4-[(9-cyclopentyl-5,7,7-trimethyl-6-oxo-8h-pyrimido[4,5-b][1,4]diazepin-2-yl)amino]-3-methoxybenzamide Chemical compound COC1=CC(C(=O)NC2CCN(CC2)C(C)(C)C)=CC=C1NC(N=C12)=NC=C1N(C)C(=O)C(C)(C)CN2C1CCCC1 URIITZNDQCGUGM-UHFFFAOYSA-N 0.000 description 2
• VQABXGLCIBLPOI-UHFFFAOYSA-N n-(2-chloropyridin-4-yl)-4-[(9-cyclopentyl-5,7,7-trimethyl-6-oxo-8h-pyrimido[4,5-b][1,4]diazepin-2-yl)amino]-3-methoxybenzamide Chemical compound COC1=CC(C(=O)NC=2C=C(Cl)N=CC=2)=CC=C1NC(N=C12)=NC=C1N(C)C(=O)C(C)(C)CN2C1CCCC1 VQABXGLCIBLPOI-UHFFFAOYSA-N 0.000 description 2
• IKOYBKSNMRYXOZ-UHFFFAOYSA-N n-(cyanomethyl)-4-[(9-cyclopentyl-5,7,7-trimethyl-6-oxo-8h-pyrimido[4,5-b][1,4]diazepin-2-yl)amino]-3-methoxybenzamide Chemical compound COC1=CC(C(=O)NCC#N)=CC=C1NC1=NC=C(N(C)C(=O)C(C)(C)CN2C3CCCC3)C2=N1 IKOYBKSNMRYXOZ-UHFFFAOYSA-N 0.000 description 2
• NERLPHKZMCBFPP-UHFFFAOYSA-N n-(cyclobutylmethyl)-4-[(9-cyclopentyl-5,7,7-trimethyl-6-oxo-8h-pyrimido[4,5-b][1,4]diazepin-2-yl)amino]-3-methoxybenzamide Chemical compound COC1=CC(C(=O)NCC2CCC2)=CC=C1NC(N=C12)=NC=C1N(C)C(=O)C(C)(C)CN2C1CCCC1 NERLPHKZMCBFPP-UHFFFAOYSA-N 0.000 description 2
• ZHEGAZKODCWEBM-UHFFFAOYSA-N n-(cyclohexylmethyl)-4-[(9-cyclopentyl-5,7,7-trimethyl-6-oxo-8h-pyrimido[4,5-b][1,4]diazepin-2-yl)amino]-3-methoxybenzamide Chemical compound COC1=CC(C(=O)NCC2CCCCC2)=CC=C1NC(N=C12)=NC=C1N(C)C(=O)C(C)(C)CN2C1CCCC1 ZHEGAZKODCWEBM-UHFFFAOYSA-N 0.000 description 2
• QAJALZJPTGXLHN-UHFFFAOYSA-N n-(cyclopentylmethyl)-4-[(9-cyclopentyl-5,7,7-trimethyl-6-oxo-8h-pyrimido[4,5-b][1,4]diazepin-2-yl)amino]-3-methoxybenzamide Chemical compound COC1=CC(C(=O)NCC2CCCC2)=CC=C1NC(N=C12)=NC=C1N(C)C(=O)C(C)(C)CN2C1CCCC1 QAJALZJPTGXLHN-UHFFFAOYSA-N 0.000 description 2
• LVXGGSTXTLXQMQ-UHFFFAOYSA-N n-cyclobutyl-4-[(9-cyclopentyl-5,7,7-trimethyl-6-oxo-8h-pyrimido[4,5-b][1,4]diazepin-2-yl)amino]-3-methoxybenzamide Chemical compound COC1=CC(C(=O)NC2CCC2)=CC=C1NC(N=C12)=NC=C1N(C)C(=O)C(C)(C)CN2C1CCCC1 LVXGGSTXTLXQMQ-UHFFFAOYSA-N 0.000 description 2
• ANTWPJPZFVLZPS-MRXNPFEDSA-N n-cyclobutyl-4-[[(7r)-9-cyclopentyl-5,7-dimethyl-6-oxo-7,8-dihydropyrimido[4,5-b][1,4]diazepin-2-yl]amino]-3-methoxybenzamide Chemical compound C([C@@H](C)C(=O)N(C)C1=CN=C(N=C11)NC2=CC=C(C=C2OC)C(=O)NC2CCC2)N1C1CCCC1 ANTWPJPZFVLZPS-MRXNPFEDSA-N 0.000 description 2
• GZOUZDNUISIKSY-KRWDZBQOSA-N n-cyclobutyl-4-[[(7s)-9-cyclopentyl-7-ethyl-5-methyl-6-oxo-7,8-dihydropyrimido[4,5-b][1,4]diazepin-2-yl]amino]-3-methoxybenzamide Chemical compound C([C@@H](C(N(C)C1=CN=C(NC=2C(=CC(=CC=2)C(=O)NC2CCC2)OC)N=C11)=O)CC)N1C1CCCC1 GZOUZDNUISIKSY-KRWDZBQOSA-N 0.000 description 2
• JQNVMLKGUBCNHT-UHFFFAOYSA-N n-cyclopentyl-4-[(9-cyclopentyl-5,7,7-trimethyl-6-oxo-8h-pyrimido[4,5-b][1,4]diazepin-2-yl)amino]-3-methoxybenzamide Chemical compound COC1=CC(C(=O)NC2CCCC2)=CC=C1NC(N=C12)=NC=C1N(C)C(=O)C(C)(C)CN2C1CCCC1 JQNVMLKGUBCNHT-UHFFFAOYSA-N 0.000 description 2
• HAVZUXSUOYXIKT-UHFFFAOYSA-N n-cyclopentyl-4-[(9-cyclopentyl-5-methyl-6-oxospiro[8h-pyrimido[4,5-b][1,4]diazepine-7,1'-cyclopropane]-2-yl)amino]-3-methoxybenzamide Chemical compound COC1=CC(C(=O)NC2CCCC2)=CC=C1NC(N=C1N(C2CCCC2)C2)=NC=C1N(C)C(=O)C12CC1 HAVZUXSUOYXIKT-UHFFFAOYSA-N 0.000 description 2
• OJMFTGXNNVNPKN-UHFFFAOYSA-N n-tert-butyl-4-[(9-cyclopentyl-5,7,7-trimethyl-6-oxo-8h-pyrimido[4,5-b][1,4]diazepin-2-yl)amino]-3-methoxybenzamide Chemical compound COC1=CC(C(=O)NC(C)(C)C)=CC=C1NC1=NC=C(N(C)C(=O)C(C)(C)CN2C3CCCC3)C2=N1 OJMFTGXNNVNPKN-UHFFFAOYSA-N 0.000 description 2
• 239000007922 nasal spray Substances 0.000 description 2
• 201000008026 nephroblastoma Diseases 0.000 description 2
• 229910052759 nickel Inorganic materials 0.000 description 2
• 231100000344 non-irritating Toxicity 0.000 description 2
• 208000002154 non-small cell lung carcinoma Diseases 0.000 description 2
• ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 2
• 235000008390 olive oil Nutrition 0.000 description 2
• 235000005985 organic acids Nutrition 0.000 description 2
• 239000012044 organic layer Substances 0.000 description 2
• 201000008968 osteosarcoma Diseases 0.000 description 2
• 239000001301 oxygen Substances 0.000 description 2
• 229960001592 paclitaxel Drugs 0.000 description 2
• 201000002528 pancreatic cancer Diseases 0.000 description 2
• 208000008443 pancreatic carcinoma Diseases 0.000 description 2
• 201000010198 papillary carcinoma Diseases 0.000 description 2
• 230000037361 pathway Effects 0.000 description 2
• 230000035515 penetration Effects 0.000 description 2
• VLTRZXGMWDSKGL-UHFFFAOYSA-N perchloric acid Chemical compound OCl(=O)(=O)=O VLTRZXGMWDSKGL-UHFFFAOYSA-N 0.000 description 2
• 239000002304 perfume Substances 0.000 description 2
• 229940066842 petrolatum Drugs 0.000 description 2
• WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 2
• XHXFXVLFKHQFAL-UHFFFAOYSA-N phosphoryl trichloride Chemical compound ClP(Cl)(Cl)=O XHXFXVLFKHQFAL-UHFFFAOYSA-N 0.000 description 2
• 230000026731 phosphorylation Effects 0.000 description 2
• 238000006366 phosphorylation reaction Methods 0.000 description 2
• 239000003757 phosphotransferase inhibitor Substances 0.000 description 2
• 125000004483 piperidin-3-yl group Chemical group N1CC(CCC1)* 0.000 description 2
• JSPCTNUQYWIIOT-UHFFFAOYSA-N piperidine-1-carboxamide Chemical compound NC(=O)N1CCCCC1 JSPCTNUQYWIIOT-UHFFFAOYSA-N 0.000 description 2
• 229920000058 polyacrylate Polymers 0.000 description 2
• 239000001267 polyvinylpyrrolidone Substances 0.000 description 2
• 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
• 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
• 229910000027 potassium carbonate Inorganic materials 0.000 description 2
• 239000004302 potassium sorbate Substances 0.000 description 2
• 235000010241 potassium sorbate Nutrition 0.000 description 2
• 229940069338 potassium sorbate Drugs 0.000 description 2
• 229920001592 potato starch Polymers 0.000 description 2
• 239000000047 product Substances 0.000 description 2
• 229950008679 protamine sulfate Drugs 0.000 description 2
• 238000000746 purification Methods 0.000 description 2
• 206010038038 rectal cancer Diseases 0.000 description 2
• 201000001275 rectum cancer Diseases 0.000 description 2
• 230000009467 reduction Effects 0.000 description 2
• 238000010992 reflux Methods 0.000 description 2
• 201000009410 rhabdomyosarcoma Diseases 0.000 description 2
• 239000000523 sample Substances 0.000 description 2
• 239000008159 sesame oil Substances 0.000 description 2
• 235000011803 sesame oil Nutrition 0.000 description 2
• 230000035939 shock Effects 0.000 description 2
• 229910052710 silicon Inorganic materials 0.000 description 2
• 239000010703 silicon Substances 0.000 description 2
• 239000000377 silicon dioxide Substances 0.000 description 2
• 208000000649 small cell carcinoma Diseases 0.000 description 2
• 210000000813 small intestine Anatomy 0.000 description 2
• 239000011734 sodium Substances 0.000 description 2
• 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 2
• 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 2
• 239000011780 sodium chloride Substances 0.000 description 2
• 235000019333 sodium laurylsulphate Nutrition 0.000 description 2
• HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical class O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 2
• 239000004334 sorbic acid Substances 0.000 description 2
• 235000010199 sorbic acid Nutrition 0.000 description 2
• 229940075582 sorbic acid Drugs 0.000 description 2
• 241000894007 species Species 0.000 description 2
• 239000007921 spray Substances 0.000 description 2
• 239000008107 starch Substances 0.000 description 2
• 210000002784 stomach Anatomy 0.000 description 2
• 238000003860 storage Methods 0.000 description 2
• KDYFGRWQOYBRFD-UHFFFAOYSA-N succinic acid Chemical compound OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 2
• 238000001308 synthesis method Methods 0.000 description 2
• 230000002194 synthesizing effect Effects 0.000 description 2
• 239000000454 talc Substances 0.000 description 2
• 229910052623 talc Inorganic materials 0.000 description 2
• 235000012222 talc Nutrition 0.000 description 2
• RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 2
• 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
• 201000003120 testicular cancer Diseases 0.000 description 2
• 238000004809 thin layer chromatography Methods 0.000 description 2
• 125000004001 thioalkyl group Chemical group 0.000 description 2
• 210000002105 tongue Anatomy 0.000 description 2
• 238000001890 transfection Methods 0.000 description 2
• 125000001425 triazolyl group Chemical group 0.000 description 2
• 230000001960 triggered effect Effects 0.000 description 2
• PYOKUURKVVELLB-UHFFFAOYSA-N trimethyl orthoformate Chemical compound COC(OC)OC PYOKUURKVVELLB-UHFFFAOYSA-N 0.000 description 2
• 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 description 2
• 201000005112 urinary bladder cancer Diseases 0.000 description 2
• 235000013311 vegetables Nutrition 0.000 description 2
• 235000021119 whey protein Nutrition 0.000 description 2
• 150000003751 zinc Chemical class 0.000 description 2
• VCGRFBXVSFAGGA-UHFFFAOYSA-N (1,1-dioxo-1,4-thiazinan-4-yl)-[6-[[3-(4-fluorophenyl)-5-methyl-1,2-oxazol-4-yl]methoxy]pyridin-3-yl]methanone Chemical compound CC=1ON=C(C=2C=CC(F)=CC=2)C=1COC(N=C1)=CC=C1C(=O)N1CCS(=O)(=O)CC1 VCGRFBXVSFAGGA-UHFFFAOYSA-N 0.000 description 1
• SHAHPWSYJFYMRX-GDLCADMTSA-N (2S)-2-(4-{[(1R,2S)-2-hydroxycyclopentyl]methyl}phenyl)propanoic acid Chemical compound C1=CC([C@@H](C(O)=O)C)=CC=C1C[C@@H]1[C@@H](O)CCC1 SHAHPWSYJFYMRX-GDLCADMTSA-N 0.000 description 1
• DOMQFIFVDIAOOT-ROUUACIJSA-N (2S,3R)-N-[4-(2,6-dimethoxyphenyl)-5-(5-methylpyridin-3-yl)-1,2,4-triazol-3-yl]-3-(5-methylpyrimidin-2-yl)butane-2-sulfonamide Chemical compound COC1=C(C(=CC=C1)OC)N1C(=NN=C1C=1C=NC=C(C=1)C)NS(=O)(=O)[C@@H](C)[C@H](C)C1=NC=C(C=N1)C DOMQFIFVDIAOOT-ROUUACIJSA-N 0.000 description 1
• JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical compound OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 1
• NDVRKEKNSBMTAX-BTVCFUMJSA-N (2r,3s,4r,5r)-2,3,4,5,6-pentahydroxyhexanal;phosphoric acid Chemical class OP(O)(O)=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O NDVRKEKNSBMTAX-BTVCFUMJSA-N 0.000 description 1
• MAYZWDRUFKUGGP-VIFPVBQESA-N (3s)-1-[5-tert-butyl-3-[(1-methyltetrazol-5-yl)methyl]triazolo[4,5-d]pyrimidin-7-yl]pyrrolidin-3-ol Chemical compound CN1N=NN=C1CN1C2=NC(C(C)(C)C)=NC(N3C[C@@H](O)CC3)=C2N=N1 MAYZWDRUFKUGGP-VIFPVBQESA-N 0.000 description 1
• MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 1
• 125000006570 (C5-C6) heteroaryl group Chemical group 0.000 description 1
• UKGJZDSUJSPAJL-YPUOHESYSA-N (e)-n-[(1r)-1-[3,5-difluoro-4-(methanesulfonamido)phenyl]ethyl]-3-[2-propyl-6-(trifluoromethyl)pyridin-3-yl]prop-2-enamide Chemical compound CCCC1=NC(C(F)(F)F)=CC=C1\C=C\C(=O)N[C@H](C)C1=CC(F)=C(NS(C)(=O)=O)C(F)=C1 UKGJZDSUJSPAJL-YPUOHESYSA-N 0.000 description 1
• DQXKOHDUMJLXKH-PHEQNACWSA-N (e)-n-[2-[2-[[(e)-oct-2-enoyl]amino]ethyldisulfanyl]ethyl]oct-2-enamide Chemical compound CCCCC\C=C\C(=O)NCCSSCCNC(=O)\C=C\CCCCC DQXKOHDUMJLXKH-PHEQNACWSA-N 0.000 description 1
• ZGYIXVSQHOKQRZ-COIATFDQSA-N (e)-n-[4-[3-chloro-4-(pyridin-2-ylmethoxy)anilino]-3-cyano-7-[(3s)-oxolan-3-yl]oxyquinolin-6-yl]-4-(dimethylamino)but-2-enamide Chemical compound N#CC1=CN=C2C=C(O[C@@H]3COCC3)C(NC(=O)/C=C/CN(C)C)=CC2=C1NC(C=C1Cl)=CC=C1OCC1=CC=CC=N1 ZGYIXVSQHOKQRZ-COIATFDQSA-N 0.000 description 1
• MOWXJLUYGFNTAL-DEOSSOPVSA-N (s)-[2-chloro-4-fluoro-5-(7-morpholin-4-ylquinazolin-4-yl)phenyl]-(6-methoxypyridazin-3-yl)methanol Chemical compound N1=NC(OC)=CC=C1[C@@H](O)C1=CC(C=2C3=CC=C(C=C3N=CN=2)N2CCOCC2)=C(F)C=C1Cl MOWXJLUYGFNTAL-DEOSSOPVSA-N 0.000 description 1
• 125000004502 1,2,3-oxadiazolyl group Chemical group 0.000 description 1
• 125000004511 1,2,3-thiadiazolyl group Chemical group 0.000 description 1
• 125000001399 1,2,3-triazolyl group Chemical group N1N=NC(=C1)* 0.000 description 1
• 125000004504 1,2,4-oxadiazolyl group Chemical group 0.000 description 1
• 125000004506 1,2,5-oxadiazolyl group Chemical group 0.000 description 1
• 125000004517 1,2,5-thiadiazolyl group Chemical group 0.000 description 1
• LRANPJDWHYRCER-UHFFFAOYSA-N 1,2-diazepine Chemical compound N1C=CC=CC=N1 LRANPJDWHYRCER-UHFFFAOYSA-N 0.000 description 1
• 125000004520 1,3,4-thiadiazolyl group Chemical group 0.000 description 1
• 125000003363 1,3,5-triazinyl group Chemical group N1=C(N=CN=C1)* 0.000 description 1
• 229940058015 1,3-butylene glycol Drugs 0.000 description 1
• APWRZPQBPCAXFP-UHFFFAOYSA-N 1-(1-oxo-2H-isoquinolin-5-yl)-5-(trifluoromethyl)-N-[2-(trifluoromethyl)pyridin-4-yl]pyrazole-4-carboxamide Chemical compound O=C1NC=CC2=C(C=CC=C12)N1N=CC(=C1C(F)(F)F)C(=O)NC1=CC(=NC=C1)C(F)(F)F APWRZPQBPCAXFP-UHFFFAOYSA-N 0.000 description 1
• ABDDQTDRAHXHOC-QMMMGPOBSA-N 1-[(7s)-5,7-dihydro-4h-thieno[2,3-c]pyran-7-yl]-n-methylmethanamine Chemical compound CNC[C@@H]1OCCC2=C1SC=C2 ABDDQTDRAHXHOC-QMMMGPOBSA-N 0.000 description 1
• 125000004214 1-pyrrolidinyl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
• 125000001462 1-pyrrolyl group Chemical group [*]N1C([H])=C([H])C([H])=C1[H] 0.000 description 1
• INUSQTPGSHFGHM-UHFFFAOYSA-N 2,4-dichloro-5-nitropyrimidine Chemical compound [O-][N+](=O)C1=CN=C(Cl)N=C1Cl INUSQTPGSHFGHM-UHFFFAOYSA-N 0.000 description 1
• HIXDQWDOVZUNNA-UHFFFAOYSA-N 2-(3,4-dimethoxyphenyl)-5-hydroxy-7-methoxychromen-4-one Chemical compound C=1C(OC)=CC(O)=C(C(C=2)=O)C=1OC=2C1=CC=C(OC)C(OC)=C1 HIXDQWDOVZUNNA-UHFFFAOYSA-N 0.000 description 1
• HHJRAPWGDBLANS-UHFFFAOYSA-N 2-(3-aminoanilino)-9-cyclopentyl-5,7,7-trimethyl-8h-pyrimido[4,5-b][1,4]diazepin-6-one Chemical compound N1=C2N(C3CCCC3)CC(C)(C)C(=O)N(C)C2=CN=C1NC1=CC=CC(N)=C1 HHJRAPWGDBLANS-UHFFFAOYSA-N 0.000 description 1
• SKDJWBCTSQLYAZ-UHFFFAOYSA-N 2-chloro-9-cyclopentyl-7,7-dimethyl-5,8-dihydropyrimido[4,5-b][1,4]diazepin-6-one Chemical compound C12=NC(Cl)=NC=C2NC(=O)C(C)(C)CN1C1CCCC1 SKDJWBCTSQLYAZ-UHFFFAOYSA-N 0.000 description 1
• 125000002941 2-furyl group Chemical group O1C([*])=C([H])C([H])=C1[H] 0.000 description 1
• WVKPYYLOFMTDHB-UHFFFAOYSA-N 2-norbornyl radical Chemical group C1CC2[CH]CC1C2 WVKPYYLOFMTDHB-UHFFFAOYSA-N 0.000 description 1
• LEACJMVNYZDSKR-UHFFFAOYSA-N 2-octyldodecan-1-ol Chemical compound CCCCCCCCCCC(CO)CCCCCCCC LEACJMVNYZDSKR-UHFFFAOYSA-N 0.000 description 1
• 125000004485 2-pyrrolidinyl group Chemical group [H]N1C([H])([H])C([H])([H])C([H])([H])C1([H])* 0.000 description 1
• 125000000389 2-pyrrolyl group Chemical group [H]N1C([*])=C([H])C([H])=C1[H] 0.000 description 1
• 125000000175 2-thienyl group Chemical group S1C([*])=C([H])C([H])=C1[H] 0.000 description 1
• KGUHUVQIJHGHLX-UHFFFAOYSA-N 2h-triazolo[4,5-b]pyridin-5-amine Chemical compound NC1=CC=C2NN=NC2=N1 KGUHUVQIJHGHLX-UHFFFAOYSA-N 0.000 description 1
• HCDMJFOHIXMBOV-UHFFFAOYSA-N 3-(2,6-difluoro-3,5-dimethoxyphenyl)-1-ethyl-8-(morpholin-4-ylmethyl)-4,7-dihydropyrrolo[4,5]pyrido[1,2-d]pyrimidin-2-one Chemical compound C=1C2=C3N(CC)C(=O)N(C=4C(=C(OC)C=C(OC)C=4F)F)CC3=CN=C2NC=1CN1CCOCC1 HCDMJFOHIXMBOV-UHFFFAOYSA-N 0.000 description 1
• BYHQTRFJOGIQAO-GOSISDBHSA-N 3-(4-bromophenyl)-8-[(2R)-2-hydroxypropyl]-1-[(3-methoxyphenyl)methyl]-1,3,8-triazaspiro[4.5]decan-2-one Chemical compound C[C@H](CN1CCC2(CC1)CN(C(=O)N2CC3=CC(=CC=C3)OC)C4=CC=C(C=C4)Br)O BYHQTRFJOGIQAO-GOSISDBHSA-N 0.000 description 1
• YGYGASJNJTYNOL-CQSZACIVSA-N 3-[(4r)-2,2-dimethyl-1,1-dioxothian-4-yl]-5-(4-fluorophenyl)-1h-indole-7-carboxamide Chemical compound C1CS(=O)(=O)C(C)(C)C[C@@H]1C1=CNC2=C(C(N)=O)C=C(C=3C=CC(F)=CC=3)C=C12 YGYGASJNJTYNOL-CQSZACIVSA-N 0.000 description 1
• WNEODWDFDXWOLU-QHCPKHFHSA-N 3-[3-(hydroxymethyl)-4-[1-methyl-5-[[5-[(2s)-2-methyl-4-(oxetan-3-yl)piperazin-1-yl]pyridin-2-yl]amino]-6-oxopyridin-3-yl]pyridin-2-yl]-7,7-dimethyl-1,2,6,8-tetrahydrocyclopenta[3,4]pyrrolo[3,5-b]pyrazin-4-one Chemical compound C([C@@H](N(CC1)C=2C=NC(NC=3C(N(C)C=C(C=3)C=3C(=C(N4C(C5=CC=6CC(C)(C)CC=6N5CC4)=O)N=CC=3)CO)=O)=CC=2)C)N1C1COC1 WNEODWDFDXWOLU-QHCPKHFHSA-N 0.000 description 1
• SRVXSISGYBMIHR-UHFFFAOYSA-N 3-[3-[3-(2-amino-2-oxoethyl)phenyl]-5-chlorophenyl]-3-(5-methyl-1,3-thiazol-2-yl)propanoic acid Chemical compound S1C(C)=CN=C1C(CC(O)=O)C1=CC(Cl)=CC(C=2C=C(CC(N)=O)C=CC=2)=C1 SRVXSISGYBMIHR-UHFFFAOYSA-N 0.000 description 1
• BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
• 125000003682 3-furyl group Chemical group O1C([H])=C([*])C([H])=C1[H] 0.000 description 1
• QOXOZONBQWIKDA-UHFFFAOYSA-N 3-hydroxypropyl Chemical group [CH2]CCO QOXOZONBQWIKDA-UHFFFAOYSA-N 0.000 description 1
• XMIIGOLPHOKFCH-UHFFFAOYSA-N 3-phenylpropionic acid Chemical class OC(=O)CCC1=CC=CC=C1 XMIIGOLPHOKFCH-UHFFFAOYSA-N 0.000 description 1
• 125000001397 3-pyrrolyl group Chemical group [H]N1C([H])=C([*])C([H])=C1[H] 0.000 description 1
• 125000001541 3-thienyl group Chemical group S1C([H])=C([*])C([H])=C1[H] 0.000 description 1
• VJPPLCNBDLZIFG-ZDUSSCGKSA-N 4-[(3S)-3-(but-2-ynoylamino)piperidin-1-yl]-5-fluoro-2,3-dimethyl-1H-indole-7-carboxamide Chemical compound C(C#CC)(=O)N[C@@H]1CN(CCC1)C1=C2C(=C(NC2=C(C=C1F)C(=O)N)C)C VJPPLCNBDLZIFG-ZDUSSCGKSA-N 0.000 description 1
• IAESHQLORVVSTM-UHFFFAOYSA-N 4-[(9-cyclopentyl-5,7,7-trimethyl-6-oxo-8h-pyrimido[4,5-b][1,4]diazepin-2-yl)sulfanyl]benzoic acid Chemical compound N1=C2N(C3CCCC3)CC(C)(C)C(=O)N(C)C2=CN=C1SC1=CC=C(C(O)=O)C=C1 IAESHQLORVVSTM-UHFFFAOYSA-N 0.000 description 1
• YFCIFWOJYYFDQP-PTWZRHHISA-N 4-[3-amino-6-[(1S,3S,4S)-3-fluoro-4-hydroxycyclohexyl]pyrazin-2-yl]-N-[(1S)-1-(3-bromo-5-fluorophenyl)-2-(methylamino)ethyl]-2-fluorobenzamide Chemical compound CNC[C@@H](NC(=O)c1ccc(cc1F)-c1nc(cnc1N)[C@H]1CC[C@H](O)[C@@H](F)C1)c1cc(F)cc(Br)c1 YFCIFWOJYYFDQP-PTWZRHHISA-N 0.000 description 1
• XYWIPYBIIRTJMM-IBGZPJMESA-N 4-[[(2S)-2-[4-[5-chloro-2-[4-(trifluoromethyl)triazol-1-yl]phenyl]-5-methoxy-2-oxopyridin-1-yl]butanoyl]amino]-2-fluorobenzamide Chemical compound CC[C@H](N1C=C(OC)C(=CC1=O)C1=C(C=CC(Cl)=C1)N1C=C(N=N1)C(F)(F)F)C(=O)NC1=CC(F)=C(C=C1)C(N)=O XYWIPYBIIRTJMM-IBGZPJMESA-N 0.000 description 1
• JNFGLYJROFAOQP-UHFFFAOYSA-N 4-amino-3-methoxybenzoic acid Chemical compound COC1=CC(C(O)=O)=CC=C1N JNFGLYJROFAOQP-UHFFFAOYSA-N 0.000 description 1
• KVCQTKNUUQOELD-UHFFFAOYSA-N 4-amino-n-[1-(3-chloro-2-fluoroanilino)-6-methylisoquinolin-5-yl]thieno[3,2-d]pyrimidine-7-carboxamide Chemical compound N=1C=CC2=C(NC(=O)C=3C4=NC=NC(N)=C4SC=3)C(C)=CC=C2C=1NC1=CC=CC(Cl)=C1F KVCQTKNUUQOELD-UHFFFAOYSA-N 0.000 description 1
• PHNDZBFLOPIMSM-UHFFFAOYSA-N 4-morpholin-4-ylaniline Chemical compound C1=CC(N)=CC=C1N1CCOCC1 PHNDZBFLOPIMSM-UHFFFAOYSA-N 0.000 description 1
• KDDQRKBRJSGMQE-UHFFFAOYSA-N 4-thiazolyl Chemical group [C]1=CSC=N1 KDDQRKBRJSGMQE-UHFFFAOYSA-N 0.000 description 1
• IRPVABHDSJVBNZ-RTHVDDQRSA-N 5-[1-(cyclopropylmethyl)-5-[(1R,5S)-3-(oxetan-3-yl)-3-azabicyclo[3.1.0]hexan-6-yl]pyrazol-3-yl]-3-(trifluoromethyl)pyridin-2-amine Chemical compound C1=C(C(F)(F)F)C(N)=NC=C1C1=NN(CC2CC2)C(C2[C@@H]3CN(C[C@@H]32)C2COC2)=C1 IRPVABHDSJVBNZ-RTHVDDQRSA-N 0.000 description 1
• 125000006163 5-membered heteroaryl group Chemical group 0.000 description 1
• CWDWFSXUQODZGW-UHFFFAOYSA-N 5-thiazolyl Chemical group [C]1=CN=CS1 CWDWFSXUQODZGW-UHFFFAOYSA-N 0.000 description 1
• KCBWAFJCKVKYHO-UHFFFAOYSA-N 6-(4-cyclopropyl-6-methoxypyrimidin-5-yl)-1-[[4-[1-propan-2-yl-4-(trifluoromethyl)imidazol-2-yl]phenyl]methyl]pyrazolo[3,4-d]pyrimidine Chemical compound C1(CC1)C1=NC=NC(=C1C1=NC=C2C(=N1)N(N=C2)CC1=CC=C(C=C1)C=1N(C=C(N=1)C(F)(F)F)C(C)C)OC KCBWAFJCKVKYHO-UHFFFAOYSA-N 0.000 description 1
• CYJRNFFLTBEQSQ-UHFFFAOYSA-N 8-(3-methyl-1-benzothiophen-5-yl)-N-(4-methylsulfonylpyridin-3-yl)quinoxalin-6-amine Chemical compound CS(=O)(=O)C1=C(C=NC=C1)NC=1C=C2N=CC=NC2=C(C=1)C=1C=CC2=C(C(=CS2)C)C=1 CYJRNFFLTBEQSQ-UHFFFAOYSA-N 0.000 description 1
• HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 1
• YKSPTILLIBXGII-UHFFFAOYSA-N 8-chloro-6-cyclopentyl-4,4-dimethyl-5,6-dihydro-4h-2,3,6,7,9,10b-hexaazabenzo[e]azulene Chemical compound C12=NC(Cl)=NC=C2N2C=NN=C2C(C)(C)CN1C1CCCC1 YKSPTILLIBXGII-UHFFFAOYSA-N 0.000 description 1
• YZUFMZSZWFLZDH-UHFFFAOYSA-N 9-benzyl-2-chloro-5,7,7-trimethyl-8h-pyrimido[4,5-b][1,4]diazepin-6-one Chemical compound C1C(C)(C)C(=O)N(C)C2=CN=C(Cl)N=C2N1CC1=CC=CC=C1 YZUFMZSZWFLZDH-UHFFFAOYSA-N 0.000 description 1
• NEDIGACWKVQDAE-UHFFFAOYSA-N 9-cyclopentyl-2-(1h-indazol-4-ylamino)-5,7,7-trimethyl-8h-pyrimido[4,5-b][1,4]diazepin-6-one Chemical compound C1C(C)(C)C(=O)N(C)C2=CN=C(NC=3C=4C=NNC=4C=CC=3)N=C2N1C1CCCC1 NEDIGACWKVQDAE-UHFFFAOYSA-N 0.000 description 1
• XBIRNKAGDXWNEE-UHFFFAOYSA-N 9-cyclopentyl-2-(2-methoxyanilino)-5,7,7-trimethyl-8h-pyrimido[4,5-b][1,4]diazepin-6-one Chemical compound COC1=CC=CC=C1NC1=NC=C(N(C)C(=O)C(C)(C)CN2C3CCCC3)C2=N1 XBIRNKAGDXWNEE-UHFFFAOYSA-N 0.000 description 1
• LUZHCQWNCOYFSK-UHFFFAOYSA-N 9-cyclopentyl-5,7,7-trimethyl-2-(3-nitroanilino)-8h-pyrimido[4,5-b][1,4]diazepin-6-one Chemical compound N1=C2N(C3CCCC3)CC(C)(C)C(=O)N(C)C2=CN=C1NC1=CC=CC([N+]([O-])=O)=C1 LUZHCQWNCOYFSK-UHFFFAOYSA-N 0.000 description 1
• 239000005541 ACE inhibitor Substances 0.000 description 1
• ZRPZPNYZFSJUPA-UHFFFAOYSA-N ARS-1620 Chemical compound Oc1cccc(F)c1-c1c(Cl)cc2c(ncnc2c1F)N1CCN(CC1)C(=O)C=C ZRPZPNYZFSJUPA-UHFFFAOYSA-N 0.000 description 1
• 108091006112 ATPases Proteins 0.000 description 1
• 244000215068 Acacia senegal Species 0.000 description 1
• 208000031261 Acute myeloid leukaemia Diseases 0.000 description 1
• 208000003200 Adenoma Diseases 0.000 description 1
• 102100034540 Adenomatous polyposis coli protein Human genes 0.000 description 1
• 102000057290 Adenosine Triphosphatases Human genes 0.000 description 1
• 239000005995 Aluminium silicate Substances 0.000 description 1
• 235000017060 Arachis glabrata Nutrition 0.000 description 1
• 244000105624 Arachis hypogaea Species 0.000 description 1
• 235000010777 Arachis hypogaea Nutrition 0.000 description 1
• 235000018262 Arachis monticola Nutrition 0.000 description 1
• 241000416162 Astragalus gummifer Species 0.000 description 1
• 206010003571 Astrocytoma Diseases 0.000 description 1
• 108700020462 BRCA2 Proteins 0.000 description 1
• 102000052609 BRCA2 Human genes 0.000 description 1
• 206010004146 Basal cell carcinoma Diseases 0.000 description 1
• 206010004593 Bile duct cancer Diseases 0.000 description 1
• 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
• 101150008921 Brca2 gene Proteins 0.000 description 1
• BVLLBTWBAUEOOL-IPKLBLQBSA-N CC(C)(CN(C1CCCC1)/C(/CN1C)=N/C(/Nc(ccc(C(N[C@H]2C[C@H](CO)CC2)=O)c2)c2OC)=N\C)C1=O Chemical compound CC(C)(CN(C1CCCC1)/C(/CN1C)=N/C(/Nc(ccc(C(N[C@H]2C[C@H](CO)CC2)=O)c2)c2OC)=N\C)C1=O BVLLBTWBAUEOOL-IPKLBLQBSA-N 0.000 description 1
• LAGLGFBALKKABO-UHFFFAOYSA-O CC(C)(CN(C1CCCC1)c(nc(NC(C1=N)=CC=CC1=C[NH2+]C)nc1)c1N1C)C1=O Chemical compound CC(C)(CN(C1CCCC1)c(nc(NC(C1=N)=CC=CC1=C[NH2+]C)nc1)c1N1C)C1=O LAGLGFBALKKABO-UHFFFAOYSA-O 0.000 description 1
• UWYFNNNOAAICEE-UHFFFAOYSA-N CC(C)(CN(C1CCCC1)c(nc(NCCc1ccccc1)nc1)c1N1C)C1=O Chemical compound CC(C)(CN(C1CCCC1)c(nc(NCCc1ccccc1)nc1)c1N1C)C1=O UWYFNNNOAAICEE-UHFFFAOYSA-N 0.000 description 1
• VUCLBKNZSAHVIB-UHFFFAOYSA-N CC(C)(CN(C1CCCC1)c(nc(Nc(c(OC)c1)ccc1C(NC1CCN(CC2CC2)CC1)=O)nc1)c1N1C)C1=O Chemical compound CC(C)(CN(C1CCCC1)c(nc(Nc(c(OC)c1)ccc1C(NC1CCN(CC2CC2)CC1)=O)nc1)c1N1C)C1=O VUCLBKNZSAHVIB-UHFFFAOYSA-N 0.000 description 1
• NABLIRBDQYAFFE-OAQYLSRUSA-N CC(C)(CN(C1CCCC1)c(nc(Nc(cc1)c(C)cc1C(NCCOC(N(CC1)C[C@@H]1F)=O)=O)nc1)c1N1C)C1=O Chemical compound CC(C)(CN(C1CCCC1)c(nc(Nc(cc1)c(C)cc1C(NCCOC(N(CC1)C[C@@H]1F)=O)=O)nc1)c1N1C)C1=O NABLIRBDQYAFFE-OAQYLSRUSA-N 0.000 description 1
• HKIFBHKDQPBQCI-UHFFFAOYSA-N CC(C)(CN(C1CCCC1)c(nc(Nc(cc1)cc2c1[nH]nc2)nc1)c1N1C)C1=O Chemical compound CC(C)(CN(C1CCCC1)c(nc(Nc(cc1)cc2c1[nH]nc2)nc1)c1N1C)C1=O HKIFBHKDQPBQCI-UHFFFAOYSA-N 0.000 description 1
• MTBYUKCPWJAZGK-UHFFFAOYSA-N CC(C)(CN(C1CCCC1)c(nc(Nc(cc1)cc2c1[n](C)nc2)nc1)c1N1C)C1=O Chemical compound CC(C)(CN(C1CCCC1)c(nc(Nc(cc1)cc2c1[n](C)nc2)nc1)c1N1C)C1=O MTBYUKCPWJAZGK-UHFFFAOYSA-N 0.000 description 1
• UYKGXIJUXWNSDF-UHFFFAOYSA-N CC(C)(CN(C1CCCC1)c(nc(Nc(cc1)ccc1-[n]1ncnc1)nc1)c1N1C)C1=O Chemical compound CC(C)(CN(C1CCCC1)c(nc(Nc(cc1)ccc1-[n]1ncnc1)nc1)c1N1C)C1=O UYKGXIJUXWNSDF-UHFFFAOYSA-N 0.000 description 1
• NUZMLGLULNNITL-UHFFFAOYSA-N CC(C)(CN(C1CCCC1)c(nc(Nc(cc1)ccc1C(NCCO)=O)nc1)c1N1C)C1=O Chemical compound CC(C)(CN(C1CCCC1)c(nc(Nc(cc1)ccc1C(NCCO)=O)nc1)c1N1C)C1=O NUZMLGLULNNITL-UHFFFAOYSA-N 0.000 description 1
• KVDADAFWXJPUDS-UHFFFAOYSA-N CC(C)(CN(C1CCCC1)c(nc(Nc(cc1)ccc1N(C)C(C)=O)nc1)c1N1C)C1=O Chemical compound CC(C)(CN(C1CCCC1)c(nc(Nc(cc1)ccc1N(C)C(C)=O)nc1)c1N1C)C1=O KVDADAFWXJPUDS-UHFFFAOYSA-N 0.000 description 1
• LFOXUNWCSGGHNO-UHFFFAOYSA-N CC(C)(CN(C1CCCC1)c(nc(Nc(cc1)ccc1N1CCOCC1)nc1)c1N1C)C1=O Chemical compound CC(C)(CN(C1CCCC1)c(nc(Nc(cc1)ccc1N1CCOCC1)nc1)c1N1C)C1=O LFOXUNWCSGGHNO-UHFFFAOYSA-N 0.000 description 1
• BAOOTXQQFTZLAA-UHFFFAOYSA-N CC(C)(CN(C1CCCC1)c(nc(Nc(ccc(C(NC1(CO)CC1)=O)c1)c1OC)nc1)c1N1C)C1=O Chemical compound CC(C)(CN(C1CCCC1)c(nc(Nc(ccc(C(NC1(CO)CC1)=O)c1)c1OC)nc1)c1N1C)C1=O BAOOTXQQFTZLAA-UHFFFAOYSA-N 0.000 description 1
• CTYOHHYDHUKUIO-UHFFFAOYSA-N CC(C)(CN(C1CCCC1)c(nc(Nc(ccc(C(NC1CCN(C)CC1)=O)c1)c1OC)nc1)c1N1C)C1=O Chemical compound CC(C)(CN(C1CCCC1)c(nc(Nc(ccc(C(NC1CCN(C)CC1)=O)c1)c1OC)nc1)c1N1C)C1=O CTYOHHYDHUKUIO-UHFFFAOYSA-N 0.000 description 1
• SZDQCQSMXFPQGV-UHFFFAOYSA-N CC(C)(CN(C1CCCC1)c(nc(Nc(ccc(C(NCC(C(F)(F)F)O)=O)c1)c1OC)nc1)c1N1C)C1=O Chemical compound CC(C)(CN(C1CCCC1)c(nc(Nc(ccc(C(NCC(C(F)(F)F)O)=O)c1)c1OC)nc1)c1N1C)C1=O SZDQCQSMXFPQGV-UHFFFAOYSA-N 0.000 description 1
• PXUYBXKBQLUBHC-UHFFFAOYSA-N CC(C)(CN(C1CCCC1)c(nc(Nc(ccc(C(NCCCOC(C)=O)=O)c1)c1OC)nc1)c1N1C)C1=O Chemical compound CC(C)(CN(C1CCCC1)c(nc(Nc(ccc(C(NCCCOC(C)=O)=O)c1)c1OC)nc1)c1N1C)C1=O PXUYBXKBQLUBHC-UHFFFAOYSA-N 0.000 description 1
• IABIPJNQDHKXLV-UHFFFAOYSA-N CC(C)(CN(C1CCCC1)c(nc(Nc(ccc(C(NCCOC)=O)c1)c1OC)nc1)c1N1C)C1=O Chemical compound CC(C)(CN(C1CCCC1)c(nc(Nc(ccc(C(NCCOC)=O)c1)c1OC)nc1)c1N1C)C1=O IABIPJNQDHKXLV-UHFFFAOYSA-N 0.000 description 1
• QCMBKQDSYOTFIY-WIYYLYMNSA-N CC(C)(CN(C1CCCC1)c(nc(Nc(ccc(C(NC[C@H](CC1)C[C@@H]1O)=O)c1)c1OC)nc1)c1N1C)C1=O Chemical compound CC(C)(CN(C1CCCC1)c(nc(Nc(ccc(C(NC[C@H](CC1)C[C@@H]1O)=O)c1)c1OC)nc1)c1N1C)C1=O QCMBKQDSYOTFIY-WIYYLYMNSA-N 0.000 description 1
• OISKQPUPRVEMAH-AFARHQOCSA-N CC(C)(CN(C1CCCC1)c(nc(Nc(ccc(C(N[C@H](CC1)CC[C@@H]1OC(C)=O)=O)c1)c1OC)nc1)c1N1C)C1=O Chemical compound CC(C)(CN(C1CCCC1)c(nc(Nc(ccc(C(N[C@H](CC1)CC[C@@H]1OC(C)=O)=O)c1)c1OC)nc1)c1N1C)C1=O OISKQPUPRVEMAH-AFARHQOCSA-N 0.000 description 1
• YLZZQMBPXPUEKJ-BGYRXZFFSA-N CC(C)(CN(C1CCCC1)c(nc(Nc(ccc(C(N[C@H](CC1)CC[C@H]1F)=O)c1)c1OC)nc1)c1N1C)C1=O Chemical compound CC(C)(CN(C1CCCC1)c(nc(Nc(ccc(C(N[C@H](CC1)CC[C@H]1F)=O)c1)c1OC)nc1)c1N1C)C1=O YLZZQMBPXPUEKJ-BGYRXZFFSA-N 0.000 description 1
• SJFFXDABYKSIBJ-UHFFFAOYSA-N CC(C)(CN(C1CCCC1)c(nc(Nc(ccc(C(Nc1ncncc1)=O)c1)c1OC)nc1)c1N1C)C1=O Chemical compound CC(C)(CN(C1CCCC1)c(nc(Nc(ccc(C(Nc1ncncc1)=O)c1)c1OC)nc1)c1N1C)C1=O SJFFXDABYKSIBJ-UHFFFAOYSA-N 0.000 description 1
• GTZUOYCYEIDXLJ-UHFFFAOYSA-N CC(C)(CN(C1CCCC1)c(nc(Nc(ccc(F)c1NC(C)=O)c1F)nc1)c1N1C)C1=O Chemical compound CC(C)(CN(C1CCCC1)c(nc(Nc(ccc(F)c1NC(C)=O)c1F)nc1)c1N1C)C1=O GTZUOYCYEIDXLJ-UHFFFAOYSA-N 0.000 description 1
• ULCXIYVGESGDEF-UHFFFAOYSA-N CC(C)(CN(C1CCCC1)c(nc(Nc1ccc(CN2CCOCC2)cc1)nc1)c1N1C)C1=O Chemical compound CC(C)(CN(C1CCCC1)c(nc(Nc1ccc(CN2CCOCC2)cc1)nc1)c1N1C)C1=O ULCXIYVGESGDEF-UHFFFAOYSA-N 0.000 description 1
• AHLAPSWQDYUHJX-UHFFFAOYSA-N CC(C)(CN(C1CCCC1)c(nc(Nc1ccc[n]2ncnc12)nc1)c1N1C)C1=O Chemical compound CC(C)(CN(C1CCCC1)c(nc(Nc1ccc[n]2ncnc12)nc1)c1N1C)C1=O AHLAPSWQDYUHJX-UHFFFAOYSA-N 0.000 description 1
• HAXMPJDSBMKQMV-UHFFFAOYSA-N CC(C)(CN(C1CCCC1)c(nc(Nc1cccc(N)c1C=N)nc1)c1N1C)C1=O Chemical compound CC(C)(CN(C1CCCC1)c(nc(Nc1cccc(N)c1C=N)nc1)c1N1C)C1=O HAXMPJDSBMKQMV-UHFFFAOYSA-N 0.000 description 1
• NWAMFHXEWCPTAM-UHFFFAOYSA-N CC(C)(CN(C1CCCC1)c(nc(Nc1cccc2c1[nH]nc2)nc1)c1N1C)C1=O Chemical compound CC(C)(CN(C1CCCC1)c(nc(Nc1cccc2c1[nH]nc2)nc1)c1N1C)C1=O NWAMFHXEWCPTAM-UHFFFAOYSA-N 0.000 description 1
• UOVJMKOMRYZVHZ-UHFFFAOYSA-N CC(C)(CN(CC1CC1)c(nc(Nc(ccc(C(NC)=O)c1)c1OC)nc1)c1N1C)C1=O Chemical compound CC(C)(CN(CC1CC1)c(nc(Nc(ccc(C(NC)=O)c1)c1OC)nc1)c1N1C)C1=O UOVJMKOMRYZVHZ-UHFFFAOYSA-N 0.000 description 1
• VKRHQNUTSRSYOJ-UHFFFAOYSA-N CC(C)(CN(CC1CCC1)c(nc(Nc(ccc(C(NC)=O)c1)c1OC)nc1)c1N1C)C1=O Chemical compound CC(C)(CN(CC1CCC1)c(nc(Nc(ccc(C(NC)=O)c1)c1OC)nc1)c1N1C)C1=O VKRHQNUTSRSYOJ-UHFFFAOYSA-N 0.000 description 1
• BGJMTKLIUALVRQ-UHFFFAOYSA-N CC(C)Oc(cc(cc1)C(NC2CCN(C)CC2)=O)c1Nc(nc1)nc(N(CC2(C)C)C3CCCC3)c1N(C)C2=O Chemical compound CC(C)Oc(cc(cc1)C(NC2CCN(C)CC2)=O)c1Nc(nc1)nc(N(CC2(C)C)C3CCCC3)c1N(C)C2=O BGJMTKLIUALVRQ-UHFFFAOYSA-N 0.000 description 1
• SGXCWAPQGYPNTI-UHFFFAOYSA-O CC(OC(CC1)CCC1NC(c(cc1)cc(OC)c1[NH2+]c(nc1)nc(N(CC23CC2)C2CCCC2)c1N(C)C3=O)=O)=O Chemical compound CC(OC(CC1)CCC1NC(c(cc1)cc(OC)c1[NH2+]c(nc1)nc(N(CC23CC2)C2CCCC2)c1N(C)C3=O)=O)=O SGXCWAPQGYPNTI-UHFFFAOYSA-O 0.000 description 1
• LFYLNCNDTFUZCQ-UHFFFAOYSA-N CC(OC(CCC1)C1NC(c(cc1)cc(OC)c1Nc(nc1)nc(N(CC23CC2)C2CCCC2)c1N(C)C3=O)=O)=O Chemical compound CC(OC(CCC1)C1NC(c(cc1)cc(OC)c1Nc(nc1)nc(N(CC23CC2)C2CCCC2)c1N(C)C3=O)=O)=O LFYLNCNDTFUZCQ-UHFFFAOYSA-N 0.000 description 1
• VWSLLSXLURJCDF-UHFFFAOYSA-N CC1=NCCN1 Chemical compound CC1=NCCN1 VWSLLSXLURJCDF-UHFFFAOYSA-N 0.000 description 1
• FYDFQCRZFJVNDH-UHFFFAOYSA-N CN(C1=CN=[IH](Nc(ccc(C(NCCCO)=O)c2)c2OC)N=C1N(CC12CC1)C1CCCC1)C2=O Chemical compound CN(C1=CN=[IH](Nc(ccc(C(NCCCO)=O)c2)c2OC)N=C1N(CC12CC1)C1CCCC1)C2=O FYDFQCRZFJVNDH-UHFFFAOYSA-N 0.000 description 1
• JFRNFMQDZRWAQB-UHFFFAOYSA-N CN(CC1)CCC1NC(c(cc1)cc(OC)c1Nc(nc1)nc(N(CC2)C3CCCC3)c1N(C)C2=O)=O Chemical compound CN(CC1)CCC1NC(c(cc1)cc(OC)c1Nc(nc1)nc(N(CC2)C3CCCC3)c1N(C)C2=O)=O JFRNFMQDZRWAQB-UHFFFAOYSA-N 0.000 description 1
• AYZFYPQZAGESSO-UHFFFAOYSA-N CN(c1c(N(CC23CC2)C2CCCC2)nc(Nc(c(OC)c2)ccc2C(NC(CC2)CCC2(F)F)=O)nc1)C3=O Chemical compound CN(c1c(N(CC23CC2)C2CCCC2)nc(Nc(c(OC)c2)ccc2C(NC(CC2)CCC2(F)F)=O)nc1)C3=O AYZFYPQZAGESSO-UHFFFAOYSA-N 0.000 description 1
• AYSSHTSMNJEXEY-RTBURBONSA-N CN(c1c(N(CC23CC2)C2CCCC2)nc(Nc(c(OC)c2)ccc2C(N[C@H](CC2)C[C@@H]2F)=O)nc1)C3=O Chemical compound CN(c1c(N(CC23CC2)C2CCCC2)nc(Nc(c(OC)c2)ccc2C(N[C@H](CC2)C[C@@H]2F)=O)nc1)C3=O AYSSHTSMNJEXEY-RTBURBONSA-N 0.000 description 1
• NWJIAHKJGUWWLP-UHFFFAOYSA-N CN(c1c(N(CC23CC2)C2CCCC2)nc(Nc(ccc(C(NC(CC2)CC2(F)F)=O)c2)c2OC)nc1)C3=O Chemical compound CN(c1c(N(CC23CC2)C2CCCC2)nc(Nc(ccc(C(NC(CC2)CC2(F)F)=O)c2)c2OC)nc1)C3=O NWJIAHKJGUWWLP-UHFFFAOYSA-N 0.000 description 1
• FGWAEUCRIADWCQ-UHFFFAOYSA-N CN(c1c(N(CC23CC2)C2CCCC2)nc(Nc(ccc(C(NC(CC2)CCC2F)=O)c2)c2OC)nc1)C3=O Chemical compound CN(c1c(N(CC23CC2)C2CCCC2)nc(Nc(ccc(C(NC(CC2)CCC2F)=O)c2)c2OC)nc1)C3=O FGWAEUCRIADWCQ-UHFFFAOYSA-N 0.000 description 1
• AQBRFKVEKIVMQL-UHFFFAOYSA-N CN(c1c(N(CC23CC2)C2CCCC2)nc(Nc(ccc(C(NC(CC2)CCC2OC)=O)c2)c2OC)nc1)C3=O Chemical compound CN(c1c(N(CC23CC2)C2CCCC2)nc(Nc(ccc(C(NC(CC2)CCC2OC)=O)c2)c2OC)nc1)C3=O AQBRFKVEKIVMQL-UHFFFAOYSA-N 0.000 description 1
• XTYATBRETNMAEI-UHFFFAOYSA-N CN(c1c(N(CC23CC2)C2CCCC2)nc(Nc(ccc(C(NC(CCC2)C2OC)=O)c2)c2OC)nc1)C3=O Chemical compound CN(c1c(N(CC23CC2)C2CCCC2)nc(Nc(ccc(C(NC(CCC2)C2OC)=O)c2)c2OC)nc1)C3=O XTYATBRETNMAEI-UHFFFAOYSA-N 0.000 description 1
• COHHQNBDIDGAKH-QSVWIEALSA-N CN(c1c(N(CC23CC2)C2CCCC2)nc(Nc(ccc(C(N[C@H](CC2)CC2O)=O)c2)c2OC)nc1)C3=O Chemical compound CN(c1c(N(CC23CC2)C2CCCC2)nc(Nc(ccc(C(N[C@H](CC2)CC2O)=O)c2)c2OC)nc1)C3=O COHHQNBDIDGAKH-QSVWIEALSA-N 0.000 description 1
• PEAQLXYHCWXLFB-DENIHFKCSA-N CN(c1c(N(CC23CC2)C2CCCC2)nc(Nc(ccc(C(N[C@H](CCC2)[C@@H]2O)=O)c2)c2OC)nc1)C3=O Chemical compound CN(c1c(N(CC23CC2)C2CCCC2)nc(Nc(ccc(C(N[C@H](CCC2)[C@@H]2O)=O)c2)c2OC)nc1)C3=O PEAQLXYHCWXLFB-DENIHFKCSA-N 0.000 description 1
• MHTVJVKHRWEXFI-VQTJNVASSA-N CN(c1c(N(CC23CC2)C2CCCC2)nc(Nc(ccc(C(N[C@H](CCC2)[C@H]2F)=O)c2)c2OC)nc1)C3=O Chemical compound CN(c1c(N(CC23CC2)C2CCCC2)nc(Nc(ccc(C(N[C@H](CCC2)[C@H]2F)=O)c2)c2OC)nc1)C3=O MHTVJVKHRWEXFI-VQTJNVASSA-N 0.000 description 1
• BADIOXPYAWHQIP-ROPPNANJSA-N CN(c1c(N(CC23CC2)C2CCCC2)nc(Nc(ccc(C(N[C@H]2CC(CF)CC2)=O)c2)c2OC)nc1)C3=O Chemical compound CN(c1c(N(CC23CC2)C2CCCC2)nc(Nc(ccc(C(N[C@H]2CC(CF)CC2)=O)c2)c2OC)nc1)C3=O BADIOXPYAWHQIP-ROPPNANJSA-N 0.000 description 1
• YWBDFIZWILGVOS-UHFFFAOYSA-N CNC(c(cc1)cc(OC)c1Nc(nc1)nc(N(CC23CC2)C2CCCC2)c1N(C)C3=O)=O Chemical compound CNC(c(cc1)cc(OC)c1Nc(nc1)nc(N(CC23CC2)C2CCCC2)c1N(C)C3=O)=O YWBDFIZWILGVOS-UHFFFAOYSA-N 0.000 description 1
• QCPACNCZCBQULP-UHFFFAOYSA-N CNC(c(cc1)cc(OC)c1Nc(nc1)nc(N(CC23CCC2)C2CCCC2)c1N(C)C3=O)=O Chemical compound CNC(c(cc1)cc(OC)c1Nc(nc1)nc(N(CC23CCC2)C2CCCC2)c1N(C)C3=O)=O QCPACNCZCBQULP-UHFFFAOYSA-N 0.000 description 1
• XZSYZCHWGONALF-UHFFFAOYSA-N COC1=CC(C(=O)NC)=CC=C1NC1=NC=C2N3C=NN=C3CCN(C3CCCC3)C2=N1 Chemical compound COC1=CC(C(=O)NC)=CC=C1NC1=NC=C2N3C=NN=C3CCN(C3CCCC3)C2=N1 XZSYZCHWGONALF-UHFFFAOYSA-N 0.000 description 1
• GMYBDIFIGGQNMC-INIZCTEOSA-N C[C@@H](CO)NC(c(cc1)cc(OC)c1Nc(nc1)nc(N(CC2(C)C)C3CCCC3)c1N(C)C2=O)=O Chemical compound C[C@@H](CO)NC(c(cc1)cc(OC)c1Nc(nc1)nc(N(CC2(C)C)C3CCCC3)c1N(C)C2=O)=O GMYBDIFIGGQNMC-INIZCTEOSA-N 0.000 description 1
• LJRZCDPUYWZGSU-CQSZACIVSA-N C[C@H](C1)N(C2CCCC2)c(nc(Nc(ccc(C(NC)=O)c2)c2OC)nc2)c2N(C)C1=O Chemical compound C[C@H](C1)N(C2CCCC2)c(nc(Nc(ccc(C(NC)=O)c2)c2OC)nc2)c2N(C)C1=O LJRZCDPUYWZGSU-CQSZACIVSA-N 0.000 description 1
• JWIYBGVEKGCORU-CQSZACIVSA-N C[C@H](CN(C1CCCC1)c(nc(Nc(ccc(C(NC)=O)c1)c1OC)nc1)c1N1C)C1=O Chemical compound C[C@H](CN(C1CCCC1)c(nc(Nc(ccc(C(NC)=O)c1)c1OC)nc1)c1N1C)C1=O JWIYBGVEKGCORU-CQSZACIVSA-N 0.000 description 1
• OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
• 229940127291 Calcium channel antagonist Drugs 0.000 description 1
• OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
• 208000009458 Carcinoma in Situ Diseases 0.000 description 1
• 208000006029 Cardiomegaly Diseases 0.000 description 1
• VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
• 229920001268 Cholestyramine Polymers 0.000 description 1
• 208000005243 Chondrosarcoma Diseases 0.000 description 1
• 201000009047 Chordoma Diseases 0.000 description 1
• 208000006332 Choriocarcinoma Diseases 0.000 description 1
• 102000002427 Cyclin B Human genes 0.000 description 1
• 108010068150 Cyclin B Proteins 0.000 description 1
• PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 1
• 108010036949 Cyclosporine Proteins 0.000 description 1
• 201000003883 Cystic fibrosis Diseases 0.000 description 1
• 102000004127 Cytokines Human genes 0.000 description 1
• 108090000695 Cytokines Proteins 0.000 description 1
• FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
• RGHNJXZEOKUKBD-SQOUGZDYSA-M D-gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O RGHNJXZEOKUKBD-SQOUGZDYSA-M 0.000 description 1
• YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 description 1
• FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
• 235000019739 Dicalciumphosphate Nutrition 0.000 description 1
• 101000582926 Dictyostelium discoideum Probable serine/threonine-protein kinase PLK Proteins 0.000 description 1
• 208000007033 Dysgerminoma Diseases 0.000 description 1
• 206010058314 Dysplasia Diseases 0.000 description 1
• LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
• 241000792859 Enema Species 0.000 description 1
• 206010014967 Ependymoma Diseases 0.000 description 1
• 208000000461 Esophageal Neoplasms Diseases 0.000 description 1
• 239000001856 Ethyl cellulose Substances 0.000 description 1
• ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
• 241000400611 Eucalyptus deanei Species 0.000 description 1
• 208000006168 Ewing Sarcoma Diseases 0.000 description 1
• GISRWBROCYNDME-PELMWDNLSA-N F[C@H]1[C@H]([C@H](NC1=O)COC1=NC=CC2=CC(=C(C=C12)OC)C(=O)N)C Chemical compound F[C@H]1[C@H]([C@H](NC1=O)COC1=NC=CC2=CC(=C(C=C12)OC)C(=O)N)C GISRWBROCYNDME-PELMWDNLSA-N 0.000 description 1
• 201000001342 Fallopian tube cancer Diseases 0.000 description 1
• 208000013452 Fallopian tube neoplasm Diseases 0.000 description 1
• 206010073153 Familial medullary thyroid cancer Diseases 0.000 description 1
• 208000007659 Fibroadenoma Diseases 0.000 description 1
• 206010053717 Fibrous histiocytoma Diseases 0.000 description 1
• GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 1
• WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 1
• 201000003741 Gastrointestinal carcinoma Diseases 0.000 description 1
• 241000206672 Gelidium Species 0.000 description 1
• 208000000527 Germinoma Diseases 0.000 description 1
• 208000007569 Giant Cell Tumors Diseases 0.000 description 1
• 108010072051 Glatiramer Acetate Proteins 0.000 description 1
• 201000005409 Gliomatosis cerebri Diseases 0.000 description 1
• AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Polymers OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 1
• 229920000084 Gum arabic Polymers 0.000 description 1
• 229940121710 HMGCoA reductase inhibitor Drugs 0.000 description 1
• 206010019629 Hepatic adenoma Diseases 0.000 description 1
• 206010019842 Hepatomegaly Diseases 0.000 description 1
• 101000924577 Homo sapiens Adenomatous polyposis coli protein Proteins 0.000 description 1
• 101000721661 Homo sapiens Cellular tumor antigen p53 Proteins 0.000 description 1
• 101000624643 Homo sapiens M-phase inducer phosphatase 3 Proteins 0.000 description 1
• 101001059454 Homo sapiens Serine/threonine-protein kinase MARK2 Proteins 0.000 description 1
• 101000729945 Homo sapiens Serine/threonine-protein kinase PLK2 Proteins 0.000 description 1
• 101000691614 Homo sapiens Serine/threonine-protein kinase PLK3 Proteins 0.000 description 1
• 101000582914 Homo sapiens Serine/threonine-protein kinase PLK4 Proteins 0.000 description 1
• UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
• 206010048643 Hypereosinophilic syndrome Diseases 0.000 description 1
• DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
• 206010061598 Immunodeficiency Diseases 0.000 description 1
• 208000029462 Immunodeficiency disease Diseases 0.000 description 1
• 108090000467 Interferon-beta Proteins 0.000 description 1
• 102000003996 Interferon-beta Human genes 0.000 description 1
• 108090000862 Ion Channels Proteins 0.000 description 1
• 102000004310 Ion Channels Human genes 0.000 description 1
• UETNIIAIRMUTSM-UHFFFAOYSA-N Jacareubin Natural products CC1(C)OC2=CC3Oc4c(O)c(O)ccc4C(=O)C3C(=C2C=C1)O UETNIIAIRMUTSM-UHFFFAOYSA-N 0.000 description 1
• 208000002260 Keloid Diseases 0.000 description 1
• WTDRDQBEARUVNC-LURJTMIESA-N L-DOPA Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-LURJTMIESA-N 0.000 description 1
• WTDRDQBEARUVNC-UHFFFAOYSA-N L-Dopa Natural products OC(=O)C(N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-UHFFFAOYSA-N 0.000 description 1
• 150000000994 L-ascorbates Chemical class 0.000 description 1
• AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 1
• OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
• 239000005517 L01XE01 - Imatinib Substances 0.000 description 1
• 239000004166 Lanolin Substances 0.000 description 1
• 206010023825 Laryngeal cancer Diseases 0.000 description 1
• WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
• 208000002404 Liver Cell Adenoma Diseases 0.000 description 1
• 208000028018 Lymphocytic leukaemia Diseases 0.000 description 1
• 102100023330 M-phase inducer phosphatase 3 Human genes 0.000 description 1
• FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
• 208000006644 Malignant Fibrous Histiocytoma Diseases 0.000 description 1
• 240000003183 Manihot esculenta Species 0.000 description 1
• 235000016735 Manihot esculenta subsp esculenta Nutrition 0.000 description 1
• 229930195725 Mannitol Natural products 0.000 description 1
• 208000037196 Medullary thyroid carcinoma Diseases 0.000 description 1
• 208000000172 Medulloblastoma Diseases 0.000 description 1
• 206010027406 Mesothelioma Diseases 0.000 description 1
• 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
• 239000004909 Moisturizer Substances 0.000 description 1
• UCHDWCPVSPXUMX-TZIWLTJVSA-N Montelukast Chemical compound CC(C)(O)C1=CC=CC=C1CC[C@H](C=1C=C(\C=C\C=2N=C3C=C(Cl)C=CC3=CC=2)C=CC=1)SCC1(CC(O)=O)CC1 UCHDWCPVSPXUMX-TZIWLTJVSA-N 0.000 description 1
• 208000006876 Multiple Endocrine Neoplasia Type 2b Diseases 0.000 description 1
• 206010073148 Multiple endocrine neoplasia type 2A Diseases 0.000 description 1
• 241000699666 Mus <mouse, genus> Species 0.000 description 1
• 241000699670 Mus sp. Species 0.000 description 1
• 201000003793 Myelodysplastic syndrome Diseases 0.000 description 1
• 206010028561 Myeloid metaplasia Diseases 0.000 description 1
• 208000033833 Myelomonocytic Chronic Leukemia Diseases 0.000 description 1
• 208000037538 Myelomonocytic Juvenile Leukemia Diseases 0.000 description 1
• 208000014767 Myeloproliferative disease Diseases 0.000 description 1
• ZKGNPQKYVKXMGJ-UHFFFAOYSA-N N,N-dimethylacetamide Chemical compound CN(C)C(C)=O.CN(C)C(C)=O ZKGNPQKYVKXMGJ-UHFFFAOYSA-N 0.000 description 1
• AYCPARAPKDAOEN-LJQANCHMSA-N N-[(1S)-2-(dimethylamino)-1-phenylethyl]-6,6-dimethyl-3-[(2-methyl-4-thieno[3,2-d]pyrimidinyl)amino]-1,4-dihydropyrrolo[3,4-c]pyrazole-5-carboxamide Chemical compound C1([C@H](NC(=O)N2C(C=3NN=C(NC=4C=5SC=CC=5N=C(C)N=4)C=3C2)(C)C)CN(C)C)=CC=CC=C1 AYCPARAPKDAOEN-LJQANCHMSA-N 0.000 description 1
• GXCLVBGFBYZDAG-UHFFFAOYSA-N N-[2-(1H-indol-3-yl)ethyl]-N-methylprop-2-en-1-amine Chemical compound CN(CCC1=CNC2=C1C=CC=C2)CC=C GXCLVBGFBYZDAG-UHFFFAOYSA-N 0.000 description 1
• FEYNFHSRETUBEM-UHFFFAOYSA-N N-[3-(1,1-difluoroethyl)phenyl]-1-(4-methoxyphenyl)-3-methyl-5-oxo-4H-pyrazole-4-carboxamide Chemical compound COc1ccc(cc1)N1N=C(C)C(C(=O)Nc2cccc(c2)C(C)(F)F)C1=O FEYNFHSRETUBEM-UHFFFAOYSA-N 0.000 description 1
• 229910002651 NO3 Inorganic materials 0.000 description 1
• 108010025020 Nerve Growth Factor Proteins 0.000 description 1
• 102000007072 Nerve Growth Factors Human genes 0.000 description 1
• 201000004404 Neurofibroma Diseases 0.000 description 1
• NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
• 208000015914 Non-Hodgkin lymphomas Diseases 0.000 description 1
• IDRGFNPZDVBSSE-UHFFFAOYSA-N OCCN1CCN(CC1)c1ccc(Nc2ncc3cccc(-c4cccc(NC(=O)C=C)c4)c3n2)c(F)c1F Chemical compound OCCN1CCN(CC1)c1ccc(Nc2ncc3cccc(-c4cccc(NC(=O)C=C)c4)c3n2)c(F)c1F IDRGFNPZDVBSSE-UHFFFAOYSA-N 0.000 description 1
• 206010030155 Oesophageal carcinoma Diseases 0.000 description 1
• 240000007817 Olea europaea Species 0.000 description 1
• 201000010133 Oligodendroglioma Diseases 0.000 description 1
• 108700020796 Oncogene Proteins 0.000 description 1
• 206010057444 Oropharyngeal neoplasm Diseases 0.000 description 1
• 206010031149 Osteitis Diseases 0.000 description 1
• 208000000035 Osteochondroma Diseases 0.000 description 1
• 206010061332 Paraganglion neoplasm Diseases 0.000 description 1
• 208000018737 Parkinson disease Diseases 0.000 description 1
• 208000037273 Pathologic Processes Diseases 0.000 description 1
• 208000007641 Pinealoma Diseases 0.000 description 1
• 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
• 229920002732 Polyanhydride Polymers 0.000 description 1
• 208000008601 Polycythemia Diseases 0.000 description 1
• 239000004698 Polyethylene Substances 0.000 description 1
• 229920000954 Polyglycolide Polymers 0.000 description 1
• 229920001710 Polyorthoester Polymers 0.000 description 1
• 229920001214 Polysorbate 60 Polymers 0.000 description 1
• ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
• XBDQKXXYIPTUBI-UHFFFAOYSA-N Propionic acid Chemical class CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 1
• 201000004681 Psoriasis Diseases 0.000 description 1
• 201000000582 Retinoblastoma Diseases 0.000 description 1
• 208000005678 Rhabdomyoma Diseases 0.000 description 1
• 235000004443 Ricinus communis Nutrition 0.000 description 1
• FTALBRSUTCGOEG-UHFFFAOYSA-N Riluzole Chemical compound C1=C(OC(F)(F)F)C=C2SC(N)=NC2=C1 FTALBRSUTCGOEG-UHFFFAOYSA-N 0.000 description 1
• 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
• 235000019485 Safflower oil Nutrition 0.000 description 1
• MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
• 102100028904 Serine/threonine-protein kinase MARK2 Human genes 0.000 description 1
• 102100031462 Serine/threonine-protein kinase PLK2 Human genes 0.000 description 1
• 102100026209 Serine/threonine-protein kinase PLK3 Human genes 0.000 description 1
• 102100030267 Serine/threonine-protein kinase PLK4 Human genes 0.000 description 1
• 206010041067 Small cell lung cancer Diseases 0.000 description 1
• PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
• HVUMOYIDDBPOLL-XWVZOOPGSA-N Sorbitan monostearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O HVUMOYIDDBPOLL-XWVZOOPGSA-N 0.000 description 1
• SSZBUIDZHHWXNJ-UHFFFAOYSA-N Stearinsaeure-hexadecylester Natural products CCCCCCCCCCCCCCCCCC(=O)OCCCCCCCCCCCCCCCC SSZBUIDZHHWXNJ-UHFFFAOYSA-N 0.000 description 1
• 208000006011 Stroke Diseases 0.000 description 1
• QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
• 201000008736 Systemic mastocytosis Diseases 0.000 description 1
• QJJXYPPXXYFBGM-LFZNUXCKSA-N Tacrolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1\C=C(/C)[C@@H]1[C@H](C)[C@@H](O)CC(=O)[C@H](CC=C)/C=C(C)/C[C@H](C)C[C@H](OC)[C@H]([C@H](C[C@H]2C)OC)O[C@@]2(O)C(=O)C(=O)N2CCCC[C@H]2C(=O)O1 QJJXYPPXXYFBGM-LFZNUXCKSA-N 0.000 description 1
• FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
• AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
• 239000004473 Threonine Substances 0.000 description 1
• 208000005485 Thrombocytosis Diseases 0.000 description 1
• 208000033781 Thyroid carcinoma Diseases 0.000 description 1
• 229920001615 Tragacanth Polymers 0.000 description 1
• 108091023040 Transcription factor Proteins 0.000 description 1
• 102000040945 Transcription factor Human genes 0.000 description 1
• YZCKVEUIGOORGS-NJFSPNSNSA-N Tritium Chemical compound [3H] YZCKVEUIGOORGS-NJFSPNSNSA-N 0.000 description 1
• 102100040247 Tumor necrosis factor Human genes 0.000 description 1
• 208000015778 Undifferentiated pleomorphic sarcoma Diseases 0.000 description 1
• 206010046431 Urethral cancer Diseases 0.000 description 1
• 206010046458 Urethral neoplasms Diseases 0.000 description 1
• 208000002495 Uterine Neoplasms Diseases 0.000 description 1
• 241001660687 Xantho Species 0.000 description 1
• 206010048214 Xanthoma Diseases 0.000 description 1
• 206010048215 Xanthomatosis Diseases 0.000 description 1
• 240000008042 Zea mays Species 0.000 description 1
• 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
• 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
• HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
• LXRZVMYMQHNYJB-UNXOBOICSA-N [(1R,2S,4R)-4-[[5-[4-[(1R)-7-chloro-1,2,3,4-tetrahydroisoquinolin-1-yl]-5-methylthiophene-2-carbonyl]pyrimidin-4-yl]amino]-2-hydroxycyclopentyl]methyl sulfamate Chemical compound CC1=C(C=C(S1)C(=O)C1=C(N[C@H]2C[C@H](O)[C@@H](COS(N)(=O)=O)C2)N=CN=C1)[C@@H]1NCCC2=C1C=C(Cl)C=C2 LXRZVMYMQHNYJB-UNXOBOICSA-N 0.000 description 1
• 239000001089 [(2R)-oxolan-2-yl]methanol Substances 0.000 description 1
• SZPWXAOBLNYOHY-UHFFFAOYSA-N [C]1=CC=NC2=CC=CC=C12 Chemical group [C]1=CC=NC2=CC=CC=C12 SZPWXAOBLNYOHY-UHFFFAOYSA-N 0.000 description 1
• CTCBPRXHVPZNHB-VQFZJOCSSA-N [[(2r,3s,4r,5r)-5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl] phosphono hydrogen phosphate;(2r,3r,4s,5r)-2-(6-aminopurin-9-yl)-5-(hydroxymethyl)oxolane-3,4-diol Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O.C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)[C@H]1O CTCBPRXHVPZNHB-VQFZJOCSSA-N 0.000 description 1
• 239000002250 absorbent Substances 0.000 description 1
• 230000002745 absorbent Effects 0.000 description 1
• 239000003655 absorption accelerator Substances 0.000 description 1
• 235000010489 acacia gum Nutrition 0.000 description 1
• 239000000205 acacia gum Substances 0.000 description 1
• 230000002378 acidificating effect Effects 0.000 description 1
• 150000007513 acids Chemical class 0.000 description 1
• 239000013543 active substance Substances 0.000 description 1
• 208000002718 adenomatoid tumor Diseases 0.000 description 1
• WNLRTRBMVRJNCN-UHFFFAOYSA-N adipic acid Chemical class OC(=O)CCCCC(O)=O WNLRTRBMVRJNCN-UHFFFAOYSA-N 0.000 description 1
• 201000005188 adrenal gland cancer Diseases 0.000 description 1
• 208000024447 adrenal gland neoplasm Diseases 0.000 description 1
• 229940009456 adriamycin Drugs 0.000 description 1
• 239000008272 agar Substances 0.000 description 1
• NDAUXUAQIAJITI-UHFFFAOYSA-N albuterol Chemical compound CC(C)(C)NCC(O)C1=CC=C(O)C(CO)=C1 NDAUXUAQIAJITI-UHFFFAOYSA-N 0.000 description 1
• 229910052783 alkali metal Inorganic materials 0.000 description 1
• 150000001340 alkali metals Chemical class 0.000 description 1
• 150000001342 alkaline earth metals Chemical class 0.000 description 1
• 150000008055 alkyl aryl sulfonates Chemical class 0.000 description 1
• 150000008052 alkyl sulfonates Chemical class 0.000 description 1
• 125000000304 alkynyl group Chemical group 0.000 description 1
• 208000026935 allergic disease Diseases 0.000 description 1
• HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 description 1
• WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
• 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
• 235000012211 aluminium silicate Nutrition 0.000 description 1
• DKNWSYNQZKUICI-UHFFFAOYSA-N amantadine Chemical compound C1C(C2)CC3CC2CC1(N)C3 DKNWSYNQZKUICI-UHFFFAOYSA-N 0.000 description 1
• 229960003805 amantadine Drugs 0.000 description 1
• 125000000320 amidine group Chemical group 0.000 description 1
• 150000001409 amidines Chemical class 0.000 description 1
• 150000001413 amino acids Chemical class 0.000 description 1
• 229960004050 aminobenzoic acid Drugs 0.000 description 1
• 229940044094 angiotensin-converting-enzyme inhibitor Drugs 0.000 description 1
• 125000002490 anilino group Chemical group [H]N(*)C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 1
• 210000004102 animal cell Anatomy 0.000 description 1
• 229940124599 anti-inflammatory drug Drugs 0.000 description 1
• 230000000719 anti-leukaemic effect Effects 0.000 description 1
• 229940035678 anti-parkinson drug Drugs 0.000 description 1
• 230000000692 anti-sense effect Effects 0.000 description 1
• 229940125681 anticonvulsant agent Drugs 0.000 description 1
• 239000001961 anticonvulsive agent Substances 0.000 description 1
• 229940082992 antihypertensives mao inhibitors Drugs 0.000 description 1
• 239000002246 antineoplastic agent Substances 0.000 description 1
• 239000003963 antioxidant agent Substances 0.000 description 1
• 235000006708 antioxidants Nutrition 0.000 description 1
• 239000003443 antiviral agent Substances 0.000 description 1
• 239000007864 aqueous solution Substances 0.000 description 1
• 229940039856 aricept Drugs 0.000 description 1
• 125000003710 aryl alkyl group Chemical group 0.000 description 1
• 125000005160 aryl oxy alkyl group Chemical group 0.000 description 1
• 235000010323 ascorbic acid Nutrition 0.000 description 1
• CKLJMWTZIZZHCS-REOHCLBHSA-L aspartate group Chemical class N[C@@H](CC(=O)[O-])C(=O)[O-] CKLJMWTZIZZHCS-REOHCLBHSA-L 0.000 description 1
• 229940127225 asthma medication Drugs 0.000 description 1
• 230000001363 autoimmune Effects 0.000 description 1
• 229940003504 avonex Drugs 0.000 description 1
• 235000013871 bee wax Nutrition 0.000 description 1
• 239000012166 beeswax Substances 0.000 description 1
• 208000001119 benign fibrous histiocytoma Diseases 0.000 description 1
• 239000000440 bentonite Substances 0.000 description 1
• 229910000278 bentonite Inorganic materials 0.000 description 1
• SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 1
• SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical class OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 1
• MYONAGGJKCJOBT-UHFFFAOYSA-N benzimidazol-2-one Chemical compound C1=CC=CC2=NC(=O)N=C21 MYONAGGJKCJOBT-UHFFFAOYSA-N 0.000 description 1
• 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 description 1
• 125000004618 benzofuryl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 description 1
• 150000001558 benzoic acid derivatives Chemical class 0.000 description 1
• 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 description 1
• 235000019445 benzyl alcohol Nutrition 0.000 description 1
• 229960002903 benzyl benzoate Drugs 0.000 description 1
• AGEZXYOZHKGVCM-UHFFFAOYSA-N benzyl bromide Chemical compound BrCC1=CC=CC=C1 AGEZXYOZHKGVCM-UHFFFAOYSA-N 0.000 description 1
• 239000002876 beta blocker Substances 0.000 description 1
• 229940097320 beta blocking agent Drugs 0.000 description 1
• 210000000013 bile duct Anatomy 0.000 description 1
• 238000004166 bioassay Methods 0.000 description 1
• 230000004071 biological effect Effects 0.000 description 1
• 230000008827 biological function Effects 0.000 description 1
• 230000031018 biological processes and functions Effects 0.000 description 1
• 238000001574 biopsy Methods 0.000 description 1
• IPWKHHSGDUIRAH-UHFFFAOYSA-N bis(pinacolato)diboron Chemical compound O1C(C)(C)C(C)(C)OB1B1OC(C)(C)C(C)(C)O1 IPWKHHSGDUIRAH-UHFFFAOYSA-N 0.000 description 1
• QAOWNCQODCNURD-UHFFFAOYSA-M bisulphate group Chemical group S([O-])(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-M 0.000 description 1
• 210000001124 body fluid Anatomy 0.000 description 1
• 239000010839 body fluid Substances 0.000 description 1
• 230000036760 body temperature Effects 0.000 description 1
• 208000018339 bone inflammation disease Diseases 0.000 description 1
• 229940098773 bovine serum albumin Drugs 0.000 description 1
• 210000004556 brain Anatomy 0.000 description 1
• 210000000133 brain stem Anatomy 0.000 description 1
• 201000003149 breast fibroadenoma Diseases 0.000 description 1
• 229910052794 bromium Inorganic materials 0.000 description 1
• OZVBMTJYIDMWIL-AYFBDAFISA-N bromocriptine Chemical compound C1=CC(C=2[C@H](N(C)C[C@@H](C=2)C(=O)N[C@]2(C(=O)N3[C@H](C(N4CCC[C@H]4[C@]3(O)O2)=O)CC(C)C)C(C)C)C2)=C3C2=C(Br)NC3=C1 OZVBMTJYIDMWIL-AYFBDAFISA-N 0.000 description 1
• 229960002802 bromocriptine Drugs 0.000 description 1
• 201000002143 bronchus adenoma Diseases 0.000 description 1
• 239000000872 buffer Substances 0.000 description 1
• 150000004648 butanoic acid derivatives Chemical class 0.000 description 1
• FJDQFPXHSGXQBY-UHFFFAOYSA-L caesium carbonate Chemical compound [Cs+].[Cs+].[O-]C([O-])=O FJDQFPXHSGXQBY-UHFFFAOYSA-L 0.000 description 1
• 229910000024 caesium carbonate Inorganic materials 0.000 description 1
• 239000011575 calcium Substances 0.000 description 1
• 229910052791 calcium Inorganic materials 0.000 description 1
• 229910000019 calcium carbonate Inorganic materials 0.000 description 1
• 235000010216 calcium carbonate Nutrition 0.000 description 1
• 239000000480 calcium channel blocker Substances 0.000 description 1
• 239000001506 calcium phosphate Substances 0.000 description 1
• 235000013539 calcium stearate Nutrition 0.000 description 1
• 239000008116 calcium stearate Substances 0.000 description 1
• MIOPJNTWMNEORI-UHFFFAOYSA-N camphorsulfonic acid Chemical class C1CC2(CS(O)(=O)=O)C(=O)CC1C2(C)C MIOPJNTWMNEORI-UHFFFAOYSA-N 0.000 description 1
• 239000004202 carbamide Substances 0.000 description 1
• 229960004205 carbidopa Drugs 0.000 description 1
• TZFNLOMSOLWIDK-JTQLQIEISA-N carbidopa (anhydrous) Chemical compound NN[C@@](C(O)=O)(C)CC1=CC=C(O)C(O)=C1 TZFNLOMSOLWIDK-JTQLQIEISA-N 0.000 description 1
• 125000004452 carbocyclyl group Chemical group 0.000 description 1
• CREMABGTGYGIQB-UHFFFAOYSA-N carbon carbon Chemical compound C.C CREMABGTGYGIQB-UHFFFAOYSA-N 0.000 description 1
• 150000007942 carboxylates Chemical class 0.000 description 1
• 150000001733 carboxylic acid esters Chemical class 0.000 description 1
• 208000002458 carcinoid tumor Diseases 0.000 description 1
• 239000002327 cardiovascular agent Substances 0.000 description 1
• 229940125692 cardiovascular agent Drugs 0.000 description 1
• 235000019438 castor oil Nutrition 0.000 description 1
• 108020001778 catalytic domains Proteins 0.000 description 1
• 230000003197 catalytic effect Effects 0.000 description 1
• 150000001768 cations Chemical class 0.000 description 1
• 238000004113 cell culture Methods 0.000 description 1
• 230000032823 cell division Effects 0.000 description 1
• 230000004663 cell proliferation Effects 0.000 description 1
• 230000009134 cell regulation Effects 0.000 description 1
• 230000001413 cellular effect Effects 0.000 description 1
• 229920002301 cellulose acetate Polymers 0.000 description 1
• 210000003169 central nervous system Anatomy 0.000 description 1
• 201000007455 central nervous system cancer Diseases 0.000 description 1
• 210000004718 centriole Anatomy 0.000 description 1
• 210000003793 centrosome Anatomy 0.000 description 1
• 208000019065 cervical carcinoma Diseases 0.000 description 1
• 210000003679 cervix uteri Anatomy 0.000 description 1
• 229940081733 cetearyl alcohol Drugs 0.000 description 1
• 229960000541 cetyl alcohol Drugs 0.000 description 1
• DGLFSNZWRYADFC-UHFFFAOYSA-N chembl2334586 Chemical compound C1CCC2=CN=C(N)N=C2C2=C1NC1=CC=C(C#CC(C)(O)C)C=C12 DGLFSNZWRYADFC-UHFFFAOYSA-N 0.000 description 1
• 229910052729 chemical element Inorganic materials 0.000 description 1
• 229910052801 chlorine Inorganic materials 0.000 description 1
• 125000001309 chloro group Chemical group Cl* 0.000 description 1
• 239000000544 cholinesterase inhibitor Substances 0.000 description 1
• 230000001684 chronic effect Effects 0.000 description 1
• 201000010902 chronic myelomonocytic leukemia Diseases 0.000 description 1
• 229960001265 ciclosporin Drugs 0.000 description 1
• 150000001860 citric acid derivatives Chemical class 0.000 description 1
• 239000004927 clay Substances 0.000 description 1
• 208000009060 clear cell adenocarcinoma Diseases 0.000 description 1
• 239000008119 colloidal silica Substances 0.000 description 1
• 238000012875 competitive assay Methods 0.000 description 1
• 229940125890 compound Ia Drugs 0.000 description 1
• 238000009833 condensation Methods 0.000 description 1
• 230000005494 condensation Effects 0.000 description 1
• 238000013270 controlled release Methods 0.000 description 1
• 229940038717 copaxone Drugs 0.000 description 1
• 235000005822 corn Nutrition 0.000 description 1
• 239000002285 corn oil Substances 0.000 description 1
• 235000005687 corn oil Nutrition 0.000 description 1
• 239000002385 cottonseed oil Substances 0.000 description 1
• 230000008878 coupling Effects 0.000 description 1
• 238000010168 coupling process Methods 0.000 description 1
• 230000037029 cross reaction Effects 0.000 description 1
• 239000012043 crude product Substances 0.000 description 1
• 238000002425 crystallisation Methods 0.000 description 1
• 230000008025 crystallization Effects 0.000 description 1
• 201000010305 cutaneous fibrous histiocytoma Diseases 0.000 description 1
• 208000035250 cutaneous malignant susceptibility to 1 melanoma Diseases 0.000 description 1
• 125000000392 cycloalkenyl group Chemical group 0.000 description 1
• 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
• 125000004850 cyclobutylmethyl group Chemical group C1(CCC1)C* 0.000 description 1
• BALGDZWGNCXXES-UHFFFAOYSA-N cyclopentane;propanoic acid Chemical class CCC(O)=O.C1CCCC1 BALGDZWGNCXXES-UHFFFAOYSA-N 0.000 description 1
• 125000000298 cyclopropenyl group Chemical group [H]C1=C([H])C1([H])* 0.000 description 1
• 125000004186 cyclopropylmethyl group Chemical group [H]C([H])(*)C1([H])C([H])([H])C1([H])[H] 0.000 description 1
• 229930182912 cyclosporin Natural products 0.000 description 1
• 208000002445 cystadenocarcinoma Diseases 0.000 description 1
• 230000021953 cytokinesis Effects 0.000 description 1
• 229940127089 cytotoxic agent Drugs 0.000 description 1
• 230000006378 damage Effects 0.000 description 1
• 230000007547 defect Effects 0.000 description 1
• 238000010511 deprotection reaction Methods 0.000 description 1
• 229910052805 deuterium Inorganic materials 0.000 description 1
• UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 1
• 229960003957 dexamethasone Drugs 0.000 description 1
• 206010012601 diabetes mellitus Diseases 0.000 description 1
• OXIUVCGTBZTMKH-UHFFFAOYSA-N diazepin-1-amine Chemical compound NN1C=CC=CC=N1 OXIUVCGTBZTMKH-UHFFFAOYSA-N 0.000 description 1
• NEFBYIFKOOEVPA-UHFFFAOYSA-K dicalcium phosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])([O-])=O NEFBYIFKOOEVPA-UHFFFAOYSA-K 0.000 description 1
• 229940038472 dicalcium phosphate Drugs 0.000 description 1
• 229910000390 dicalcium phosphate Inorganic materials 0.000 description 1
• 125000003963 dichloro group Chemical group Cl* 0.000 description 1
• 230000004069 differentiation Effects 0.000 description 1
• VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 description 1
• 239000002934 diuretic Substances 0.000 description 1
• 229940030606 diuretics Drugs 0.000 description 1
• CETRZFQIITUQQL-UHFFFAOYSA-N dmso dimethylsulfoxide Chemical compound CS(C)=O.CS(C)=O CETRZFQIITUQQL-UHFFFAOYSA-N 0.000 description 1
• POULHZVOKOAJMA-UHFFFAOYSA-N dodecanoic acid Chemical class CCCCCCCCCCCC(O)=O POULHZVOKOAJMA-UHFFFAOYSA-N 0.000 description 1
• 230000003828 downregulation Effects 0.000 description 1
• 239000006196 drop Substances 0.000 description 1
• 239000003221 ear drop Substances 0.000 description 1
• 229940047652 ear drops Drugs 0.000 description 1
• 238000000132 electrospray ionisation Methods 0.000 description 1
• 239000003480 eluent Substances 0.000 description 1
• 239000008387 emulsifying waxe Substances 0.000 description 1
• 201000003914 endometrial carcinoma Diseases 0.000 description 1
• 239000002158 endotoxin Substances 0.000 description 1
• 239000007920 enema Substances 0.000 description 1
• 229940095399 enema Drugs 0.000 description 1
• JRURYQJSLYLRLN-BJMVGYQFSA-N entacapone Chemical compound CCN(CC)C(=O)C(\C#N)=C\C1=CC(O)=C(O)C([N+]([O-])=O)=C1 JRURYQJSLYLRLN-BJMVGYQFSA-N 0.000 description 1
• 229960003337 entacapone Drugs 0.000 description 1
• 230000007613 environmental effect Effects 0.000 description 1
• 238000007824 enzymatic assay Methods 0.000 description 1
• 201000005619 esophageal carcinoma Diseases 0.000 description 1
• AEOCXXJPGCBFJA-UHFFFAOYSA-N ethionamide Chemical compound CCC1=CC(C(N)=S)=CC=N1 AEOCXXJPGCBFJA-UHFFFAOYSA-N 0.000 description 1
• GQQQULCEHJQUJT-UHFFFAOYSA-N ethyl 4-aminopiperidine-1-carboxylate Chemical compound CCOC(=O)N1CCC(N)CC1 GQQQULCEHJQUJT-UHFFFAOYSA-N 0.000 description 1
• 229940093499 ethyl acetate Drugs 0.000 description 1
• 235000019325 ethyl cellulose Nutrition 0.000 description 1
• 229920001249 ethyl cellulose Polymers 0.000 description 1
• FAMRKDQNMBBFBR-UHFFFAOYSA-N ethyl n-ethoxycarbonyliminocarbamate Chemical compound CCOC(=O)N=NC(=O)OCC FAMRKDQNMBBFBR-UHFFFAOYSA-N 0.000 description 1
• LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
• 229940093471 ethyl oleate Drugs 0.000 description 1
• 125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 1
• 239000003889 eye drop Substances 0.000 description 1
• 229940012356 eye drops Drugs 0.000 description 1
• 235000019197 fats Nutrition 0.000 description 1
• 210000003608 fece Anatomy 0.000 description 1
• 210000001752 female genitalia Anatomy 0.000 description 1
• 238000003818 flash chromatography Methods 0.000 description 1
• 239000012530 fluid Substances 0.000 description 1
• 229910052731 fluorine Inorganic materials 0.000 description 1
• 229960002949 fluorouracil Drugs 0.000 description 1
• 235000013355 food flavoring agent Nutrition 0.000 description 1
• 239000008098 formaldehyde solution Substances 0.000 description 1
• 238000013467 fragmentation Methods 0.000 description 1
• 238000006062 fragmentation reaction Methods 0.000 description 1
• 239000012458 free base Substances 0.000 description 1
• 230000006870 function Effects 0.000 description 1
• 108010074605 gamma-Globulins Proteins 0.000 description 1
• 206010017758 gastric cancer Diseases 0.000 description 1
• 201000003115 germ cell cancer Diseases 0.000 description 1
• 229940080856 gleevec Drugs 0.000 description 1
• 208000005017 glioblastoma Diseases 0.000 description 1
• 229940050410 gluconate Drugs 0.000 description 1
• 235000001727 glucose Nutrition 0.000 description 1
• 230000004153 glucose metabolism Effects 0.000 description 1
• YQEMORVAKMFKLG-UHFFFAOYSA-N glycerine monostearate Natural products CCCCCCCCCCCCCCCCCC(=O)OC(CO)CO YQEMORVAKMFKLG-UHFFFAOYSA-N 0.000 description 1
• SVUQHVRAGMNPLW-UHFFFAOYSA-N glycerol monostearate Natural products CCCCCCCCCCCCCCCCC(=O)OCC(O)CO SVUQHVRAGMNPLW-UHFFFAOYSA-N 0.000 description 1
• ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
• 229960002449 glycine Drugs 0.000 description 1
• 150000002334 glycols Chemical class 0.000 description 1
• 210000002288 golgi apparatus Anatomy 0.000 description 1
• 230000012010 growth Effects 0.000 description 1
• 125000000262 haloalkenyl group Chemical group 0.000 description 1
• 125000004438 haloalkoxy group Chemical group 0.000 description 1
• 125000001188 haloalkyl group Chemical group 0.000 description 1
• 125000005843 halogen group Chemical group 0.000 description 1
• 229960003878 haloperidol Drugs 0.000 description 1
• 201000010536 head and neck cancer Diseases 0.000 description 1
• 208000014829 head and neck neoplasm Diseases 0.000 description 1
• 208000024348 heart neoplasm Diseases 0.000 description 1
• 201000005787 hematologic cancer Diseases 0.000 description 1
• 230000002489 hematologic effect Effects 0.000 description 1
• 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 description 1
• 208000018706 hematopoietic system disease Diseases 0.000 description 1
• 208000006359 hepatoblastoma Diseases 0.000 description 1
• 201000002735 hepatocellular adenoma Diseases 0.000 description 1
• 231100000844 hepatocellular carcinoma Toxicity 0.000 description 1
• MNWFXJYAOYHMED-UHFFFAOYSA-N heptanoic acid Chemical class CCCCCCC(O)=O MNWFXJYAOYHMED-UHFFFAOYSA-N 0.000 description 1
• 125000004475 heteroaralkyl group Chemical group 0.000 description 1
• 125000005114 heteroarylalkoxy group Chemical group 0.000 description 1
• BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 1
• FUZZWVXGSFPDMH-UHFFFAOYSA-N hexanoic acid Chemical class CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 description 1
• 229940088597 hormone Drugs 0.000 description 1
• 239000005556 hormone Substances 0.000 description 1
• XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical class I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
• 230000007062 hydrolysis Effects 0.000 description 1
• 238000006460 hydrolysis reaction Methods 0.000 description 1
• XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 description 1
• 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 description 1
• YLMAHDNUQAMNNX-UHFFFAOYSA-N imatinib methanesulfonate Chemical compound CS(O)(=O)=O.C1CN(C)CCN1CC1=CC=C(C(=O)NC=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)C=C1 YLMAHDNUQAMNNX-UHFFFAOYSA-N 0.000 description 1
• 125000002962 imidazol-1-yl group Chemical group [*]N1C([H])=NC([H])=C1[H] 0.000 description 1
• 230000002519 immonomodulatory effect Effects 0.000 description 1
• 229940125721 immunosuppressive agent Drugs 0.000 description 1
• 239000003018 immunosuppressive agent Substances 0.000 description 1
• 201000004933 in situ carcinoma Diseases 0.000 description 1
• 229910052738 indium Inorganic materials 0.000 description 1
• APFVFJFRJDLVQX-UHFFFAOYSA-N indium atom Chemical compound [In] APFVFJFRJDLVQX-UHFFFAOYSA-N 0.000 description 1
• 125000003387 indolinyl group Chemical group N1(CCC2=CC=CC=C12)* 0.000 description 1
• 125000001041 indolyl group Chemical group 0.000 description 1
• 230000006882 induction of apoptosis Effects 0.000 description 1
• 230000002757 inflammatory effect Effects 0.000 description 1
• 238000001802 infusion Methods 0.000 description 1
• 229940102223 injectable solution Drugs 0.000 description 1
• 229940102213 injectable suspension Drugs 0.000 description 1
• 150000007529 inorganic bases Chemical class 0.000 description 1
• 206010022498 insulinoma Diseases 0.000 description 1
• 230000016507 interphase Effects 0.000 description 1
• 210000002570 interstitial cell Anatomy 0.000 description 1
• 201000002313 intestinal cancer Diseases 0.000 description 1
• 238000007917 intracranial administration Methods 0.000 description 1
• 238000007918 intramuscular administration Methods 0.000 description 1
• 238000010255 intramuscular injection Methods 0.000 description 1
• 239000007927 intramuscular injection Substances 0.000 description 1
• 238000007913 intrathecal administration Methods 0.000 description 1
• 238000001990 intravenous administration Methods 0.000 description 1
• 229910052740 iodine Inorganic materials 0.000 description 1
• 239000003456 ion exchange resin Substances 0.000 description 1
• 229920003303 ion-exchange polymer Polymers 0.000 description 1
• 230000007794 irritation Effects 0.000 description 1
• SUMDYPCJJOFFON-UHFFFAOYSA-N isethionic acid Chemical class OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 description 1
• 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
• 125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 description 1
• 125000001786 isothiazolyl group Chemical group 0.000 description 1
• 239000007951 isotonicity adjuster Substances 0.000 description 1
• 201000005992 juvenile myelomonocytic leukemia Diseases 0.000 description 1
• NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
• 210000001117 keloid Anatomy 0.000 description 1
• 210000003734 kidney Anatomy 0.000 description 1
• 208000022013 kidney Wilms tumor Diseases 0.000 description 1
• 150000003903 lactic acid esters Chemical class 0.000 description 1
• 235000019388 lanolin Nutrition 0.000 description 1
• 229940039717 lanolin Drugs 0.000 description 1
• 201000003445 large cell neuroendocrine carcinoma Diseases 0.000 description 1
• 210000000867 larynx Anatomy 0.000 description 1
• 239000010410 layer Substances 0.000 description 1
• 239000003446 ligand Substances 0.000 description 1
• 125000005647 linker group Chemical group 0.000 description 1
• 150000002632 lipids Chemical class 0.000 description 1
• 206010024627 liposarcoma Diseases 0.000 description 1
• 239000002502 liposome Substances 0.000 description 1
• 239000006194 liquid suspension Substances 0.000 description 1
• 229910052744 lithium Inorganic materials 0.000 description 1
• 201000007270 liver cancer Diseases 0.000 description 1
• 208000003747 lymphoid leukemia Diseases 0.000 description 1
• 239000011777 magnesium Substances 0.000 description 1
• 229910052749 magnesium Inorganic materials 0.000 description 1
• VTHJTEIRLNZDEV-UHFFFAOYSA-L magnesium dihydroxide Chemical compound [OH-].[OH-].[Mg+2] VTHJTEIRLNZDEV-UHFFFAOYSA-L 0.000 description 1
• 239000000347 magnesium hydroxide Substances 0.000 description 1
• 229910001862 magnesium hydroxide Inorganic materials 0.000 description 1
• VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
• 239000011976 maleic acid Substances 0.000 description 1
• 150000002688 maleic acid derivatives Chemical class 0.000 description 1
• 150000004701 malic acid derivatives Chemical class 0.000 description 1
• 208000029565 malignant colon neoplasm Diseases 0.000 description 1
• 230000003211 malignant effect Effects 0.000 description 1
• 201000000289 malignant teratoma Diseases 0.000 description 1
• 150000002690 malonic acid derivatives Chemical class 0.000 description 1
• 239000000594 mannitol Substances 0.000 description 1
• 235000010355 mannitol Nutrition 0.000 description 1
• 238000004949 mass spectrometry Methods 0.000 description 1
• 239000011159 matrix material Substances 0.000 description 1
• 238000002483 medication Methods 0.000 description 1
• 208000023356 medullary thyroid gland carcinoma Diseases 0.000 description 1
• 239000000155 melt Substances 0.000 description 1
• 239000012528 membrane Substances 0.000 description 1
• AFVFQIVMOAPDHO-UHFFFAOYSA-M methanesulfonate group Chemical class CS(=O)(=O)[O-] AFVFQIVMOAPDHO-UHFFFAOYSA-M 0.000 description 1
• OKKJLVBELUTLKV-VMNATFBRSA-N methanol-d1 Chemical compound [2H]OC OKKJLVBELUTLKV-VMNATFBRSA-N 0.000 description 1
• RUZLIIJDZBWWSA-INIZCTEOSA-N methyl 2-[[(1s)-1-(7-methyl-2-morpholin-4-yl-4-oxopyrido[1,2-a]pyrimidin-9-yl)ethyl]amino]benzoate Chemical group COC(=O)C1=CC=CC=C1N[C@@H](C)C1=CC(C)=CN2C(=O)C=C(N3CCOCC3)N=C12 RUZLIIJDZBWWSA-INIZCTEOSA-N 0.000 description 1
• AHYUCALUVDREAN-UHFFFAOYSA-N methyl 3-(cyclopentylamino)propanoate Chemical compound COC(=O)CCNC1CCCC1 AHYUCALUVDREAN-UHFFFAOYSA-N 0.000 description 1
• NCCWQNGNNMNIRA-UHFFFAOYSA-N methyl 3-[cyclopentyl-(2-methyl-5-nitropyrimidin-4-yl)amino]propanoate Chemical compound N=1C(C)=NC=C([N+]([O-])=O)C=1N(CCC(=O)OC)C1CCCC1 NCCWQNGNNMNIRA-UHFFFAOYSA-N 0.000 description 1
• 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 description 1
• 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
• 239000008108 microcrystalline cellulose Substances 0.000 description 1
• 229940016286 microcrystalline cellulose Drugs 0.000 description 1
• 238000000520 microinjection Methods 0.000 description 1
• 229940042472 mineral oil Drugs 0.000 description 1
• 230000006618 mitotic catastrophe Effects 0.000 description 1
• 230000000394 mitotic effect Effects 0.000 description 1
• KKZJGLLVHKMTCM-UHFFFAOYSA-N mitoxantrone Chemical compound O=C1C2=C(O)C=CC(O)=C2C(=O)C2=C1C(NCCNCCO)=CC=C2NCCNCCO KKZJGLLVHKMTCM-UHFFFAOYSA-N 0.000 description 1
• 229960001156 mitoxantrone Drugs 0.000 description 1
• 230000001333 moisturizer Effects 0.000 description 1
• 239000002899 monoamine oxidase inhibitor Substances 0.000 description 1
• CQDGTJPVBWZJAZ-UHFFFAOYSA-N monoethyl carbonate Chemical compound CCOC(O)=O CQDGTJPVBWZJAZ-UHFFFAOYSA-N 0.000 description 1
• 229960005127 montelukast Drugs 0.000 description 1
• 201000006417 multiple sclerosis Diseases 0.000 description 1
• 230000004118 muscle contraction Effects 0.000 description 1
• RTGDFNSFWBGLEC-SYZQJQIISA-N mycophenolate mofetil Chemical compound COC1=C(C)C=2COC(=O)C=2C(O)=C1C\C=C(/C)CCC(=O)OCCN1CCOCC1 RTGDFNSFWBGLEC-SYZQJQIISA-N 0.000 description 1
• 229960004866 mycophenolate mofetil Drugs 0.000 description 1
• 206010028537 myelofibrosis Diseases 0.000 description 1
• 208000025113 myeloid leukemia Diseases 0.000 description 1
• 208000009091 myxoma Diseases 0.000 description 1
• FMASTMURQSHELY-UHFFFAOYSA-N n-(4-fluoro-2-methylphenyl)-3-methyl-n-[(2-methyl-1h-indol-4-yl)methyl]pyridine-4-carboxamide Chemical compound C1=CC=C2NC(C)=CC2=C1CN(C=1C(=CC(F)=CC=1)C)C(=O)C1=CC=NC=C1C FMASTMURQSHELY-UHFFFAOYSA-N 0.000 description 1
• VIJWNQRZLJXMTH-UHFFFAOYSA-N n-(azetidin-3-yl)-4-[(9-cyclopentyl-5,7,7-trimethyl-6-oxo-8h-pyrimido[4,5-b][1,4]diazepin-2-yl)amino]-3-methoxybenzamide Chemical compound COC1=CC(C(=O)NC2CNC2)=CC=C1NC(N=C12)=NC=C1N(C)C(=O)C(C)(C)CN2C1CCCC1 VIJWNQRZLJXMTH-UHFFFAOYSA-N 0.000 description 1
• YKYONYBAUNKHLG-UHFFFAOYSA-N n-Propyl acetate Natural products CCCOC(C)=O YKYONYBAUNKHLG-UHFFFAOYSA-N 0.000 description 1
• 125000004370 n-butenyl group Chemical group [H]\C([H])=C(/[H])C([H])([H])C([H])([H])* 0.000 description 1
• NNKPHNTWNILINE-UHFFFAOYSA-N n-cyclopropyl-3-fluoro-4-methyl-5-[3-[[1-[2-[2-(methylamino)ethoxy]phenyl]cyclopropyl]amino]-2-oxopyrazin-1-yl]benzamide Chemical compound CNCCOC1=CC=CC=C1C1(NC=2C(N(C=3C(=C(F)C=C(C=3)C(=O)NC3CC3)C)C=CN=2)=O)CC1 NNKPHNTWNILINE-UHFFFAOYSA-N 0.000 description 1
• 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
• KVBGVZZKJNLNJU-UHFFFAOYSA-N naphthalene-2-sulfonic acid Chemical class C1=CC=CC2=CC(S(=O)(=O)O)=CC=C21 KVBGVZZKJNLNJU-UHFFFAOYSA-N 0.000 description 1
• 229940097496 nasal spray Drugs 0.000 description 1
• 230000009826 neoplastic cell growth Effects 0.000 description 1
• 210000000653 nervous system Anatomy 0.000 description 1
• 208000007538 neurilemmoma Diseases 0.000 description 1
• 201000004662 neurofibroma of spinal cord Diseases 0.000 description 1
• 239000003900 neurotrophic factor Substances 0.000 description 1
• 150000002814 niacins Chemical class 0.000 description 1
• 235000001968 nicotinic acid Nutrition 0.000 description 1
• 150000002823 nitrates Chemical class 0.000 description 1
• 150000002829 nitrogen Chemical group 0.000 description 1
• GQPLMRYTRLFLPF-UHFFFAOYSA-N nitrous oxide Inorganic materials [O-][N+]#N GQPLMRYTRLFLPF-UHFFFAOYSA-N 0.000 description 1
• 239000002777 nucleoside Substances 0.000 description 1
• GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 1
• 229940126701 oral medication Drugs 0.000 description 1
• 229940041678 oral spray Drugs 0.000 description 1
• 239000000668 oral spray Substances 0.000 description 1
• 150000007530 organic bases Chemical class 0.000 description 1
• 239000012074 organic phase Substances 0.000 description 1
• 208000003388 osteoid osteoma Diseases 0.000 description 1
• 208000008798 osteoma Diseases 0.000 description 1
• 230000002611 ovarian Effects 0.000 description 1
• 235000006408 oxalic acid Nutrition 0.000 description 1
• 150000003901 oxalic acid esters Chemical class 0.000 description 1
• 125000004430 oxygen atom Chemical group O* 0.000 description 1
• LXNAVEXFUKBNMK-UHFFFAOYSA-N palladium(II) acetate Substances [Pd].CC(O)=O.CC(O)=O LXNAVEXFUKBNMK-UHFFFAOYSA-N 0.000 description 1
• YJVFFLUZDVXJQI-UHFFFAOYSA-L palladium(ii) acetate Chemical compound [Pd+2].CC([O-])=O.CC([O-])=O YJVFFLUZDVXJQI-UHFFFAOYSA-L 0.000 description 1
• 150000002942 palmitic acid derivatives Chemical class 0.000 description 1
• 125000000913 palmityl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
• 210000000496 pancreas Anatomy 0.000 description 1
• 208000021255 pancreatic insulinoma Diseases 0.000 description 1
• 239000012188 paraffin wax Substances 0.000 description 1
• 208000007312 paraganglioma Diseases 0.000 description 1
• 239000006072 paste Substances 0.000 description 1
• 230000001575 pathological effect Effects 0.000 description 1
• 230000009054 pathological process Effects 0.000 description 1
• 235000020232 peanut Nutrition 0.000 description 1
• 235000021400 peanut butter Nutrition 0.000 description 1
• 229960004851 pergolide Drugs 0.000 description 1
• YEHCICAEULNIGD-MZMPZRCHSA-N pergolide Chemical compound C1=CC([C@H]2C[C@@H](CSC)CN([C@@H]2C2)CCC)=C3C2=CNC3=C1 YEHCICAEULNIGD-MZMPZRCHSA-N 0.000 description 1
• 230000000737 periodic effect Effects 0.000 description 1
• JRKICGRDRMAZLK-UHFFFAOYSA-L persulfate group Chemical group S(=O)(=O)([O-])OOS(=O)(=O)[O-] JRKICGRDRMAZLK-UHFFFAOYSA-L 0.000 description 1
• 208000028591 pheochromocytoma Diseases 0.000 description 1
• 239000008363 phosphate buffer Substances 0.000 description 1
• 150000003014 phosphoric acid esters Chemical class 0.000 description 1
• LFGREXWGYUGZLY-UHFFFAOYSA-N phosphoryl Chemical group [P]=O LFGREXWGYUGZLY-UHFFFAOYSA-N 0.000 description 1
• OXNIZHLAWKMVMX-UHFFFAOYSA-N picric acid Chemical class OC1=C([N+]([O-])=O)C=C([N+]([O-])=O)C=C1[N+]([O-])=O OXNIZHLAWKMVMX-UHFFFAOYSA-N 0.000 description 1
• 208000024724 pineal body neoplasm Diseases 0.000 description 1
• 201000004123 pineal gland cancer Diseases 0.000 description 1
• 125000000587 piperidin-1-yl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
• 125000004482 piperidin-4-yl group Chemical group N1CCC(CC1)* 0.000 description 1
• 125000005547 pivalate group Chemical group 0.000 description 1
• 150000003057 platinum Chemical class 0.000 description 1
• 229920000573 polyethylene Polymers 0.000 description 1
• 235000010989 polyoxyethylene sorbitan monostearate Nutrition 0.000 description 1
• 239000001818 polyoxyethylene sorbitan monostearate Substances 0.000 description 1
• 229920000136 polysorbate Polymers 0.000 description 1
• 229940113124 polysorbate 60 Drugs 0.000 description 1
• LZMJNVRJMFMYQS-UHFFFAOYSA-N poseltinib Chemical compound C1CN(C)CCN1C(C=C1)=CC=C1NC1=NC(OC=2C=C(NC(=O)C=C)C=CC=2)=C(OC=C2)C2=N1 LZMJNVRJMFMYQS-UHFFFAOYSA-N 0.000 description 1
• 239000011591 potassium Substances 0.000 description 1
• 229910052700 potassium Inorganic materials 0.000 description 1
• 239000012256 powdered iron Substances 0.000 description 1
• 229960003089 pramipexole Drugs 0.000 description 1
• FASDKYOPVNHBLU-ZETCQYMHSA-N pramipexole Chemical compound C1[C@@H](NCCC)CCC2=C1SC(N)=N2 FASDKYOPVNHBLU-ZETCQYMHSA-N 0.000 description 1
• 230000002335 preservative effect Effects 0.000 description 1
• 230000002265 prevention Effects 0.000 description 1
• 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
• 238000004393 prognosis Methods 0.000 description 1
• 229940090181 propyl acetate Drugs 0.000 description 1
• 235000013772 propylene glycol Nutrition 0.000 description 1
• 210000002307 prostate Anatomy 0.000 description 1
• YQUVCSBJEUQKSH-UHFFFAOYSA-N protochatechuic acid Natural products OC(=O)C1=CC=C(O)C(O)=C1 YQUVCSBJEUQKSH-UHFFFAOYSA-N 0.000 description 1
• 238000000425 proton nuclear magnetic resonance spectrum Methods 0.000 description 1
• 125000000561 purinyl group Chemical group N1=C(N=C2N=CNC2=C1)* 0.000 description 1
• 125000003373 pyrazinyl group Chemical group 0.000 description 1
• 125000003226 pyrazolyl group Chemical group 0.000 description 1
• 125000002206 pyridazin-3-yl group Chemical group [H]C1=C([H])C([H])=C(*)N=N1 0.000 description 1
• 125000004941 pyridazin-5-yl group Chemical group N1=NC=CC(=C1)* 0.000 description 1
• 125000002098 pyridazinyl group Chemical group 0.000 description 1
• UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
• 125000000246 pyrimidin-2-yl group Chemical group [H]C1=NC(*)=NC([H])=C1[H] 0.000 description 1
• 125000004527 pyrimidin-4-yl group Chemical group N1=CN=C(C=C1)* 0.000 description 1
• 125000004528 pyrimidin-5-yl group Chemical group N1=CN=CC(=C1)* 0.000 description 1
• 125000000719 pyrrolidinyl group Chemical group 0.000 description 1
• 150000003856 quaternary ammonium compounds Chemical class 0.000 description 1
• 125000001453 quaternary ammonium group Chemical group 0.000 description 1
• ZTHJULTYCAQOIJ-WXXKFALUSA-N quetiapine fumarate Chemical compound [H+].[H+].[O-]C(=O)\C=C\C([O-])=O.C1CN(CCOCCO)CCN1C1=NC2=CC=CC=C2SC2=CC=CC=C12.C1CN(CCOCCO)CCN1C1=NC2=CC=CC=C2SC2=CC=CC=C12 ZTHJULTYCAQOIJ-WXXKFALUSA-N 0.000 description 1
• 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 description 1
• 230000005855 radiation Effects 0.000 description 1
• 150000003254 radicals Chemical class 0.000 description 1
• 238000000163 radioactive labelling Methods 0.000 description 1
• ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 description 1
• 239000000376 reactant Substances 0.000 description 1
• 230000035484 reaction time Effects 0.000 description 1
• 229940038850 rebif Drugs 0.000 description 1
• 229940100618 rectal suppository Drugs 0.000 description 1
• 239000006215 rectal suppository Substances 0.000 description 1
• 230000009712 regulation of translation Effects 0.000 description 1
• 238000011160 research Methods 0.000 description 1
• 239000011347 resin Substances 0.000 description 1
• 229920005989 resin Polymers 0.000 description 1
• 238000004007 reversed phase HPLC Methods 0.000 description 1
• 238000012552 review Methods 0.000 description 1
• 229960004181 riluzole Drugs 0.000 description 1
• 229940106887 risperdal Drugs 0.000 description 1
• RAPZEAPATHNIPO-UHFFFAOYSA-N risperidone Chemical compound FC1=CC=C2C(C3CCN(CC3)CCC=3C(=O)N4CCCCC4=NC=3C)=NOC2=C1 RAPZEAPATHNIPO-UHFFFAOYSA-N 0.000 description 1
• RADGOBKLTHEUQO-UHFFFAOYSA-N ruthenium(4+) Chemical compound [Ru+4] RADGOBKLTHEUQO-UHFFFAOYSA-N 0.000 description 1
• 239000003813 safflower oil Substances 0.000 description 1
• 235000005713 safflower oil Nutrition 0.000 description 1
• 229960002052 salbutamol Drugs 0.000 description 1
• 150000003902 salicylic acid esters Chemical class 0.000 description 1
• 210000003296 saliva Anatomy 0.000 description 1
• 201000000980 schizophrenia Diseases 0.000 description 1
• 206010039667 schwannoma Diseases 0.000 description 1
• 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
• 230000028327 secretion Effects 0.000 description 1
• XIIOFHFUYBLOLW-UHFFFAOYSA-N selpercatinib Chemical compound OC(COC=1C=C(C=2N(C=1)N=CC=2C#N)C=1C=NC(=CC=1)N1CC2N(C(C1)C2)CC=1C=NC(=CC=1)OC)(C)C XIIOFHFUYBLOLW-UHFFFAOYSA-N 0.000 description 1
• 210000000582 semen Anatomy 0.000 description 1
• 230000035945 sensitivity Effects 0.000 description 1
• 238000000926 separation method Methods 0.000 description 1
• 229940035004 seroquel Drugs 0.000 description 1
• 208000004548 serous cystadenocarcinoma Diseases 0.000 description 1
• 230000019491 signal transduction Effects 0.000 description 1
• 230000011664 signaling Effects 0.000 description 1
• 150000004760 silicates Chemical class 0.000 description 1
• RMAQACBXLXPBSY-UHFFFAOYSA-N silicic acid Chemical compound O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 description 1
• 235000012239 silicon dioxide Nutrition 0.000 description 1
• 229910052814 silicon oxide Inorganic materials 0.000 description 1
• XGVXKJKTISMIOW-ZDUSSCGKSA-N simurosertib Chemical compound N1N=CC(C=2SC=3C(=O)NC(=NC=3C=2)[C@H]2N3CCC(CC3)C2)=C1C XGVXKJKTISMIOW-ZDUSSCGKSA-N 0.000 description 1
• QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 description 1
• 229960002930 sirolimus Drugs 0.000 description 1
• 210000003491 skin Anatomy 0.000 description 1
• 201000000849 skin cancer Diseases 0.000 description 1
• 201000001839 skull cancer Diseases 0.000 description 1
• 208000000587 small cell lung carcinoma Diseases 0.000 description 1
• 229910052708 sodium Inorganic materials 0.000 description 1
• 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
• 235000017557 sodium bicarbonate Nutrition 0.000 description 1
• 229910000029 sodium carbonate Inorganic materials 0.000 description 1
• 239000001509 sodium citrate Substances 0.000 description 1
• NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
• BEOOHQFXGBMRKU-UHFFFAOYSA-N sodium cyanoborohydride Chemical compound [Na+].[B-]C#N BEOOHQFXGBMRKU-UHFFFAOYSA-N 0.000 description 1
• 229910052938 sodium sulfate Inorganic materials 0.000 description 1
• 235000011152 sodium sulphate Nutrition 0.000 description 1
• 230000003381 solubilizing effect Effects 0.000 description 1
• 235000011076 sorbitan monostearate Nutrition 0.000 description 1
• 239000001587 sorbitan monostearate Substances 0.000 description 1
• 229940035048 sorbitan monostearate Drugs 0.000 description 1
• 239000003549 soybean oil Substances 0.000 description 1
• 235000012424 soybean oil Nutrition 0.000 description 1
• 230000020347 spindle assembly Effects 0.000 description 1
• 239000008174 sterile solution Substances 0.000 description 1
• 239000008223 sterile water Substances 0.000 description 1
• 239000003206 sterilizing agent Substances 0.000 description 1
• 201000011549 stomach cancer Diseases 0.000 description 1
• 201000000498 stomach carcinoma Diseases 0.000 description 1
• 238000007920 subcutaneous administration Methods 0.000 description 1
• 238000010254 subcutaneous injection Methods 0.000 description 1
• 239000007929 subcutaneous injection Substances 0.000 description 1
• 239000001384 succinic acid Substances 0.000 description 1
• 150000003900 succinic acid esters Chemical class 0.000 description 1
• 235000000346 sugar Nutrition 0.000 description 1
• 150000008163 sugars Chemical class 0.000 description 1
• NCEXYHBECQHGNR-QZQOTICOSA-N sulfasalazine Chemical compound C1=C(O)C(C(=O)O)=CC(\N=N\C=2C=CC(=CC=2)S(=O)(=O)NC=2N=CC=CC=2)=C1 NCEXYHBECQHGNR-QZQOTICOSA-N 0.000 description 1
• 229960001940 sulfasalazine Drugs 0.000 description 1
• NCEXYHBECQHGNR-UHFFFAOYSA-N sulfasalazine Natural products C1=C(O)C(C(=O)O)=CC(N=NC=2C=CC(=CC=2)S(=O)(=O)NC=2N=CC=CC=2)=C1 NCEXYHBECQHGNR-UHFFFAOYSA-N 0.000 description 1
• 150000003459 sulfonic acid esters Chemical class 0.000 description 1
• 150000003467 sulfuric acid derivatives Chemical class 0.000 description 1
• 239000004094 surface-active agent Substances 0.000 description 1
• 239000006188 syrup Substances 0.000 description 1
• 235000020357 syrup Nutrition 0.000 description 1
• 239000002278 tabletting lubricant Substances 0.000 description 1
• 229960001967 tacrolimus Drugs 0.000 description 1
• QJJXYPPXXYFBGM-SHYZHZOCSA-N tacrolimus Natural products CO[C@H]1C[C@H](CC[C@@H]1O)C=C(C)[C@H]2OC(=O)[C@H]3CCCCN3C(=O)C(=O)[C@@]4(O)O[C@@H]([C@H](C[C@H]4C)OC)[C@@H](C[C@H](C)CC(=C[C@@H](CC=C)C(=O)C[C@H](O)[C@H]2C)C)OC QJJXYPPXXYFBGM-SHYZHZOCSA-N 0.000 description 1
• 239000011975 tartaric acid Substances 0.000 description 1
• 235000002906 tartaric acid Nutrition 0.000 description 1
• 150000003899 tartaric acid esters Chemical class 0.000 description 1
• 210000001138 tear Anatomy 0.000 description 1
• LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 description 1
• 208000001608 teratocarcinoma Diseases 0.000 description 1
• LZRDHSFPLUWYAX-UHFFFAOYSA-N tert-butyl 4-aminopiperidine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCC(N)CC1 LZRDHSFPLUWYAX-UHFFFAOYSA-N 0.000 description 1
• CWXPZXBSDSIRCS-UHFFFAOYSA-N tert-butyl piperazine-1-carboxylate Chemical class CC(C)(C)OC(=O)N1CCNCC1 CWXPZXBSDSIRCS-UHFFFAOYSA-N 0.000 description 1
• BSYVTEYKTMYBMK-UHFFFAOYSA-N tetrahydrofurfuryl alcohol Chemical compound OCC1CCCO1 BSYVTEYKTMYBMK-UHFFFAOYSA-N 0.000 description 1
• 125000003039 tetrahydroisoquinolinyl group Chemical group C1(NCCC2=CC=CC=C12)* 0.000 description 1
• 125000000147 tetrahydroquinolinyl group Chemical group N1(CCCC2=CC=CC=C12)* 0.000 description 1
• 125000003831 tetrazolyl group Chemical group 0.000 description 1
• 230000001225 therapeutic effect Effects 0.000 description 1
• 230000008719 thickening Effects 0.000 description 1
• 239000002562 thickening agent Substances 0.000 description 1
• 150000003567 thiocyanates Chemical class 0.000 description 1
• BRNULMACUQOKMR-UHFFFAOYSA-N thiomorpholine Chemical compound C1CSCCN1 BRNULMACUQOKMR-UHFFFAOYSA-N 0.000 description 1
• 210000001685 thyroid gland Anatomy 0.000 description 1
• 208000013077 thyroid gland carcinoma Diseases 0.000 description 1
• 208000030901 thyroid gland follicular carcinoma Diseases 0.000 description 1
• 208000013818 thyroid gland medullary carcinoma Diseases 0.000 description 1
• 238000011200 topical administration Methods 0.000 description 1
• 239000012049 topical pharmaceutical composition Substances 0.000 description 1
• UCFGDBYHRUNTLO-QHCPKHFHSA-N topotecan Chemical compound C1=C(O)C(CN(C)C)=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 UCFGDBYHRUNTLO-QHCPKHFHSA-N 0.000 description 1
• 229960000303 topotecan Drugs 0.000 description 1
• 231100000419 toxicity Toxicity 0.000 description 1
• 230000001988 toxicity Effects 0.000 description 1
• 235000010487 tragacanth Nutrition 0.000 description 1
• 239000000196 tragacanth Substances 0.000 description 1
• 229940116362 tragacanth Drugs 0.000 description 1
• VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
• 238000012546 transfer Methods 0.000 description 1
• 206010044412 transitional cell carcinoma Diseases 0.000 description 1
• 238000006478 transmetalation reaction Methods 0.000 description 1
• 238000002054 transplantation Methods 0.000 description 1
• 238000011269 treatment regimen Methods 0.000 description 1
• YNJBWRMUSHSURL-UHFFFAOYSA-N trichloroacetic acid Chemical compound OC(=O)C(Cl)(Cl)Cl YNJBWRMUSHSURL-UHFFFAOYSA-N 0.000 description 1
• WRECIMRULFAWHA-UHFFFAOYSA-N trimethyl borate Chemical class COB(OC)OC WRECIMRULFAWHA-UHFFFAOYSA-N 0.000 description 1
• 235000011178 triphosphate Nutrition 0.000 description 1
• 239000001226 triphosphate Substances 0.000 description 1
• JLEXUIVKURIPFI-UHFFFAOYSA-N tris phosphate Chemical compound OP(O)(O)=O.OCC(N)(CO)CO JLEXUIVKURIPFI-UHFFFAOYSA-N 0.000 description 1
• 229910052722 tritium Inorganic materials 0.000 description 1
• 238000001665 trituration Methods 0.000 description 1
• 230000004614 tumor growth Effects 0.000 description 1
• 238000007039 two-step reaction Methods 0.000 description 1
• OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
• ZDPHROOEEOARMN-UHFFFAOYSA-N undecanoic acid Chemical class CCCCCCCCCCC(O)=O ZDPHROOEEOARMN-UHFFFAOYSA-N 0.000 description 1
• 208000010576 undifferentiated carcinoma Diseases 0.000 description 1
• 201000000360 urethra cancer Diseases 0.000 description 1
• 210000002700 urine Anatomy 0.000 description 1
• 206010046766 uterine cancer Diseases 0.000 description 1
• WKOLLVMJNQIZCI-UHFFFAOYSA-N vanillic acid Chemical compound COC1=CC(C(O)=O)=CC=C1O WKOLLVMJNQIZCI-UHFFFAOYSA-N 0.000 description 1
• TUUBOHWZSQXCSW-UHFFFAOYSA-N vanillic acid Natural products COC1=CC(O)=CC(C(O)=O)=C1 TUUBOHWZSQXCSW-UHFFFAOYSA-N 0.000 description 1
• 208000009540 villous adenoma Diseases 0.000 description 1
• OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 description 1
• 229960004528 vincristine Drugs 0.000 description 1
• OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 description 1
• 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
• 229920002554 vinyl polymer Polymers 0.000 description 1
• 230000003612 virological effect Effects 0.000 description 1
• 239000003871 white petrolatum Substances 0.000 description 1
• 210000002268 wool Anatomy 0.000 description 1